Dialogues Clin. Neurosci. by Ropers, H.
ear Colleagues,
Medical genetics is the study, at the gene level, of the relationship between structures and
observed disorders (genetic diagnosis). It seeks, in particular, abnormalities in the genes and chro-
mosomes.
Genomics is the study of the functional expression of the genome, and is not restricted to one
particular gene.
The root "gen-" implies specific characteristics related to a person, and thus the identification
of specific factors (positive or favorable factors, negative factors leading to fragility or pathology).
Each individual carries specific traits which identify him or her, and which on one hand create
a tendency towards the expression of certain pathologies, and on the other hand cause individual dif-
ferences in therapeutic response, making the individual sensitive to a therapeutic approach, causing
a reaction to a particular treatment, making a particular therapeutic approach more desirable, caus-
ing drug dependence, etc.
Psychiatric disorders are the most striking example of the abovementioned points.
However, we must also accept the limits of this concept, knowing that in the field of psychia-
try, genetic investigations and the resulting knowledge have for the most part provided extremely
complex profiles, which are not always able to be implemented on a diagnostic or therapeutic level.
The correlation of genetic data and a genomic approach opens up the way to new paths of
investigation, and new possibilities of applying the resulting knowledge, providing a basis for diag-
nostic conclusions or new therapeutic strategies using this approach.
This issue of Dialogues in Clinical Neuroscience gives us an opportunity to renew our acquain-
tance with this field, and to put the new diagnostic and treatment procedures in context. It provides
us with an extremely interesting update on these various methods. We are most grateful to Margret
Hoehe, assisted by Deborah Morris-Rosendahl and Nancy Andreasen, for coordinating this issue, and
also to the authors who agreed to contribute.
Sincerely yours,
Jean-Paul Macher, MD
E d i t o r i a l
D
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I n  t h i s  i s s u e . . .
The DNA age is dawning… These past years have seen an
unprecedented transformation: from single candidate gene
studies to whole genome-based screening approaches to the
analysis of whole human genome sequences and their varia-
tion in health and disease. Whereas the first human genome
took years and US$ 3 billion to materialize, with an effort involv-
ing armies of researchers, the US$ 1000 genome is now with-
in reach, and genome sequences within 15 minutes are now
envisageable. This will revolutionize our understanding of
health and disease. Importantly, personal genomes will become
accessible not only to researchers, but in principle to every
human individual. Knowledge and insights gained from human
DNA, the very code of our existence, in its countless individual-
ly different forms, is bound to impact our personal and public
lives in significant and yet unpredictable ways: the ways we per-
ceive ourselves and each other, our attitudes and approaches
towards life, society, and mankind. Knowledge on personal
genomes will prepare the ground to learn about the interplay
between nature and nurture, the genome and the environ-
ment, in shaping the traits we observe. 
The current issue covers much of this ground. We have assem-
bled a group of outstanding international scholars, leaders at
the cutting edge in genetics and genomics, who have had, and
will have, a decisive impact on these revolutionizing develop-
ments. 
To prepare the ground, this issue begins with a State of the
art article on “Nature and nurture in neuropsychiatric genetics”
(p 7) by Prof Kendler and colleagues. They provide a most com-
prehensive and advanced review of the fields of genetic epi-
demiology and molecular genetics, examining the contribution
of both genetic and nongenetic risk factors, as well as interac-
tions and correlations between them, to the etiology of psy-
chiatric and behavioral phenotypes. They conclude that, to
date, only a few specific genetic variants influencing risk have
been unambiguously identified, the results collectively being
complex and inconsistent with a single common DNA variant
in any gene. Their hopes rely upon contemporary approaches
that promise to further elucidate liability genes and variants, as
well as their potential inter-relationships with each other and
the environment. 
Three Basic research articles follow. Prof Petronis and col-
leagues (p 25) introduce epigenetic approaches to psychiatric
disorders. These, as a relatively new field, address changes in
phenotype or gene expression caused by mechanisms other
than changes in the actual base composition of DNA sequence.
Thus, additional etiological models have become available,
compatible with mechanisms by which environmental or other
genetic influences translate into lasting imprints on the transla-
tion of sequence information. The authors outline how many
epidemiological, clinical, and molecular characteristics of psy-
chiatric diseases may be consistent with an epigenetic dysreg-
ulation and accordingly review current findings in major psy-
chosis, Alzheimer’s disease, and autism spectrum disorders. The
next article expands on search strategies to identify genetic risk
variants. The initial approach to study single selected candidate
genes has been complemented by a wave of genome-wide
association studies (GWAS). The establishment of a data base
of common human variation, the HapMap, in conjunction with
novel high-throughput SNP typing technologies, enables effec-
tive screening of the entire genome in order to identify com-
mon variants that associate with complex disease. Profs Gold-
stein and Need (p 37) provide a most comprehensive and critical
assessment of the hundreds of GWAS that have been per-
formed in recent years. Whereas some strong effects of com-
mon variants could be found in late-onset diseases and in drug
response, and the major histocompatibility complex emerged
with very strong associations, on the whole, common variation
has explained little of the high heritability of neuropsychiatric
traits. In contrast, early studies of rare structural variation, copy
number variants, have rapidly resulted in a number of genes
and loci that strongly associate with neuropsychiatric disorders.
The authors conclude that the use of whole-genome sequenc-
ing to extend the study of rare variation in neuropsychiatry will
greatly advance our understanding of neuropsychiatric genet-
ics. Whole-genome sequencing has now become an increas-
ingly affordable; technology  capable of meeting the target cost
of US$1000 or less for a diploid human genome sequence is
within reach. Motivated by the low return from common sin-
gle-nucleotide polymorphism analysis, this has caused a signif-
icant rise in interest in correlating genome sequences with com-
prehensive environmental and trait data (GET). Integrating in
principle all the various “omes” will catalyze progress in func-
tional genomics and enable systems biology-based insights into
the mechanisms of human health and disease. Prof Church and
colleagues  (p 47) introduce, in a first comprehensive paper, the
Personal Genome Project (PGP) conducted at the Department
of Genetics at Harvard Medical School. This is currently the
most ambitious and visionary human genomic research study,
ultimately aiming to recruit as many as 100 000 individuals. The
authors examine the PGP’s effort to develop a GET database as
a public genomics resource broadly accessible to both
researchers and research participants, while pursuing the high-
est standards in research ethics. 
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Higher accessibility of genome and genotypic data, coupled
with increasing public awareness of their potential impact on
health, disease prevention and treatment, the interest of indi-
viduals in learning about their genomes, themselves, has turned
out to be remarkable. In their Translational research article,
Prof Stefánsson and his team (p 61), who have significantly con-
tributed to current association findings in major common, com-
plex diseases, highlight their translational role by offering cor-
responding genetic tests direct to consumers. The overall
predictive power of common sequence variants is expected to
be considerable, due to the high incidence of the diseases
found associated with them. The authors address the past, pre-
sent, and future of direct-to-consumer (DTC) genetic tests, as
well as current concerns. They conclude that a key translation-
al role of DTC genetic tests may be seen in democratizing priv-
ileged knowledge of value for preventive medicine to the pub-
lic, thereby empowering them.
The first paper on Pharmacological aspects addresses genet-
ic testing to predict drug response. The question is, to what
extent have the numerous, solid findings in the areas of phar-
macogenomics in fact been translated into optimization of indi-
vidual treatment response? Prof Mrazek (p 69) provides an
informative overview of the clinical adoption of psychiatric phar-
macogenomic testing. He elaborates on the implementation
and implications of genotyping highly variable drug-metaboliz-
ing enzyme genes from the Cytochrome P450 family, and then
goes on to the testing of genes influencing the pharmacody-
namic response to medications, including serotonin transporter
and receptor genes. He provides moreover a quantification of
the clinical utility of pharmacogenomic testing emphasizing its
“increasingly clear” cost-effectiveness, as well as ethical con-
siderations established for testing. The following article by Profs
Gelernter and Kranzler (p 77) addresses the genetic predispo-
sition to drugs of abuse. With a particular focus on cocaine, opi-
oid, and nicotine dependence, the authors provide a detailed
review on the genetics of drug dependence, outlining signifi-
cant results from linkage, association, and genome-wide asso-
ciation study methodologies. Obviously, future prospects for risk
allele identification will also include more extensive sequencing
to identify a fuller range of risk variants. 
The Clinical research section, in its first article, extends the
appraisal of the genetics of psychiatric phenotypes to a state-of-
the-art account of the genetics of the major psychoses, schizo-
phrenia, and bipolar disorder. Prof Nöthen and colleagues (p 85)
focus on a detailed summary of systematic genome-wide asso-
ciation and follow-up studies, also outlining the small effects and
lack of diagnostic specificity of the common risk variants identi-
fied. In addition, they report on the recent—more successful—
studies that have detected large, rare structural variants (copy
number variants) conferring a greater risk for schizophrenia.
Taken together, it is increasingly evident that, for most common
diseases, the “Common Disease-Common Variant (CDCV)”
hypothesis is insufficient, and the support for GWAS is dwin-
dling. At the same time, remarkable successes have recently
been achieved in the field of Mendelian disorders, renewing
interest in these diseases. Specifically, the affordability and appli-
cation of new technologies such as exome or whole-genome
sequencing to limited numbers of extreme, clearly defined phe-
notypes has been shown to lead to new potential causative
genes for neuropsychiatric disorders being identified. Prof Rop-
ers (p 95) provides a most modern and instructive review of
these developments, while bringing back into focus also the
medical importance of these diseases. These must be far more
common than generally thought and, moreover, may provide
valuable clues to the understanding of common diseases. Effi-
cient strategies for the identification of causative single-gene
defects are outlined; in combination with novel genome parti-
tioning and sequencing technologies, these could have far-
reaching implications for health care. The third Clinical research
article by Prof Reichborn-Kjennerud (p 103) addresses a some-
what young, but nevertheless fascinating field, the analysis of
genetic factors involved in personality disorders (PDs), as sup-
ported by genetic epidemiologic studies. This field, though,
seems even more difficult and complex than what has been
attempted so far, given that it remains a major task to define and
classify the phenotypes precisely, a prerequisite for meaningful
genetic analyses. Multivariate studies suggest that three genet-
ic and environmental risk factors are common to all PDs. Previ-
ous molecular genetic studies, mostly candidate gene associa-
tion studies, have pointed to genes involved particularly in
serotonergic and dopaminergic neurotransmitter pathways. 
To conclude with the Brief report, Dr Morris-Rosendahl (p 116)
provides a most valuable and detailed glossary of genetic terms
relevant to this issue, including useful genetic databases and
additional sources of information. This material should help to
understand the current contents and prepare the readers for
this most exciting field of scientific and human enterprise.
I n  t h i s  i s s u e . . .
Margret R. Hoehe, MD, PhD
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ur knowledge of psychiatric and substance-use
genetics comes from two key fields of research, both
dynamic areas in rapid change. First, genetic epidemiol-
ogy asks whether there is risk in excess of the population
baseline in the relatives of cases, and, if so, whether the
excess risk is attributable to the genetic factors or the
environments they share. Beyond simply estimating her-
itability, genetic epidemiology has evolved to address
more sophisticated questions, such as whether liability
genes have the same effects across the lifespan, how they
may influence multiple disorders, and how they might
interact with environmental risks. 
Genetic epidemiology of psychiatric and behavioral phe-
notypes has consistently demonstrated that: i) genetic
risk factors are, in aggregate, important etiological com-
ponents; ii) they cannot completely account for observed
risk, meaning these phenotypes are multifactorial traits,
with important nongenetic (or environmental) con-
tributing factors; and iii) the risk alleles appear to be of
small effect size and to occur in a large number of genes.
Psychiatric and behavioral phenotypes are influenced by
a large number of risk factors that individually are within
the range of normal human variation and produce mod-
est individual increases in risk.
The initial goal of the second major research area, mole-
cular genetics, is to identify genes which influence these
S t a t e  o f  t h e  a r t
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Both genetic and nongenetic risk factors, as well as inter-
actions and correlations between them, are thought to
contribute to the etiology of psychiatric and behavioral
phenotypes. Genetic epidemiology consistently supports
the involvement of genes in liability. Molecular genetic
studies have been less successful in identifying liability
genes, but recent progress suggests that a number of spe-
cific genes contributing to risk have been identified.
Collectively, the results are complex and inconsistent, with
a single common DNA variant in any gene influencing
risk across human populations. Few specific genetic vari-
ants influencing risk have been unambiguously identified.
Contemporary approaches, however, hold great promise
to further elucidate liability genes and variants, as well as
their potential inter-relationships with each other and
with the environment. We will review the fields of
genetic epidemiology and molecular genetics, providing
examples from the literature to illustrate the key concepts
emerging from this work. 
© 2010, LLS SAS Dialogues Clin Neurosci. 2010;12:7-23.
DCNS_44_5.qxd:DCNS#44  10/03/10  1:44  Page 7
phenotypes and to identify the specific risk variants within
them. There are substantial differences in DNA sequences
between individuals, and gene identification methods test
whether specific alleles at these variable positions are
more common in affected than in unaffected individuals,
most commonly with linkage studies (in families) and
association studies (primarily in case/controls, but also in
numerous other designs). We will discuss the underlying
causes of these two genetic phenomena, the methods for
detecting them, and the limitations of each. 
The second goal of molecular genetics is to identify spe-
cific risk alleles and to use functional studies to elucidate
how a gene functions normally, how the risk allele alters
normal function, and how these alterations contribute to
disease. The aim of this work is to explain the aggregate
genetic risks observed through the effects of risk alleles
on gene expression, protein structure and function,
and/or biological processes. This area remains largely
unsuccessful to date for complex traits generally. 
In this review we focus on the basic methods of genetic
epidemiology and molecular genetics, and provide exam-
ples, across a variety of psychiatric and substance use dis-
orders, of questions currently being addressed. In con-
trast to this first section on genetic epidemiology, the
sections on molecular genetics focus narrowly on schiz-
ophrenia, where there is a much longer history of mole-
cular genetic studies, because we judged that emphasiz-
ing a single disorder would provide a more coherent
example of ongoing research progress and challenges. 
Basic genetic epidemiology
The most fundamental question addressed by psychiatric
genetic epidemiology is whether a particular trait or dis-
order shows evidence for genetic influence. Both twin
and adoption studies provide methods to address this
question and tease apart the degree to which genetic and
environmental influences are important on a given out-
come. Twin studies accomplish this by comparisons of
the similarity of monozygotic twins (MZs; who share
100% of their genetic variation), with dizygotic twins
(DZs; who share on average just 50% of their genetic
variation). Adoption studies compare similarity among
adopted-apart biological relatives, who share genetic
variation, but not their environments, and adoptive rel-
atives, who share their environment, but not their
genetic makeup. Through these comparisons, we can
quantify the degree to which genetic influences con-
tribute to individual differences in risk, a statistic com-
monly referred to as the heritability of the trait. These
study designs have been applied to virtually all psychi-
atric disorders and to a number of related traits, yielding
compelling evidence that genetic influences play a criti-
cal role in virtually all psychiatric outcomes. There is
considerable variability in the magnitude of genetic
influence across different disorders. On the high end are
disorders such as schizophrenia, bipolar disorder, and
autism, which yield heritability estimates of the order of
80% or higher. Alcohol and other drug dependence
shows moderate heritability, in the range of 50% to 60%.
On the lower end of the spectrum, though still showing
significant evidence of genetic influence, are anxiety and
depressive disorders, as well as eating disorders, which
yield heritability estimates of ~30% to 40%. So, while
there is variability in the magnitude of importance of
genetic effects, it is widely accepted that a significant
genetic component plays a role in virtually all psychiatric
traits. It is a sign of the paradigm shift that has taken
place in psychiatry that heritability estimates are no
longer considered controversial, since the original stud-
ies finding evidence for genetic effects represented
strong challenges to predominant views favoring envi-
ronmental theories on the causation of most psychiatric
conditions, ranging from schizophrenia to autism to alco-
hol dependence—disorders that are all now widely rec-
ognized as having genetic components. 
While demonstration of heritability played an important
role in altering fundamental assumptions about the eti-
ology of psychiatric disorders, if not understood in their
proper context, heritability estimates can also have a
number of unfortunate side effects. Firstly, the heritabil-
ity statistic created a dichotomy of genetic versus envi-
ronmental influence—nature versus nurture. How much
is genetic? How much is environmental? This is, as we
hope to show, a somewhat arbitrary distinction. Genetic
predispositions by necessity are expressed in the context
of the organism’s environment, and the environment can
differentially affect individuals based on their unique
genetic makeup. Further, many environments are not
simply “imposed” on an individual; rather, individuals
play an active role in selecting and shaping their envi-
ronments. Accordingly, it is generally more informative
to elucidate pathways of risk and show how genetic and
environmental influences come together in this process,
rather than trying to divide influence into that which is
genetic and that which is environmental. Secondly,
S t a t e  o f  t h e  a r t
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demonstration of heritability led to the idea that there
were genes “for” a given disorder. More complex mod-
els that have examined genetic influences across multi-
ple different conditions suggest that the Diagnostic and
Statistical Manual of Mental Disorders (DSM) structure
of psychiatric diagnoses often does not map onto the
underlying genetic architecture of psychiatric traits.
Genetic influences appear to be shared across many psy-
chiatric conditions, and likely operate through mediat-
ing characteristics that alter risk for a number of differ-
ent outcomes. Finally, static heritability estimates fail to
capture the dynamic nature of genetic and environmen-
tal influences on psychiatric outcome. Heritability esti-
mates are specific to the population under study. Lost in
heritability estimates are potential differences across
environmental conditions, across populations or gender,
and across ages. Accordingly, genetic epidemiology has
undergone an evolution in the kinds of questions being
addressed. No longer is the question simply “Are genetic
influences important on Trait X?” or even “How impor-
tant are genetic influences on Trait X?”. Rather, the
focus has shifted to addressing the complexities raised
here, using the paradigm we have called advanced
genetic epidemiology. 
Advanced genetic epidemiology
Moving beyond genes versus environment: 
gene-environment interaction and correlation
Parsing genetic and environmental influences into sep-
arate sources represents a necessary oversimplification,
as for most traits we know about, genetic and environ-
mental influences are inexorably intertwined. Most mea-
sures of the environment show some degree of genetic
influence, illustrating the active role that individuals play
in selecting and creating their social worlds.1 To the
extent that these choices are impacted upon by an indi-
vidual’s genetically influenced temperaments and behav-
ioral characteristics, an individual’s environment is not
purely exogenous, but rather, in some sense, is in part an
extension and reflection of the individual’s genotype.
This concept is called gene-environment correlation or,
perhaps more descriptively, genetic control of exposure
to the environment. It is likely an important process in
the risk associated with several psychiatric outcomes. For
example, there is considerable evidence for peer
deviance being associated with adolescent substance use.
However, individuals play an active role in selecting
their friends, and multiple genetically informative sam-
ples have now demonstrated that a genetic predisposi-
tion toward substance use is associated with the selec-
tion of other friends who use substances.2-4 Interestingly,
there is evidence that genetic effects on peer-group
deviance show a strong and steady increase across devel-
opment,5 suggesting that as individuals get older and
have increasing opportunities to select and create their
own social environment, genetic factors assume increas-
ing importance. Another area where gene-environment
correlation is known to play a significant role is in the
risk pathways associated with depression. Stressful life
events have been consistently associated with the man-
ifestation of depression. However, there is evidence for
genetic influence on the occurrence of stressful life
events,6,7 indicating that an individual’s predisposition
plays a role in the likelihood that they will experience
difficulties that are then associated with risk for depres-
sive episodes. For example, research has shown that a
genetic liability to major depression increases the risk
for a range of stressful life events, particularly those
reflecting interpersonal and romantic difficulties.8 These
represent only a couple of areas where individuals are
known to play an active role in shaping environmental
factors that are associated with subsequent risk for psy-
chiatric problems.
Another way that genetic and environmental influences
are linked is via gene-environment interaction or, as we
might prefer, genetic control of sensitivity to the envi-
ronment. In these situations, genetic influences may vary
in importance as a function of environmental conditions
and/or that the environment differs in importance as a
function of an individual’s genetic predisposition (these
two conceptualizations of gene-environment interaction
are indistinguishable statistically). Heritability estimates
essentially average across environments; accordingly, if
there is reason to believe that the importance of genetic
effects might vary as a function of the environment, this
information can be incorporated into the twin model to
test for significant differences in heritability as a func-
tion of the environment. Substance use provides one
area where gene-environment interaction effects have
been found to be particularly important. Environments
that exert more social control and present less opportu-
nity to engage in substance use consistently show
reduced evidence for the importance of genetic effects.
In this sense, the environment is essentially constraining
Nature and nurture in neuropsychiatric genetics - Dick et al Dialogues in Clinical Neuroscience - Vol 12 . No. 1 . 2010
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the expression of a predisposition toward substance
use/problems. This has been demonstrated with respect
to enhanced parental monitoring in adolescents,9 a more
religious upbringing,10 and enhanced community stabil-
ity,11 among other factors. One nice example of this can
be found in an analysis of the heritability of adolescent
smoking across the United States using data from the
National Longitudinal Study of Adolescent Health.
Genetic influences on daily smoking were lower in states
with relatively high taxes on cigarettes and in those with
greater controls on vending machines and cigarette
advertising, again suggesting the importance of social
control mechanisms in moderating the importance of
genetic influences on substance use.12
Delineating phenotypic boundaries of genetic risk
The rationale of the basic twin design can be expanded
to examine the extent to which genetic and environ-
mental factors contribute to the co-occurrence of psy-
chiatric conditions. Comorbidity among psychiatric dis-
orders is common, and multivariate twin studies have
helped address the etiological mechanisms that con-
tribute to these observed epidemiological patterns. A
fascinating result to emerge from these studies is that
psychiatric conditions with distinct clinical presentations
(eg, major depression and anxiety) are not necessarily
distinct genetically. For example, a study of major
depression and generalized anxiety disorder found a
genetic correlation of 1.0, suggesting that the same
genetic influences impact depression and anxiety, but
differences in environmental experiences contribute to
the manifestation of different outcomes.13 An expanded
study that examined the genetic and environmental
architecture across seven common psychiatric and sub-
stance-use disorders found that genetic influences load
broadly onto two factors that map onto internalizing dis-
orders (depression, anxiety disorders), and externalizing
disorders (alcohol and other drug dependence, child-
hood conduct problems, and adult antisocial behavior).14
These findings indicate that while distinguishing these
disorders as “separate conditions” in the DSM may be
useful for clinical purposes, these categories do not nec-
essarily reflect differences in biological etiology. These
findings, along with similar results from phenotypic
analyses (eg, refs 15,16) have led some to suggest a reor-
ganization of the “metastructure” of psychiatric disor-
ders in DSM-V. 
Another area of investigation examines whether there
are differences in the importance of genetic and envi-
ronmental factors at different stages of the disorder. For
example, the development of substance dependence is
necessarily preceded by several stages, including the ini-
tiation of the substance, the progression to regular use,
and the subsequent development of problems, whether
they be psychological, social, and/or physiological. Twin
studies can investigate the degree to which each of these
steps in the pathway of risk is influenced by genetic
and/or environmental factors, and the extent to which
the same or different genetic/environmental factors
impact different stages. For example, data from two pop-
ulation-based, longitudinal Finnish twin studies found
that shared environmental factors played a large role in
initiation of alcohol use, and a more moderate role on
frequency of use, and it was largely the same influences
acting across these stages of use. However, there was no
significant evidence of shared environmental influences
on alcohol problems in early adulthood. Problems were
largely influenced by genetic factors that overlapped
with genetic influences on frequency of use.17 In a study
from Virginia in male twins, similar results were found
for alcohol, cannabis, and nicotine.18 In the early years of
adolescence, shared environmental influences were
responsible for nearly all twin resemblance for levels of
intake of these psychoactive substances. However, as
individuals aged, the impact of shared environment
decreased and that of genetic factors increased. 
Finally, there is known to be tremendous heterogeneity
among individuals with psychiatric conditions. Twin stud-
ies can provide insight into whether clinical hetero-
geneity may reflect differences in etiological risk factors.
For example, alcohol dependence with comorbid drug
dependence has been found to be a particularly herita-
ble form of the disorder,19,20 and twin studies have sug-
gested a genetic influence on typical versus atypical
forms of major depression.21
Changing genetic influence across development
Another active area of research is the clarification of
how genetic and environmental influences may change
across development. A recent meta-analysis examined
published studies with at least two heritability time
points across adolescence and young adulthood for eight
different behavioral domains. These analyses revealed
significant cross-time heritability increases for external-
S t a t e  o f  t h e  a r t
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izing behaviors, anxiety symptoms, depressive symptoms,
IQ, and social attitudes, and nonsignificant increases for
alcohol consumption and nicotine initiation. The only
domain that showed no evidence of heritability changes
across time was attention-deficit/hyperactivity disorder.22
Similarly, in a large study of >11 000 pairs of twins from
four countries, the heritability of general cognitive abil-
ity was found to increase significantly and linearly from
41% in childhood (9 years) to 55% in adolescence (12
years) and to 66% in young adulthood (17 years).23 The
robust finding of increases in the importance of genetic
influences across development likely reflects, in part,
active gene-environment correlation, as individuals
increasingly select and create their own experiences
based on their genetic propensities. 
In addition to changes in the relative magnitude of
importance of genetic and environmental influences,
another dynamic change is that different genes may be
acting at different time points. This is nicely illustrated
in recent analyses of alcohol use problems, as assessed
at five time points from ages 19 to 28 in the Dutch Twin
Registry (Kendler et al, in preparation). Kendler and
colleagues found strong innovation and attenuation of
genetic factors across this age range—indicating that
some genetic influences on alcohol problems that were
evident at age 19 declined in importance across time,
while new genetic influences became important starting
at ages 21 and 23. Thus, although the overall heritability
of alcohol problems remained fairly stable, it appeared
that different genetic factors were important at different
timepoints. In analyses in the TCHAD Swedish study
which followed twins from ages 9 to 20 across four waves
of assessment, large changes were seen in the genetic
risk factors for fears and phobias24 and for symptoms of
anxiety and depression,25 with particularly pronounced
evidence for genetic innovation at puberty. These analy-
ses suggest that genetic influences of many psychiatric
and substance use disorders are likely to be develop-
mentally dynamic.
Sex differences
Sex differences in the prevalence of psychiatric disor-
ders, and in risk and protective factors associated with
psychiatric outcomes, are widespread in epidemiology.
Twin studies allow us to investigate the extent to which
there are differences in the relative importance of
genetic and environmental influences on outcome, and
the extent to which different genes and/or environments
may be important. Large-scale twin studies have sug-
gested, for example, that the genetic risk factors for both
depression26 and alcohol dependence,27 while correlated,
are not entirely the same for males and females. Results
from two large twin studies in the US and Sweden agree
that the genetic influences of major depression are mod-
estly stronger in women than in men.26,28
Do we still need twin studies in the era of 
gene finding?
As advances in molecular genetics and statistical analy-
sis have made it possible to conduct large-scale projects
aimed at identifying the specific genes involved in sus-
ceptibility to psychiatric outcome (detailed in the next
sections), some have raised questions about the contin-
uing utility of genetic epidemiology. The argument is that
heritability has now been established, which provides the
foundation and justification for moving beyond twin
studies, on to large-scale gene identification projects.
However, as detailed in this paper, most twin studies are
no longer conducted simply to test for the presence of
genetic effects; rather, they focus on the more complex
kinds of questions summarized above. These analyses
are not only informative about the nature of etiological
pathways of risk, but they can also be used to guide gene
identification efforts and to further our understanding
of the risk associated with specific genes as they are
identified.
Currently, gene-finding efforts for psychiatric disorders
(and other common, complex medical conditions) have
met with limited success. Findings from genetic epi-
demiology can be used to inform the phenotypes used in
gene-finding studies. For example, based on the twin lit-
erature (reviewed above) suggesting that much of the
predisposition to alcohol dependence is via a broad
externalizing factor, externalizing factor scores were cre-
ated in the Collaborative Study on the Genetics of
Alcoholism (COGA) sample, comprised of symptoms of
alcohol and other drug dependence, and childhood and
adult antisocial behavior, as well as the personality traits
of novelty-seeking and sensation-seeking, which also
index general behavioral disinhibition. This latent exter-
nalizing factor score was then used in both linkage and
association analyses, with results compared with analyz-
ing separately the individual symptoms of each of the
psychiatric disorders that went into the creation of the
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general externalizing score.29 The results demonstrated
that this broader externalizing phenotype was useful in
both linkage and association analyses, suggesting that
creating phenotypes grounded in the twin literature can
aid in identifying susceptibility genes. Twin data has also
been used to aid in genetic association studies in the area
of internalizing disorders. Using data from the Virginia
Adult Twin Study of Psychiatric and Substance Use
Disorders, multivariate structural equation modeling was
used to identify common genetic risk factors for major
depression, generalized anxiety disorder, panic disorder,
agoraphobia, social phobia, and neuroticism. Cases and
controls were then identified for genetic association
studies based on scoring at the extremes of the genetic
factor extracted from the twin analysis, with the subse-
quent association analyses yielding evidence for associ-
ation with the gene GAD1.30
Another area where genetic epidemiology intersects
with gene identification efforts is in the characterization
of risk associated with identified genes. Most major
gene identification efforts for psychiatric disorders cur-
rently focus on adult psychiatric outcomes. As we iden-
tify genes that are reliably associated with these disor-
ders, one of the next interesting research challenges will
be to study how risk associated with these genes unfolds
across development and in conjunction with the envi-
ronment. Here, findings from genetic epidemiology can
again be useful in developing hypotheses to test the risk
associated with specific genes. For example, based on
the twin literature suggesting that adult alcohol depen-
dence and childhood externalizing symptoms overlap in
large part due to a shared genetic predisposition,31 genes
that were originally identified as associated with adult
alcohol dependence (eg, GABRA2,32 CHRM233) have
been tested for association with externalizing behavior
in younger samples of children and adolescents. These
studies suggest that children carrying the genetic vari-
ants associated with alcohol problems later in life dis-
play elevated rates of conduct problems earlier in devel-
opment, before any association with alcohol
dependence has manifested.34-36 Further, based on the
twin literatures suggesting that genetic influences on
externalizing behaviors are moderated by parental
monitoring9 and peer deviance,37,38 further analyses
demonstrated that the associations between these genes
and externalizing behavior were stronger under condi-
tions of lower parental monitoring and higher peer
deviance. Characterizing the risk pathways associated
with identified genes will be critical in eventually trans-
lating this information into improved prevention and
intervention programs. 
Gene identification methods
The field of psychiatric genetics has used two different
methods to attempt to identify individual risk genes:
linkage and association. These are fundamentally differ-
ent approaches with different study designs applied, until
recently, to very different research questions. It is impor-
tant to understand both in order to understand why
association approaches have become the norm in follow-
up studies of linkage regions as well as the primary cur-
rent approach in genome-wide studies.
DNA polymorphisms
Humans are ~99.9% identical at the nucleotide level on
average. Molecular genetic studies depend critically on
the remaining 0.1% (~3 million nucleotides) where vari-
ation occurs between individuals, collectively known as
genetic polymorphisms or markers. Linkage studies gen-
erally use short tandem repeat polymorphisms (STRs).
STR alleles are differing numbers of a repeating unit of
nucleotides and have specific sequence lengths and mol-
ecular weights as a result, allowing them to be separated
and identified. STRs are very common and tend to be
extremely polymorphic (ie, to have many alleles—where
an allele is one of the possible variants that exist in a
population at a particular genetic locus) and therefore
to have high heterozygosity (the proportion of individ-
uals who have two different alleles at the marker locus).
This high heterozygosity is important for linkage analy-
ses, which require a unique allele at each position on
each homologous chromosome to be informative. 
In contrast, single nucleotide polymorphisms (SNPs) are
changes of a single base or insertion/deletion variation
up to a few nucleotides in size. SNPs generally have only
two alleles, and have lower heterozygosity and lower
information content. Association studies tend to use
SNPs as the marker of choice, because alleles of these
markers evolve more slowly than those of STRs and pre-
serve more of the evolutionary relationships on which
genetic association is based. SNPs can also be used for
linkage, but about ten times as many SNPs as STRs are
required to capture the linkage information. 
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Linkage
In marker genotype data from families, new combina-
tions of alleles at a series of markers on individual chro-
mosomes are observed in each generation. This recom-
bination of alleles is observed because there is at least
one physical exchange of material (or crossover)
between each homologous chromosome pair in every
meiosis (Figure 1). Recombination between loci on dif-
ferent chromosomes (because of independent assort-
ment of homologous chromosome pairs) or far apart on
the same chromosome (because of crossover at meiosis)
is observed 50% of the time. Linkage is observed
between loci in close proximity on a chromosome
because their alleles are separated by crossover less than
50% of the time. 
Mendelian diseases are caused by mutations in a single
gene at a single chromosomal location, so disease phe-
notypes can be treated as marker alleles in linkage
analysis. Because these illnesses are rare, for a dominant
disorder, the rare risk allele must segregate from one
parent (often affected or with family history) into
affected offspring, or arise as an even rarer de novo
mutation. By following the segregation of marker alle-
les from the affected lineage into offspring, linkage
between markers and phenotypes can be observed when
affected offspring inherit a particular set of marker alle-
les (and thus a specific parental chromosomal segment)
compared with their unaffected relatives.
Association
While linkage occurs in families, association is a popu-
lation-based phenomenon. Genetic association studies
test whether specific alleles at variable sites are more
common in individuals affected by a disease (cases) than
individuals not affected by the disease (controls). This
association between allele and phenotype can occur for
two reasons. Either the allele being studied directly influ-
ences risk for the disorder or, more commonly, the allele
is in linkage disequilibrium (LD) with the disease-pre-
disposing allele. Linkage disequilibrium means that spe-
cific alleles at two nearby loci tend to occur together in
an entire population. Linkage, (the cosegregation of a
chromosome region and a disease observed in families),
occurs at scales of tens of millions of base pairs because
of the limited number of recombinations observed in
each generation of a family. Association (and LD) are
seen at scales of thousands to tens of thousands of base
pairs, because the number of recombinations present in
the evolutionary history of a population is large, mean-
ing that the physical distances between loci in LD must
be correspondingly small if recombination is to occur
rarely (if ever) between them. 
LD occurs because a new allele always arises on a spe-
cific background chromosome (and its existing haplo-
type of marker alleles), and will, until separated by
recombination, only exist in conjunction with the other
alleles present on that background. Over time, the orig-
inal LD (and thus the genetic association) between more
distant loci decays as a result of recombination events,
while the rarity of recombination between nearby loci
preserves the original LD and association. Association
can also be detected spuriously, eg, if observed differ-
ences in allele frequency are due to population differ-
ences rather than to true association between marker
and phenotype. Association approaches are also sub-
stantially reduced in power in the presence of allelic het-
erogeneity (the existence of more than one risk allele at
a locus), while this phenomenon has no effect on the
detection of linkage.
Challenges associated with gene identification in psy-
chiatric and substance-use disorders
A number of features of psychiatric and behavioral phe-
notypes contribute to an overall reduction in study
power. Association is more powerful, generally for
detecting genes of small effect,39 but the specific features
of psychiatric and behavioral phenotypes also reduce the
power of association studies. 
First, psychiatric phenotypes are almost certainly influ-
enced by multiple common alleles of small effect in many
genes. Both linkage and association study designs are
more powerful for alleles of large effect size, and are
much less powerful when examining highly polygenic
phenotypes. Replication studies are hampered by the
need for sample sizes larger than the discovery sample
(in order to maintain power) and stochastic sampling
variation, the expected variation in the extent to which
any specific risk factor is present (and association
detectable) in any particular sample. 
Second, interactions between genes (GxG) or between
genes and environmental variables (GxE) seem necessary
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to account for observed risks, but we rely heavily on ana-
lytic approaches that assess single genes. In a few cases,
genes with known molecular interactions with the can-
didates have also generated replicated association.
Environmental risk factors remain largely unknown and
are difficult or very expensive to test in many samples. 
Third, these phenotypes are common, so the liability alle-
les seem likely to be common, although increased rates of
rare deletions and duplications (structural or copy num-
ber variants) in cases have been observed multiple times
and suggest that rare variation may also contribute to
risk in a proportion of cases. The common risk variants
are expected to occur with relatively high frequency in
the general population, reducing contrast between
affected and unaffected individuals and reducing power.
The impact of individual rare structural variants in the
subset of cases where they are observed is harder to
assess currently, but the observation of an aggregate
increase appears robust, further increasing the apparent
etiological complexity. 
Fourth, the expected frequency of risk alleles and the
clinical variability in presentation, course, and outcome
suggest that the etiology of individual cases may be het-
erogeneous, derived from different specific genes or alle-
les between individuals. Allelic heterogeneity substan-
tially reduces the power of association designs. 
Fifth, diagnostic boundaries are difficult to draw, and the
best phenotype to study is a complex choice. It is criti-
cally important to consider this last point and the phe-
notypes that yield the strongest evidence in some detail. 
An example: schizophrenia
gene identification
Through 2004, 25 complete or nearly complete genome
scans for schizophrenia (in which about 400 individual
genetic markers are genotyped at regular intervals over
the entire human genome) were published (for review
see refs 40,41). None provided evidence for genes of
major effect. Some linkage regions were replicated in
these studies, and a number of promising genes emerged
from sequential linkage and association studies and mul-
tiple replication reports. We focus here on those regions
with the best replication record and with evidence
emerging from other contemporary studies: 22q12-q13,
8p22-p21, 6p24-p22, and 1q32-42. Two additional regions
with little support in the primary literature, 2p11.1-q21.1
and 3p25.3-p22.1, were among the most significant in a
meta-analysis of schizophrenia genome scans. A number
of other regions (including 5q22-q31 and 15q13-q14)
have less strong summary evidence but also overlap with
evidence from more recent GWAS and structural varia-
tion studies. 
Chromosome 22q, the VCFS microdeletion, 
and COMT
Chromosome 22q has been widely studied using many
different designs. Primary linkage signals were observed
in a few samples but have generally been widely repli-
cated. However, the cosegregation of a known
microdeletion in the region with a phenotype in which
psychosis is a common feature added significantly to
interest in this region. Velo-cardio-facial syndrome
(VCFS) is caused by two overlapping, recurrent dele-
tions at 22q11. Historically, about 10% of VCFS patients
were thought to present with a psychotic phenotype, but
more recent studies suggest much higher rates of 25%
to 29%.42,43 Conversely, preliminary results suggest that
about 2% of adult onset and 6% of childhood onset
schizophrenic patients have microdeletions in this
region, in excess of the estimated general population fre-
quency of such deletions of 0.025%.44 Interest in this
region has been further increased recently by studies
assessing structural variation (see below). The gene for
catechol-O-methyl transferase (COMT), involved in the
degradation of catecholamines, maps to this region; the
enzyme is functionally polymorphic with a variable
amino acid, Val158Met, affecting activity. Although
widely studied, the results from genetic studies of
COMT are inconclusive as reviewed recently.45
Chromosome 8p22-p21, NRG1, and ERBB4
Studies of pedigrees from numerous different ethnic
backgrounds have detected linkage to schizophrenia on
8p, as did a statistically robust meta-analysis.46 Although
numerous samples support a locus on 8p, comparison
between individual studies is consistent with the pres-
ence of multiple susceptibility genes, a feature of a num-
ber of linkage regions. Almost certainly the most impor-
tant result on 8p so far is the widely replicated
association with the neuregulin 1 (NRG1) gene in fami-
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lies and case/controls from Iceland.47 NRG1 is a large
gene with multiple transcripts yielding distinct protein
molecules. It is expressed at central nervous system
synapses and is involved in the expression and activation
of neurotransmitter (including glutamate) receptors.
Initial replication studies48,49 detected association on hap-
lotypes identical or closely related to those identified in
the Icelandic cases; 13 additional studies in multiple pop-
ulations reported association with more variation in
associated alleles or haplotypes,50-62 while nine studies did
not.63-71 A meta-analysis of studies of NRG1 supported
involvement of the gene in schizophrenia liability, but
did not provide evidence supporting association of the
most prominent marker in the original studies.72 In a pat-
tern observed for a number of the best supported schiz-
ophrenia genes, several studies have also shown associ-
ation between NRG1 and bipolar disorder.62,73,74
ErbB4, encoded by the ERBB4 gene, is a receptor for
NRG1 and has important roles in neurodevelopment
and the modulation of NMDA receptor functioning.
Both activation of ErbB4 and suppression of NMDA
receptor activation by NRG1 are increased in the pre-
frontal cortex in individuals with schizophrenia com-
pared with controls.75 This functional relationship
prompted genetic study of ERBB4, which demonstrated
association in ERBB4 and evidence of interaction with
NRG1.59,76-78 Associated alleles in ERBB4 alter splice-
variant expression79 and both NRG1 and ErbB4 protein
are increased in the brain in schizophrenia. These results
may be of particular importance as there is a biologically
plausible mechanism for gene x gene interactions, and
even if the interaction is not confirmed, both genes
impact the glutamatergic system (supporting the widely
held view that part of the complexity may be explained
by effects at the level of the pathway or system).
Important tests of both interaction and system effects
unbiased by candidate selection will be undertaken in
the current GWAS datasets.
Chromosome 6p24-p22, DTNBP1, and the 
HLA region
Chromosome 6 has a long history in genetic studies of
schizophrenia with major shifts in the apparent impor-
tance of particular results. Early linkage studies observed
evidence of linkage in human leukocyte antigen (HLA)
genes in the major histocompatibility complex (MHC)
region on chromosome 6p21.3-22.1, but the limited
genome coverage (only ~6%) and lack of replication
reduced the apparent importance of these findings. The
first strong evidence for linkage of schizophrenia to the
6p region came from studies of Irish families with a high
density of disease.80 This study was also important
because it addressed the question of diagnostic bound-
aries in some detail. Evidence for linkage was modest
under a narrow diagnostic model, increased substantially
as the diagnostic definition broadened to include psy-
chosis spectrum disorders, and fell when the definition
was broadened further to include nonspectrum disor-
ders, in keeping with observed risks in relatives for these
traits. Multiple independent studies of this region of 6p
observed evidence for linkage, as did a multicenter col-
laborative study81 and a robust meta-analysis.46
The dystrobrevin binding protein 1 or dysbindin
(DTNBP1) gene was first reported to be associated in
the same Irish families.82,83 Many studies support associ-
ation in DTNBP1 in samples from diverse ethnic back-
grounds although the markers, alleles and haplotypes
associated vary significantly from study to study: 13 stud-
ies of 15 independent samples reported significant pos-
itive association with schizophrenia (most consistently
with common alleles and the highest frequency common
allele haplotype),70,82-93 while 14 studies of 18 independent
samples did not.61,63,85,94-104 A further four studies have also
provided positive evidence for association of DTNBP1
with bipolar disorder.105-108 Although the function of
DTNBP1 in brain is unknown, both RNA109 and pro-
tein110 expression is reduced in cases. 
Chromosome 1q and DISC1
Interest in chromosome 1 in schizophrenia began with
reports of a balanced 1:11 translocation segregating with
serious mental illness in a large pedigree from
Scotland.111 The chromosome 1 breakpoint lies at 1q42.1,
and the breakpoint directly disrupts a novel gene,
Disrupted in Schizophrenia 1 (DISC1).112 There are now
nine positive reports of association of DISC1 with schiz-
ophrenia74,113-120 and 2 of association with positive symp-
toms121,122 suggesting that this gene influences schizo-
phrenia liability in the general population, as well as in
the family with the chromosomal anomaly. Other rare
variants in this gene besides the breakpoint have also
been reported to be associated with schizophrenia123,124
and association has been reported for additional psy-
chiatric diagnoses, reviewed in ref 125, and for bipolar
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disorder.126 A smaller number of negative reports have
also been published.103,127-130
Other chromosomal regions and genes
Two additional chromosome regions, 5q22-q31, where
association was recently reported in the interleukin-3
(IL3) gene131 and 15q13-q14, where evidence for linkage
of an evoked potential abnormality common in
patients132 was supported by five additional studies
reporting linkage of schizophrenia to the same narrow
region,133-137 show some overlap with the results of cur-
rent studies discussed below. Other high-profile candi-
date genes such as PRODH2 on 22q138 and PPP3CC on
8p139 have not replicated well. One exception is AKT1,140
which has similar numbers of positive141-145 and nega-
tive61,103,146-149 replications.
Genome-wide association studies
By assaying 500 000 to 1 000 000 DNA variants in a sin-
gle experiment, GWAS provide unbiased genome-wide
coverage, avoiding selection of candidate genes. They use
an association framework for analysis, avoiding the
weaknesses of linkage in complex traits. They impose
stringent criteria due to the number of tests performed
(typically around P<5 x 10-8 for genome-wide signifi-
cance). They hold enormous potential to move beyond
the identification of single genes (which may show small
effects and be difficult to detect individually) toward the
simultaneous identification of multiple genes through
their interactions or involvement in systems.
Seven GWAS of schizophrenia have been published to
date, four of which were small and underpowered. The
first (320 cases, 325 controls) was of limited density as it
genotyped only 25 000 SNPs in 14 000 known genes, and
did not detect any association that reached genome-wide
significance150; nominal association was reported in the
plexin A2 (PLXNA2) gene. Only one of four samples
tested in three independent studies replicates the asso-
ciation.151-153 The second (extremely underpowered with
178 cases, 144 controls) identified one genome-wide sig-
nificant association in the X/Y pseudoautosomal region
(a homologous region of the sex chromosomes where
recombination can occur), near the interleukin 3 recep-
tor (IL3R) gene.154 Cytokines have been suggested as
possible candidates previously and IL3 (in the 5q link-
age region) was associated with schizophrenia in one
study.131 One replication attempt supported association
in IL3R.155 The third, using the CATIE156 sample (738
cases, 733 controls), did not detect any genome-wide sig-
nificant results in its primary analysis.157 The fourth, using
a multistage design of discovery (479 cases, 2937 con-
trols) and targeted replication (6666 cases, 9897 controls)
samples, identified one genome-wide significant SNP in
the zinc-finger protein transcription factor ZNF804A
gene,158 but only in the meta-analysis including the orig-
inal sample. One independent replication attempt sup-
ported the association of ZNF804A, and showed that
expression was increased from the associated haplo-
type.159
Three substantially larger GWAS of schizophrenia were
published in 2009, in the SGENE+ sample160 (multiple
European sites, 2663 cases/13498 controls), the
International Schizophrenia Consortium (ISC) sample161
(multiple European sites, 3322 cases/3587 controls) and
the Molecular Genetics of Schizophrenia (MGS) sam-
ple162 (multiple US sites, European ancestry: 2681
cases/2653 controls; African ancestry: 1286 cases/973
controls), analyzed both separately and together. The
one region of the genome with significant overlap in sig-
nals from the 3 studies was the MHC region on chro-
mosome 6p21.3-p22.1, site of some of the earliest genetic
evidence in schizophrenia discussed above. The
SGENE+ sample detected significant association with
several markers spanning the MHC region, as well as
signals upstream of the neurogranin (NRGN) gene on
11q24.2 and in intron four of the transcription factor 4
(TCF4) gene on 18q21.2. The ISC sample detected asso-
ciation in ~450 SNPs spanning the MHC region and the
myosin XVIIIB (MYO18B) gene on 22q and supported
ZNF804A. The MGS sample did not detect any individ-
ual genome-wide significant signals, but detected signals
in the range of 10-5-10-7 in the CENTG2 gene (reported
deleted in autism cases163) on chromosome 2q37.2 and
JARID2 (the gene adjacent to DTNBP1) in European-
ancestry subjects, and in ERBB4 and NRG1 in African-
American subjects. 
Meta-analysis of data from all European-ancestry MGS,
ISC and SGENE samples detected genome-wide signif-
icant association signals for 7 SNPs spanning 209 Kb of
the MHC region. LD is high between the 7 SNPs and
extends over a region of 1.5 Mb on chromosome 6p22.1,
making it difficult to determine if the signal is driven by
one or many genes. The genic content of this region is not
limited to histocompatibility loci, and also includes genes
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involved in transcriptional regulation, DNA repair, chro-
matin structure, G-protein-coupled-receptor signaling
and the nuclear pore complex. 
Meta-analyses of schizophrenia linkage and 
association data
The strongest linkage meta-analysis approach ranks 30 cM
bins of the genome from most positive to least positive for
each study, and then sums the ranks for each bin.
Significance levels are calculated by simulation, and this
method can identify regions of the genome where modest
positive results occur across many studies. Results of this
approach supported linkage to chromosomes 6p and 8p
among the previously identified regions discussed above.46
The strongest evidence for a potential locus was on chro-
mosome 2p11.1-q21.1, a region suggested by only a few
studies and not widely followed up, and on 3p, the site of
an early linkage finding that could never be replicated. 
A recent effort has been made to systematize the collec-
tion and archiving of association data from studies of schiz-
ophrenia, and to provide a framework for continuous
updating of both the data and the meta-analytic results164
in the SzGene database (http://www.szgene.org/). Meta-
analyses of the data contained in this resource provided
support of varying degrees for 24 SNPs in 16 previously
reported genes, including older candidate genes (eg,
dopamine receptor 2 (DRD2) gene, those resulting from
association-based follow-up of linkage data (eg, DTNBP1)
and one suggested by one of the smaller GWAS
(PLXNA2). Meta-analyses of schizophrenia GWAS data
from at least 15 000 cases and 15 000 controls are sched-
uled for completion in 2010.
Rare structural variation in schizophrenia
The epidemiological and genetic data above seems most
consistent with the common disease/common variant
hypothesis of the genetic risks for complex traits and the
results of GWAS in other complex traits like type 2 dia-
betes provided a major validation of this model.165-168 The
alternative common disease/rare variant hypothesis of
genetic risks for complex traits has been proposed in
schizophrenia,169 largely based on the reduction in fertil-
ity observed in cases. A key focus of research in this area
has been the deletions, duplications, and inversions of a
few thousand (Kb) to a few million (Mb) base pairs col-
lectively known as structural variants, an area of intense
research interest generally since 2004,170-172 reviewed in
ref 173. As a class, these genomic rearrangements are
common: ~360 Mb or 12% of the genome is included in
structural variation.174 A few such variants occur at high
frequency due to apparent selection in certain con-
texts,175,176 but studies of large samples consistently show
that the majority of structural variants are rare (~50%
detected in only one individual).174
The aggregate rate of such rare structural variants is sig-
nificantly increased in individuals with schizophrenia in
all four studies that have examined this question.177-180
Critically, there is substantial overlap in the regions
where excess structural variation is observed, most
notably on chromosomes 22q11, 15q13.3 and 1q21.1,
with some evidence that neurodevelopmental genes are
overrepresented, as in181 and more recently on 16p11.2.182
However, even considered in aggregate, structural vari-
ants are observed in only 15% of schizophrenia cases,
and so cannot account for a substantial fraction of the
total population risk. Because they are rare, the true
impact of individual structural variants on schizophre-
nia is difficult to validate and interpret, although the
replication of excess structural variation in cases on
chromosomes 22q11, 15q13.3, and 1q21.1 is extremely
encouraging.
Summary of current gene-finding studies
At both the technical/molecular and statistical/concep-
tual levels, the science of gene discovery in complex dis-
ease genetics is moving rapidly. By the time this paper is
published, new developments are sure to have arisen. As
is common in science in the state of rapid flux, the direc-
tion ahead is far from clear. How will the modest but
hard-fought advances obtained in more traditional posi-
tional cloning and candidate gene work integrate with
the new findings from GWAS? How will the common-
variant SNP-based approach inter-relate with the emerg-
ing rare-variant copy number variant findings? Will
advances in phenotypic assessment or endophenotypes
provide critical new insights? How will the burgeoning
fields of bioinformatics, expression arrays, and pro-
teomics impact on our gene-finding efforts? 
One emerging consensus is that the field needs to move
from a “gene-centric” approach toward one that consid-
ers “gene networks.” For example, many of the candidate
genes discussed above are involved in glutamatergic
neurotransmission, which may be an important systemic
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element in the etiology of schizophrenia. Although a
detailed discussion of this theory is outside the scope of
this summary, recent reviews of the genetic183 and neu-
roscience184 data and evidence from other studies high-
light the positions of the gene products of NRG1,
COMT, and possibly DTNBP1 among others, in the bio-
chemical and functional pathways influencing the gluta-
matergic system. Many other possible networks may be
involved in the etiology of schizophrenia that, if prop-
erly articulated, could aid in our gene-discovery efforts. 
Conclusion
We have attempted in this article to review the rapidly
evolving field of psychiatric genetics. In the section on
genetic epidemiology, we took a conceptual approach
focusing on a range of the most interesting questions
now being confronted by the field, with the goal of giv-
ing the reader a “feel” for the issues. While examining
a wide range of disorders, we focused on substance use
and externalizing disorders because they clearly illus-
trated the points we wanted to make. In the section on
gene-finding, we decided it would be more useful to
“drill down” and illustrate our important themes by
focusing on one disorder—schizophrenia. 
The major theme that cuts across these two sections is
the complexity of the pathways from genetic variation
to psychiatric and substance use disorders. Results of the
last 20 years have shown that the early prior simple
hypothesis of large effect genes that directly causes psy-
chiatric illness was seriously misplaced. We now know
that multiple gene variants (as well as—for at least some
disorders—genomic rearrangements) are involved at the
DNA level. These genetic risk factors then act and inter-
act with each other and with the environment in a com-
plex developmental “dance” to produce individuals at
high versus low risk of illness. It is this kind of complex-
ity that the field is now confronting directly.
As one might hope, progress is being made in multiple
ways. The field that is moving downward—in a reduction-
ist sense—to more detailed biological mechanisms at the
DNA, RNA, and protein levels. These efforts are being dri-
ven by rapid technological advances. However, we are
straining to develop the conceptual and analytic tools to
keep pace with the information generated by these new
generation technologies. At the same time, the field is mov-
ing out into the environment to clarify the often critical
inter-relationship between these two broad classes of risk
factors. Equally importantly, it is moving “forward” in
emphasizing the importance of time and development. 
This can all be confusing and sometimes a bit overwhelm-
ing. In a desire to simplify, some, in the “glow” of the new
biological tools now available, have devalued the genetic
epidemiologic approaches. These approaches, they suggest,
focus on “statistics” but not “real genes.” However, knowl-
edge gained from genetic epidemiology, in addition to pro-
vide a guiding light for molecular approaches, also have
their own inherent validity. Studying aggregate genetic risk
factors allows us to build etiologic models that can inform
prevention efforts, aid policy makers in planning for
research programs, and provide critical input into revisions
of psychiatric nosology. 
We would like to close by emphasizing that knowledge
about the role of genetic factors in the etiology of psy-
chiatric illness can be profitably understood from sev-
eral perspectives. The human mind/brain system—the
organ that instantiates psychiatric illness—is surely influ-
enced by processes occurring at the levels of basic mol-
ecular biology, neural systems and networks, and psy-
chological, social, and cultural processes.185 A full
understanding of the processes whereby genetic risks
lead to the development of psychiatric disorders will
surely require considering all these perspectives, each of
which contributes a useful viewpoint with methodolo-
gies that have important (and different) strengths and
limitations. 
S t a t e  o f  t h e  a r t
REFERENCES
1. Kendler KS, Baker JH. Genetic influences on measures of the environ-
ment: a systematic review. Psychol Med. 2007;37:615-626.
2. Harden KP, Hill JE, Turkheimer E, Emery RE. Gene-environment corre-
lation and interaction in peer effects on adolescent alcohol and tobacco
use. Behav Genet. 2008;38:339-347.
3. Hill J, Emery RE, Harden KP, Mendle J, Turkheimer E. Alcohol use in
adolescent twins and affiliation with substance using peers. J Abnorm Child
Psychol. 2008;36:81-94.
4. Dick DM, Pagan JL, Holliday C, et al. Gender differences in friends'
influences on adolescent drinking: a genetic epidemiological study.
Alcoholism: Clin Exp Res. 2007;31: 2012-2019. 
5. Kendler KS, Jacobson KC, Gardner CO, Gillespie N, Aggen SA, Prescott
CA. Creating a social world: a developmental twin study of peer-group
deviance. Arch Gen Psychiatry. 2007;64:958-965.
6. Kendler KS, Neale M, Kessler R, Heath A, Eaves L. A twin study of
recent life events and difficulties. Arch Gen Psychiatry. 1993;50:789-796.
7. Plomin R, Lichtenstein P, Pedersen NL, McClearn GE, Nesselroade JR.
Genetic influence on life events during the last half of the life span. Psychol
Aging. 1990;5:25-30.
DCNS_44_5.qxd:DCNS#44  10/03/10  1:44  Page 18
Nature and nurture in neuropsychiatric genetics - Dick et al Dialogues in Clinical Neuroscience - Vol 12 . No. 1 . 2010
Lo innato y lo adquirido en la genética 
neuropsiquiátrica: ¿dónde estamos? 
Se piensa que los factores de riesgo tanto genéticos
como no genéticos, al igual que las interacciones y
correlaciones entre ellos contribuyen a la etiología
de los fenotipos psiquiátricos y conductuales. La
epidemiología genética confirma consistentemente
la participación de genes en estos defectos. Los
estudios de genética molecular han resultado
menos exitosos en la identificación de genes defec-
tuosos, pero el progreso reciente sugiere que se ha
identificado un número de genes específicos que
contribuyen al riesgo. En  conjunto los resultados
son complejos e inconsistentes, al considerar una
sola variante común de ADN en algún gen que
influya en el riesgo en poblaciones humanas. Son
pocas las variantes genéticas específicas que influ-
yen en el riesgo que se han identificado en forma
inequívoca. Sin embargo, las aproximaciones actua-
les son prometedoras respecto a dilucidar más
genes y variantes defectuosas, como también sus
potenciales interrelaciones entre ellos y con el
ambiente. Se revisarán los campos de la genética
molecular y de la epidemiología genética, apor-
tando ejemplos de la literatura para ilustrar los con-
ceptos clave que surgen de este trabajo.  
L’inné et l’acquis en génétique 
neuropsychiatrique : où en sommes-nous ?
Des facteurs de risque génétiques et non géné-
tiques, et leurs interactions et leurs corrélations
mutuelles, participeraient à l’étiologie des phéno-
types psychiatriques et comportementaux.
L’implication  des gènes de susceptibilité est régu-
lièrement confirmée par l’épidémiologie génétique.
Des études de génétique moléculaire ont été moins
heureuses dans l’identification des gènes de sus-
ceptibilité, mais des progrès récents suggèrent que
plusieurs gènes spécifiques participant au risque ont
été identifiés. Pris collectivement, les résultats sont
complexes et contradictoires avec un variant ADN
unique présent dans un gène,  influant sur le risque
à travers les populations humaines. Les variants
génétiques spécifiques influant sur le risque sont
peu nombreux à avoir été identifiés sans ambiguïté.
Les approches actuelles sont cependant très pro-
metteuses pour l’identification future des gènes de
susceptibilité et de leurs variants, de leurs interre-
lations éventuelles les uns avec les autres et avec
l’environnement. Dans cette revue, nous analyse-
rons les domaines de l’épidémiologie génétique et
de la génétique moléculaire, des exemples de la lit-
térature illustrant les idées phares de notre travail.
8. Kendler KS, Karkowski-Shuman L. Stressful life events and genetic lia-
bility to major depression: genetic control of exposure to the environ-
ment? Psychol Med. 1997;27:539-547.
9. Dick DM, Viken R, Purcell S, Kaprio J, Pulkkinen L, Rose RJ. Parental
monitoring moderates the importance of genetic and environmental
influences on adolescent smoking. J Abnorm Psychol. 2007;116:213-218.
10. Koopmans JR, Slutske WS, van Baal GC, Boomsma DI. The influence of
religion on alcohol use initiation: evidence for genotype X environment
interaction. Behav Genet. 1999;29:445-453.
11. Dick DM, Rose RJ, Viken RJ, Kaprio J, Koskenvuo M. Exploring gene-
environment interactions: Socioregional moderation of alcohol use. J
Abnorm Psychol. 2001;110:625-632.
12. Boardman JD. State-level moderation of genetic tendencies to smoke.
Am J Public Health. 2009;99:480-486.
13. Kendler KS, Neale MC, Kessler RC, Heath AC, Eaves LJ. Major depres-
sion and generalized anxiety disorder: Same genes, (partly) different envi-
ronments? Arch Gen Psychiatry. 1992;49:716-722.
14. Kendler KS, Prescott CA, Myers J, Neale MC. The structure of genetic
and environmental risk factors for common psychiatric and substance use
disorders in men and women. Arch Gen Psychiatry. 2003;60:929-937.
15. Krueger RF. The structure of common mental disorders. Arch Gen
Psychiatry. 1999;56:921-926.
16. Vollebergh WAM, Iedema J, Bijl RV, de Graaf R, Smit F, Ormel J. The
structure and stability of common mental disorders - The NEMESIS Study.
Arch Gen Psychiatry. 2001;58:597-603.
17. Pagan JL, Rose RJ, Viken RJ, Pulkkinen L, Kaprio J, Dick DM. Genetic
and environmental influences on stages of alcohol use across adolescence
and into young adulthood. Behavior Genetics. 2006;36:483-497.
18. Kendler KS, Schmitt E, Aggen SH, Prescott CA. Genetic and environ-
mental influences on alcohol, caffeine, cannabis, and nicotine use from early
adolescence to middle adulthood. Arch Gen Psychiatry. 2008;65:674-682.
19. Pickens RW, Svikis DS, McGue M, Lykken DT, Heston LL, Clayton PJ.
Heterogeneity in the inheritance of alcoholism. Arch Gen Psychiatry.
1991;48:19-28.
20. Johnson EO, van den Bree MB, Pickens RW. Subtypes of alcohol-
dependent men: a typology based on relative genetic and environmental
loading. Alcoholism: Clin Exp Res. 1996;20:1472-1480.
21. Kendler KS, Eaves LJ, Walters EE, Neale MC, Heath AC, Kessler RC. The
identification and validation of distinct depressive syndromes in a popula-
tion-based sample of female twins. Arch Gen Psychiatry. 1996;53:391-399.
22. Bergen SE, Gardner CO, Kendler KS. Age-related changes in heritabil-
ity of behavioral phenotypes over adolescence and young adulthood: a
meta-analysis. Twin Res Hum Genet. 2007;10:423-433.
23. Haworth CM, Wright MJ, Luciano M, et al. The heritability of general
cognitive ability increases linearly from childhood to young adulthood.
Mol Psychiatry. In press.
24. Kendler KS, Gardner CO, Annas P, Neale MC, Eaves LJ, Lichtenstein P.
A longitudinal twin study of fears from middle childhood to early adult-
hood: evidence for a developmentally dynamic genome. Arch Gen
Psychiatry. 2008;65:421-429.
DCNS_44_5.qxd:DCNS#44  10/03/10  1:44  Page 19
S t a t e  o f  t h e  a r t
25. Kendler KS, Gardner CO, Lichtenstein P. A developmental twin study
of symptoms of anxiety and depression: evidence for genetic innovation
and attenuation. Psychol Med. 2008;38:1567-1575.
26. Kendler KS, Gatz M, Gardner C, Pedersen N. A Swedish national twin
study of lifetime major depression. Am J Psychiatry. 2006;163:109-114.
27. Prescott CA, Aggen SH, Kendler KS. Sex differences in the sources of
genetic liability to alcohol abuse and dependence in a population-based
sample of U.S. twins. Alcohol Clin Exp Res. 1999;23:1136-1144.
28. Kendler KS. Gender differences in the genetic epidemiology of major
depression. J Gend Specif Med. 1998;1:28-31.
29. Dick DM, Aliev F, Wang JC, et al. Using dimensional models of exter-
nalizing psychopathology to aid in gene identification. Arch Gen Psychiatry.
2008;65:310-318.
30. Hettema JM, An SS, Neale MC, et al. Association between glutamic
acid decarboxylase genes and anxiety disorders, major depression, and
neuroticism. Mol Psychiatry. 2006;11:752-762.
31. Slutske WS, Heath AC, Dinwiddle SH, et al. Common genetic risk factors
for conduct disorder and alcohol dependence. J Abn Psychol 1998;107:363-374.
32. Edenberg HJ, Dick DM, Xuei X, et al. Variations in GABRA2, encoding
the a2 subunit of the GABA-A receptor are associated with alcohol depen-
dence and with brain oscillations. Am J Hum Genet. 2004;74:705-714.
33. Wang JC, Hinrichs AL, Stock H, et al. Evidence of common and specif-
ic genetic effects: Association of the muscarinic acetylcholine receptor M2
(CHRM2) gene with alcohol dependence and major depressive syndrome.
Hum Mol Genet. 2004;13:1903-1911.
34. Dick DM, Latendresse SJ, Lansford JE, et al. The role of GABRA2 in tra-
jectories of externalizing behavior across development and evidence of
moderation by parental monitoring. Arch Gen Psychiatry. 2009;66:649-657.
35. Latendresse SJ, Bates J, Goodnight JA, et al. Differential susceptibility
to discrete patterns of adolescent externalizing behavior: examining the
interplay between CHRM2 and Peer group deviance. Child Dev. 2009. In
press.
36. Dick DM, Bierut L, Hinrichs AL,et al. The role of GABRA2 in risk for
conduct disorder and alcohol and drug dependence across developmental
stages. Behavior Genetics. 2006;36:577-590.
37. Dick DM, Pagan JL, Viken R, et al. Changing environmental influences
on substance use across development. twin research and human genetics
2007;10:315-326. 
38. Button TM, Corley RP, Rhee SH, Hewitt JK, Young SE, Stallings MC.
Delinquent peer affiliation and conduct problems: a twin study. J Abnorm
Psychol. 2007;116:554-564.
39. Risch N, Merikangas K. The future of genetic studies of complex
human diseases. Science. 1996;273:1516-1517.
40. Riley BP, McGuffin P. Linkage and associated studies of schizophrenia.
Am J Med Genet Sem Med Genet. 2000;97:23-44.
41. Sullivan PF. The genetics of schizophrenia. PLoS Med. 2005;2:e212.
42. Murphy KC, Jones LA, Owen MJ. High rates of schizophrenia in adults
with velo-cardio-facial syndrome. Arch Gen Psychiatry. 1999;56:940-945.
43. Pulver AE, Nestadt G, Goldberg R, et al. Psychotic illness in patients
diagnosed with velo-cardio-facial syndrome and their relatives. J Nerv Ment
Dis. 1994;182:476-478.
44. Karayiorgou M, Morris MA, Morrow B, et al. Schizophrenia suscepti-
bility associated with interstitial deletions of chromosome 22q11. Proc Natl
Acad Sci U S A. 1995;92:7612-7616.
45. Williams HJ, Owen MJ, O'Donovan MC. Is COMT a susceptibility gene
for schizophrenia? Schizophr Bull. 2007;33:635-641.
46. Lewis CM, Levinson DF, Wise LH, et al. Genome scan meta-analysis of
schizophrenia and bipolar disorder, part II: Schizophrenia. Am J Hum Genet.
2003;73:34-48.
47. Stefansson H, Sigurdsson E, Steinthorsdottir V, et al. Neuregulin 1 and
susceptibility to schizophrenia. Am J Hum Genet. 2002;71:877-892.
48. Stefansson H, Sarginson J, Kong A, et al. Association of neuregulin 1
with schizophrenia confirmed in a Scottish population. Am J Hum Genet.
2003;72:83-87.
49. Corvin AP, Morris DW, McGhee K, et al. Confirmation and refinement
of an 'at-risk' haplotype for schizophrenia suggests the EST cluster,
Hs.97362, as a potential susceptibility gene at the Neuregulin-1 locus. Mol
Psychiatry. 2004;9:208-213.
50. Williams NM, Preece A, Spurlock G, et al. Support for genetic variation
in neuregulin 1 and susceptibility to schizophrenia. Mol Psychiatry.
2003;8:485-487.
51. Yang JZ, Si TM, Ruan Y, et al. Association study of neuregulin 1 gene
with schizophrenia. Mol Psychiatry. 2003;8:706-709.
52. Bakker SC, Hoogendoorn ML, Selten JP, et al. Neuregulin 1: genetic
support for schizophrenia subtypes. Mol Psychiatry. 2004;9:1061-1063.
53. Li T, Stefansson H, Gudfinnsson E, et al. Identification of a novel
neuregulin 1 at-risk haplotype in Han schizophrenia Chinese patients, but
no association with the Icelandic/Scottish risk haplotype. Mol Psychiatry.
2004;9:698-704.
54. Tang JX, Chen WY, He G, et al. Polymorphisms within 5' end of the
Neuregulin 1 gene are genetically associated with schizophrenia in the
Chinese population. Mol Psychiatry. 2004;9:11-12.
55. Zhao X, Shi Y, Tang J, et al. A case control and family based association
study of the neuregulin1 gene and schizophrenia. J Med Genet. 2004;41:31-34.
56. Petryshen TL, Middleton FA, Kirby A, et al. Support for involvement of
neuregulin 1 in schizophrenia pathophysiology. Mol Psychiatry.
2005;10:366-374.
57. Fukui N, Muratake T, Kaneko N, Amagane H, Someya T. Supportive
evidence for neuregulin 1 as a susceptibility gene for schizophrenia in a
Japanese population. Neurosci Lett. 2006;396:117-120.
58. Hall J, Whalley HC, Job DE, et al. A neuregulin 1 variant associated
with abnormal cortical function and psychotic symptoms. Nat Neurosci.
2006;9:1477-1478.
59. Norton N, Moskvina V, Morris DW, et al. Evidence that interaction
between neuregulin 1 and its receptor erbB4 increases susceptibility to
schizophrenia. Am J Med Genet B Neuropsychiatr Genet. 2006;141:96-101.
60. Thomson PA, Christoforou A, Morris SW, et al. Association of
Neuregulin 1 with schizophrenia and bipolar disorder in a second cohort
from the Scottish population. Mol Psychiatry. 2007;12:94-104.
61. Turunen JA, Peltonen JO, Pietilainen OP, et al. The role of DTNBP1,
NRG1, and AKT1 in the genetics of schizophrenia in Finland. Schizophr Res.
2007;91:27-36.
62. Georgieva L, Dimitrova A, Ivanov D, et al. Support for Neuregulin 1 as
a susceptibility gene for bipolar disorder and schizophrenia. Biol Psychiatry.
2008;64:419-427.
63. Hall D, Gogos JA, Karayiorgou M. The contribution of three strong
candidate schizophrenia susceptibility genes in demographically distinct
populations. Genes Brain Behav. 2004;3:240-248.
64. Iwata N, Suzuki T, Ikeda M, et al. No association with the neuregulin
1 haplotype to Japanese schizophrenia. Mol Psychiatry. 2004;9:126-127.
65. Thiselton DL, Webb BT, Neale BM, et al. No evidence for linkage or
association of neuregulin-1 (NRG1) with disease in the Irish study of high-
density schizophrenia families (ISHDSF). Mol Psychiatry. 2004;9:777-783.
66. Duan J, Martinez M, Sanders AR, et al. Neuregulin 1 (NRG1 ) and schiz-
ophrenia: analysis of a US family sample and the evidence in the balance.
Psychol Med. 2005;35:1599-1610.
67. Ingason A, Soeby K, Timm S, et al. No significant association of the 5'
end of neuregulin 1 and schizophrenia in a large Danish sample. Schizophr
Res. 2006;83:1-5.
68. Walss-Bass C, Raventos H, Montero AP, et al. Association analyses of
the neuregulin 1 gene with schizophrenia and manic psychosis in a
Hispanic population. Acta Psychiatr Scand. 2006;113:314-321.
69. Rosa A, Gardner M, Cuesta MJ, et al. Family-based association study of
neuregulin-1 gene and psychosis in a Spanish sample. Am J Med Genet B
Neuropsychiatr Genet. 2007;144B:954-957.
70. Vilella E, Costas J, Sanjuan J, et al. Association of schizophrenia with
DTNBP1 but not with DAO, DAOA, NRG1 and RGS4 nor their genetic inter-
action. J Psychiatr Res. 2008;42:278-288.
71. Ikeda M, Takahashi N, Saito S, et al. Failure to replicate the association
between NRG1 and schizophrenia using Japanese large sample. Schizophr
Res. 2008;101:1-8.
72. Munafo MR, Thiselton DL, Clark TG, Flint J. Association of the NRG1
gene and schizophrenia: a meta-analysis. Mol Psychiatry. 2006;11:539-546.
73. Green EK, Raybould R, Macgregor S, et al. Operation of the schizophre-
nia susceptibility gene, neuregulin 1, across traditional diagnostic boundaries
to increase risk for bipolar disorder. Arch Gen Psychiatry. 2005;62:642-648.
DCNS_44_5.qxd:DCNS#44  10/03/10  1:44  Page 20
Nature and nurture in neuropsychiatric genetics - Dick et al Dialogues in Clinical Neuroscience - Vol 12 . No. 1 . 2010
74. Thomson PA, Wray NR, Millar JK, et al. Association between the
TRAX/DISC locus and both bipolar disorder and schizophrenia in the
Scottish population. Mol Psychiatry. 2005;10:657-668.
75. Hahn CG, Wang HY, Cho DS, et al. Altered neuregulin 1-erbB4 signal-
ing contributes to NMDA receptor hypofunction in schizophrenia. Nat
Med. 2006;12:824-828.
76. Nicodemus KK, Luna A, Vakkalanka R, al. Further evidence for associ-
ation between ErbB4 and schizophrenia and influence on cognitive inter-
mediate phenotypes in healthy controls. Mol Psychiatry. 2006;11:1062-1065.
77. Silberberg G, Darvasi A, Pinkas-Kramarski R, Navon R. The involve-
ment of ErbB4 with schizophrenia: association and expression studies. Am
J Med Genet B Neuropsychiatr Genet. 2006;141B:142-148.
78. Benzel I, Bansal A, Browning BL, et al. Interactions among genes in
the ErbB-Neuregulin signalling network are associated with increased sus-
ceptibility to schizophrenia. Behav Brain Funct. 2007;3:31.
79. Law AJ, Kleinman JE, Weinberger DR, Weickert CS. Disease-associated
intronic variants in the ErbB4 gene are related to altered ErbB4 splice-variant
expression in the brain in schizophrenia. Hum Mol Genet. 2007;16:129-141.
80. Straub RE, MacLean CJ, O'Neill FA, et al. A potential vulnerability locus
for schizophrenia on chromosome 6p24-22: Evidence for genetic hetero-
geneity. Nature Genetics. 1995;11:287-293.
81. Levinson DF, Wildenauer DB, Schwab SG, et al. Additional support for
schizophrenia linkage on chromosomes 6 and 8: A multicenter study. Am J
Med Genet Neuropsych Genet. 1996;67:580-594.
82. Straub RE, Jiang Y, MacLean CJ, et al. Genetic variation in the 6p22.3
gene DTNBP1, the human ortholog of mouse dysbindin, is associated with
schizophrenia. Am J Hum Genet. 2002;71:337-348.
83. van den Oord E, Sullivan PF, Chen X, Kendler KS, Riley B. Identification
of a high risk haplotype for the dystrobrevin binding protein 1 (DTNBP1)
gene in the Irish study of high density schizophrenia families. Mol
Psychiatry. 2003;8:499-510.
84. Schwab SG, Knapp M, Mondabon S, et al. Support for association of
schizophrenia with genetic variation in the 6p22.3 gene, dysbindin, in sib-
pair families with linkage and in an additional sample of triad families. Am
J Hum Genet. 2003;72:185-190.
85. Van Den Bogaert A, Schumacher J, Schulze TG, et al. The DTNBP1 (dys-
bindin) gene contributes to schizophrenia, depending on family history of
the disease. Am J Hum Genet. 2003;73:1438-1443.
86. Tang JX, Zhou J, Fan JB, Li XW, et al. Family-based association study of
DTNBP1 in 6p22.3 and schizophrenia. Mol Psychiatry. 2003;8:717-718.
87. Funke B, Finn CT, Plocik AM, et al. Association of the DTNBP1 locus
with schizophrenia in a U.S. population. Am J Hum Genet. 2004;75:891-898.
88. Kirov G, Ivanov D, Williams NM, et al. Strong evidence for association
between the dystrobrevin binding protein 1 gene (DTNBP1) and schizo-
phrenia in 488 parent-offspring trios from Bulgaria. Biol Psychiatry.
2004;55:971-975.
89. Numakawa T, Yagasaki Y, Ishimoto T, et al. Evidence of novel neuronal
functions of dysbindin, a susceptibility gene for schizophrenia. Hum Mol
Genet. 2004;13:2699-2708.
90. Williams NM, Preece A, Morris DW, et al. Identification in 2 indepen-
dent samples of a novel schizophrenia risk haplotype of the dystrobrevin
binding protein gene (DTNBP1). Arch Gen Psychiatry. 2004;61:336-344.
91. Li T, Zhang F, Liu X, et al. Identifying potential risk haplotypes for
schizophrenia at the DTNBP1 locus in Han Chinese and Scottish popula-
tions. Mol Psychiatry. 2005;10:1037-1044.
92. Tochigi M, Zhang X, Ohashi J, et al. Association study of the dysbindin
(DTNBP1) gene in schizophrenia from the Japanese population. Neurosci
Res. 2006;56:154-158.
93. Tosato S, Ruggeri M, Bonetto C, et al. Association study of dysbindin
gene with clinical and outcome measures in a representative cohort of
Italian schizophrenic patients. Am J Med Genet B Neuropsychiatr Genet.
2007;144B:647-659.
94. DeLuca V, Voineskos D, Shinkai T, Wong G, Kennedy JL. Untranslated
region haplotype in dysbindin gene: analysis in schizophrenia. J Neural
Transm. 2005;112:1263-1267.
95. Holliday EG, Handoko HY, James MR, et al. Association study of the
dystrobrevin-binding gene with schizophrenia in Australian and Indian
samples. Twin Res Hum Genet. 2006;9:531-539.
96. Joo EJ, Lee KY, Jeong SH, Ahn YM, Koo YJ, Kim YS. The dysbindin gene
(DTNBP1) and schizophrenia: no support for an association in the Korean
population. Neurosci Lett. 2006;407:101-106.
97. Liu CM, Liu YL, Fann CS, et al. No association evidence between schiz-
ophrenia and dystrobrevin-binding protein 1 (DTNBP1) in Taiwanese fam-
ilies. Schizophr Res. 2007;doi:10.1016/j.schres.2007.02.003.
98. Pedrosa E, Ye K, Nolan KA, et al. Positive association of schizophrenia
to JARID2 gene. Am J Med Genet B Neuropsychiatr Genet. 2007;144B:45-51.
99. Wood LS, Pickering EH, Dechairo BM. Significant support for DAO as
a schizophrenia susceptibility locus: examination of five genes putatively
associated with schizophrenia. Biol Psychiatry. 2007;61:1195-1199.
100.Bakker SC, Hoogendoorn ML, Hendriks J, Verzijlbergen K, Caron S,
Verduijn W, et al. The PIP5K2A and RGS4 genes are differentially associat-
ed with deficit and non-deficit schizophrenia. Genes Brain Behav.
2007;6:113-119.
101.Datta SR, McQuillin A, Puri V, et al. Failure to confirm allelic and hap-
lotypic association between markers at the chromosome 6p22.3 dystro-
brevin-binding protein 1 (DTNBP1) locus and schizophrenia. Behav Brain
Funct. 2007;3:50.
102.Peters K, Wiltshire S, Henders AK, et al. Comprehensive analysis of
tagging sequence variants in DTNBP1 shows no association with schizo-
phrenia or with its composite neurocognitive endophenotypes. Am J Med
Genet B Neuropsychiatr Genet. 2008;147B:1159-1166.
103.Sanders AR, Duan J, Levinson DF, et al. No significant association of 14
candidate genes with schizophrenia in a large European ancestry sample:
implications for psychiatric genetics. Am J Psychiatry. 2008;165:497-506.
104.Morris DW, McGhee KA, Schwaiger S, et al. No evidence for associa-
tion of the dysbindin gene [DTNBP1] with schizophrenia in an Irish popu-
lation-based study. Schizophr Res. 2003;60:167-172.
105.Fallin MD, Lasseter VK, Avramopoulos D, et al. Bipolar I disorder and
schizophrenia: a 440-single-nucleotide polymorphism screen of 64 candi-
date genes among Ashkenazi Jewish case-parent trios. Am J Hum Genet.
2005;77:918-936.
106.Breen G, Prata D, Osborne S, et al. Association of the dysbindin gene
with bipolar affective disorder. Am J Psychiatry. 2006;163:1636-1638.
107. Joo EJ, Lee KY, Jeong SH, et al. Dysbindin gene variants are associated
with bipolar I disorder in a Korean population. Neurosci Lett. 2007;418:272-275.
108.Pae CU, Serretti A, Mandelli L, et al. Effect of 5-haplotype of dysbindin
gene (DTNBP1) polymorphisms for the susceptibility to bipolar I disorder.
Am J Med Genet B Neuropsychiatr Genet. 2007;144B:701-703.
109.Weickert CS, Straub RE, McClintock BW, et al. Human dysbindin
(DTNBP1) gene expression in normal brain and in schizophrenic prefrontal
cortex and midbrain. Arch Gen Psychiatry. 2004;61:544-555.
110.Talbot K, Eidem WL, Tinsley CL, et al. Dysbindin-1 is reduced in intrin-
sic, glutamatergic terminals of the hippocampal formation in schizophre-
nia. J Clin Invest. 2004;113:1353-1363.
111.St Clair D, Blackwood D, Muir W, et al. Association within a family of
a balanced autosomal translocation with major mental illness. Lancet.
1990;336:13-16.
112.Millar JK, Wilson-Annan JC, Anderson S, et al. Disruption of two novel
genes by a translocation co-segregating with schizophrenia. Hum Mol
Genet. 2000;9:1415-1423.
113.Hennah W, Varilo T, Kestila M, et al. Haplotype transmission analysis
provides evidence of association for DISC1 to schizophrenia and suggests
sex-dependent effects. Hum Mol Genet. 2003;12:3151-3159.
114.Hodgkinson CA, Goldman D, Jaeger J, et al. Disrupted in schizophre-
nia 1 (DISC1): association with schizophrenia, schizoaffective disorder, and
bipolar disorder. Am J Hum Genet. 2004;75:862-872.
115.Callicott JH, Straub RE, Pezawas L, et al. Variation in DISC1 affects hip-
pocampal structure and function and increases risk for schizophrenia. Proc
Natl Acad Sci U S A. 2005;102:8627-8632.
116. Cannon TD, Hennah W, van Erp TG, et al. Association of DISC1/TRAX hap-
lotypes with schizophrenia, reduced prefrontal gray matter, and impaired
short- and long-term memory. Arch Gen Psychiatry. 2005;62:1205-1213.
117.Liu YL, Fann CS, Liu CM, et al. A single nucleotide polymorphism fine
mapping study of chromosome 1q42.1 reveals the vulnerability genes for
schizophrenia, GNPAT and DISC1: Association with impairment of sus-
tained attention. Biol Psychiatry. 2006;60:554-562.
DCNS_44_5.qxd:DCNS#44  10/03/10  1:44  Page 21
S t a t e  o f  t h e  a r t
118.Zhang F, Sarginson J, Crombie C, Walker N, St CD, Shaw D. Genetic
association between schizophrenia and the DISC1 gene in the Scottish
population. Am J Med Genet B Neuropsychiatr Genet. 2006;141:155-159.
119.Palo OM, Antila M, Silander K, et al. Association of distinct allelic hap-
lotypes of DISC1 with psychotic and bipolar spectrum disorders and with
underlying cognitive impairments. Hum Mol Genet. 2007;16:2517-2528.
120.Qu M, Tang F, Yue W, et al. Positive association of the Disrupted-in-
Schizophrenia-1 gene (DISC1) with schizophrenia in the Chinese Han pop-
ulation. Am J Med Genet B Neuropsychiatr Genet. 2007;144:266-270.
121.DeRosse P, Hodgkinson CA, Lencz T, et al. Disrupted in schizophrenia
1 genotype and positive symptoms in schizophrenia. Biol Psychiatry.
2007;61:1208-1210.
122.Szeszko PR, Hodgkinson CA, Robinson DG, , et al. DISC1 is associated
with prefrontal cortical gray matter and positive symptoms in schizophre-
nia. Biol Psychol. 2007;79:103-110.
123. Sachs NA, Sawa A, Holmes SE, Ross CA, DeLisi LE, Margolis RL. A frameshift
mutation in Disrupted in Schizophrenia 1 in an American family with schizo-
phrenia and schizoaffective disorder. Mol Psychiatry. 2005;10:758-764.
124.Song W, Li W, Feng J, Heston LL, Scaringe WA, Sommer SS.
Identification of high risk DISC1 structural variants with a 2% attributable
risk for schizophrenia. Biochem Biophys Res Commun. 2008;367:700-706.
125.Hennah W, Thomson P, McQuillin A, et al. DISC1 association, hetero-
geneity and interplay in schizophrenia and bipolar disorder. Mol Psychiatry.
2008;14:865-873.
126.Perlis RH, Purcell S, Fagerness J, et al. Family-based association study
of lithium-related and other candidate genes in bipolar disorder. Arch Gen
Psychiatry. 2008;65:53-61.
127.Kockelkorn TT, Arai M, Matsumoto H, et al. Association study of poly-
morphisms in the 5' upstream region of human DISC1 gene with schizo-
phrenia. Neurosci Lett. 2004;368:41-45.
128.Zhang X, Tochigi M, Ohashi J, et al. Association study of the
DISC1/TRAX locus with schizophrenia in a Japanese population. Schizophr
Res. 2005;79:175-180.
129.Chen QY, Chen Q, Feng GY, et al. Case-control association study of
Disrupted-in-Schizophrenia-1 (DISC1) gene and schizophrenia in the
Chinese population. J Psychiatr Res. 2007;41:428-434.
130.Kim HJ, Park HJ, Jung KH, et al. Association study of polymorphisms
between DISC1 and schizophrenia in a Korean population. Neurosci Lett.
2008;430:60-63.
131.Chen X, Wang X, Hossain S, et al. Interleukin 3 and schizophrenia: the
impact of sex and family history. Mol Psychiatry. 2007;12:273-282.
132.Freedman R, Coon H, Myles-Worsley M, et al. Linkage of a neuro-
physiological deficit in schizophrenia to a chromosome 15 locus. Proc Natl
Acad Sci U S A. 1997;94:587-592.
133.Riley BP, Makoff A, Mogudi-Carter M, et al. Haplotype transmission
disequilibrium and evidence for linkage of the CHRNA7 gene region to
schizophrenia in southern African Bantu families. Am J Med Genet
Neuropsychiatric Genet. 2000;96:196-201.
134.Liu CM, Hwu HG, Lin MW, et al. Suggestive evidence for linkage of
schizophrenia to markers at chromosome 15q13-14 in Taiwanese families.
Am J Med Genet. 2001;105:658-661.
135.Tsuang DW, Skol AD, Faraone SV, et al. Examination of genetic link-
age of chromosome 15 to schizophrenia in a large Veterans Affairs
Cooperative Study sample. Am J Med Genet. 2001;105:662-668.
136.Xu J, Pato MT, Torre CD, et al. Evidence for linkage disequilibrium
between the alpha 7-nicotinic receptor gene (CHRNA7) locus and schizo-
phrenia in Azorean families. Am J Med Genet. 2001;105:669-674.
137.Gejman PV, Sanders AR, Badner JA, Cao Q, Zhang J. Linkage analysis
of schizophrenia to chromosome 15. Am J Med Genet. 2001;105:789-793.
138.Liu H, Heath SC, Sobin C, et al. Genetic variation at the 22q11
PRODH2/DGCR6 locus presents an unusual pattern and increases suscepti-
bility to schizophrenia. Proc Natl Acad Sci U S A. 2002;99:3717-3722.
139.Gerber DJ, Hall D, Miyakawa T, , et al. Evidence for association of schiz-
ophrenia with genetic variation in the 8p21.3 gene, PPP3CC, encoding the
calcineurin gamma subunit. Proc Natl Acad Sci U S A. 2003;100:8993-8998.
140.Emamian ES, Hall D, Birnbaum MJ, Karayiorgou M, Gogos JA.
Convergent evidence for impaired AKT1-GSK3beta signaling in schizo-
phrenia. Nat Genet. 2004;36:131-137.
141. Ikeda M, Iwata N, Suzuki T, et al. Association of AKT1 with schizophre-
nia confirmed in a Japanese population. Biol Psychiatry. 2004;56:698-700.
142.Schwab SG, Hoefgen B, Hanses C, et al. Further evidence for associa-
tion of variants in the AKT1 gene with schizophrenia in a sample of
European sib-pair families. Biol Psychiatry. 2005;58:446-450.
143.Bajestan SN, Sabouri AH, Nakamura M, et al. Association of AKT1 hap-
lotype with the risk of schizophrenia in Iranian population. Am J Med
Genet B Neuropsychiatr Genet. 2006;141:383-386.
144.Xu MQ, Xing QH, Zheng YL, et al. Association of AKT1 gene polymor-
phisms with risk of schizophrenia and with response to antipsychotics in
the Chinese population. J Clin Psychiatry. 2007;68:1358-1367.
145.Thiselton DL, Vladimirov VI, Kuo PH, et al. AKT1 is associated with
schizophrenia across multiple symptom dimensions in the Irish study of
high density schizophrenia families. Biol Psychiatry. 2008;63:449-457.
146.Ohtsuki T, Inada T, Arinami T. Failure to confirm association between
AKT1 haplotype and schizophrenia in a Japanese case-control population.
Mol Psychiatry. 2004;9:981-983.
147. Ide M, Ohnishi T, Murayama M, et al. Failure to support a genetic con-
tribution of AKT1 polymorphisms and altered AKT signaling in schizo-
phrenia. J Neurochem. 2006;99:277-287.
148.Liu YL, Fann CS, Liu CM, et al. Absence of significant associations
between four AKT1 SNP markers and schizophrenia in the Taiwanese pop-
ulation. Psychiatr Genet. 2006;16:39-41.
149.Norton N, Williams HJ, Dwyer S, et al. Association analysis of AKT1 and
schizophrenia in a UK case control sample. Schizophr Res. 2007;97:271-276.
150.Mah S, Nelson MR, DeLisi LE, et al. Identification of the semaphorin
receptor PLXNA2 as a candidate for susceptibility to schizophrenia. Mol
Psychiatry. 2006;11:471-478.
151.Fujii T, Iijima Y, Kondo H, et al. Failure to confirm an association
between the PLXNA2 gene and schizophrenia in a Japanese population.
Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:873-877.
152.Takeshita M, Yamada K, Hattori E, et al. Genetic examination of the
PLXNA2 gene in Japanese and Chinese people with schizophrenia.
Schizophr Res. 2008;99:359-364.
153.Budel S, Shim SO, Feng Z, Zhao H, Hisama F, Strittmatter SM. No asso-
ciation between schizophrenia and polymorphisms of the PlexinA2 gene
in Chinese Han Trios. Schizophr Res. 2008;99:365-366.
154.Lencz T, Morgan TV, Athanasiou M, et al. Converging evidence for a
pseudoautosomal cytokine receptor gene locus in schizophrenia. Mol
Psychiatry. 2007;12:572-580.
155.Sun S, Wang F, Wei J, et al. Association between interleukin-3 recep-
tor alpha polymorphism and schizophrenia in the Chinese population.
Neurosci Lett. 2008;440:35-37.
156.Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsy-
chotic drugs in patients with chronic schizophrenia. N Engl J Med.
2005;353:1209-1223.
157.Sullivan PF, Lin D, Tzeng JY, et al. Genomewide association for schizo-
phrenia in the CATIE study: results of stage 1. Mol Psychiatry. 2008;13:570-
584.
158.O'Donovan MC, Craddock N, Norton N, et al. Identification of loci
associated with schizophrenia by genome-wide association and follow-
up. Nat Genet. 2008;40:1053-1055.
159.Riley B, Thiselton D, Maher BS, et al. Replication of association
between schizophrenia and ZNF804A in the Irish Case–Control Study of
Schizophrenia sample. Mol Psychiatry. 2010;15:29-37.
160.Stefansson H, Ophoff RA, Steinberg S, et al. Common variants confer-
ring risk of schizophrenia. Nature. 2009;460:744-747.
161.Purcell SM, Wray NR, Stone JL, et al. Common polygenic variation con-
tributes to risk of schizophrenia and bipolar disorder. Nature.
2009;460:748-752.
162.Shi J, Levinson DF, Duan J, et al. Common variants on chromosome
6p22.1 are associated with schizophrenia. Nature. 2009;460:753-757.
163.Wassink TH, Piven J, Vieland VJ, et al. Evaluation of the chromosome
2q37.3 gene CENTG2 as an autism susceptibility gene. Am J Med Genet B
Neuropsychiatr Genet. 2005;136B:36-44.
164.Allen NC, Bagade S, McQueen MB, et al. Systematic meta-analyses and
field synopsis of genetic association studies in schizophrenia: the SzGene
database. Nat Genet. 2008;40:827-834.
DCNS_44_5.qxd:DCNS#44  10/03/10  1:44  Page 22
165.Saxena R, Voight BF, Lyssenko V, et al. Genome-wide association analy-
sis identifies loci for type 2 diabetes and triglyceride levels. Science.
2007;316:1331-1336.
166.Scott LJ, Mohlke KL, Bonnycastle LL, et al. A genome-wide association
study of type 2 diabetes in finns detects multiple susceptibility variants.
Science. 2007;316:1341-1345.
167.Sladek R, Rocheleau G, Rung J, et al. A genome-wide association study
identifies novel risk loci for type 2 diabetes. Nature. 2007;445:881-885.
168.Steinthorsdottir V, Thorleifsson G, Reynisdottir I, et al. A variant in
CDKAL1 influences insulin response and risk of type 2 diabetes. Nat Genet.
2007;39:770-775.
169.McClellan JM, Susser E, King MC. Schizophrenia: a common disease
caused by multiple rare alleles. Br J Psychiatry. 2007;190:194-199.
170.Sebat J, Lakshmi B, Troge J, et al. Large-scale copy number polymor-
phism in the human genome. Science. 2004;305:525-528.
171. Iafrate AJ, Feuk L, Rivera MN, et al. Detection of large-scale variation
in the human genome. Nat Genet. 2004;36:949-951.
172.Tuzun E, Sharp AJ, Bailey JA, et al. Fine-scale structural variation of the
human genome. Nat Genet. 2005;37:727-732.
173.Bailey JA, Eichler EE. Primate segmental duplications: crucibles of evo-
lution, diversity and disease. Nat Rev Genet. 2006;7:552-564.
174.Redon R, Ishikawa S, Fitch KR, et al. Global variation in copy number
in the human genome. Nature. 2006;444:444-454.
175.Gonzalez E, Kulkarni H, Bolivar H, et al. The influence of CCL3L1 gene-
containing segmental duplications on HIV-1/AIDS susceptibility. Science.
2005;307:1434-1440.
176.Perry GH, Dominy NJ, Claw KG, et al. Diet and the evolution of
human amylase gene copy number variation. Nat Genet. 2007;39:1256-
1260.
177.Xu B, Roos JL, Levy S, van Rensburg EJ, Gogos JA, Karayiorgou M.
Strong association of de novo copy number mutations with sporadic schiz-
ophrenia. Nat Genet. 2008;40:880-885.
178.Walsh T, McClellan JM, McCarthy SE, et al. Rare structural variants dis-
rupt multiple genes in neurodevelopmental pathways in schizophrenia.
Science. 2008;320:539-543.
179.Stefansson H, Rujescu D, Cichon S, et al. Large recurrent microdele-
tions associated with schizophrenia. Nature. 2008;455:232-236.
180.International Schizophrenia Consortium. Rare chromosomal dele-
tions and duplications increase risk of schizophrenia. Nature. 2008;455:
237-241.
181.Rujescu D, Ingason A, Cichon S, et al. Disruption of the neurexin 1
gene is associated with schizophrenia. Hum Mol Genet. 2009;18:988-996.
182.McCarthy SE, Makarov V, Kirov G, et al. Microduplications of 16p11.2
are associated with schizophrenia. Nat Genet. 2009;41:1223-1227.
183.Harrison PJ, Owen MJ. Genes for schizophrenia? Recent findings and
their pathophysiological implications. Lancet. 2003;361:417-419.
184.Moghaddam B. Bringing order to the glutamate chaos in schizophre-
nia. Neuron. 2003;40:881-884.
185.Kendler KS, Parnas J. Philosophical Issues in Psychiatry: Explanation,
Phenomenology and Nosology. First ed. Baltimore, MD: Johns Hopkins
University Press; 2008.
Nature and nurture in neuropsychiatric genetics - Dick et al Dialogues in Clinical Neuroscience - Vol 12 . No. 1 . 2010
DCNS_44_5.qxd:DCNS#44  10/03/10  1:44  Page 23
Epigenetics, complex disease, and the brain
n general, epigenetics refers to the regulation
of DNA sequences that does not involve alteration of
their actual base composition. Transcription and numer-
ous other genomic functions are epigenetically con-
trolled via heritable, but potentially reversible, changes
in modification of DNA and histones (acetylation,
methylation, phosphorylation, etc),1 and epigenomics is
the application of these processes across the genome. 
The normal functioning of genomes is tightly connected
to their epigenetic regulation, and epimutations can be
harmful in the presence of impeccable DNA sequences.
The epigenetic theory of complex non-Mendelian dis-
ease is based on three key postulates. Firstly, an organ-
ism's epigenetic status is far more dynamic than its DNA
sequence, and may be altered by a number of factors,
such as environment, developmental programs,2 or even
as a result of stochasticity.3 Secondly, certain epigenetic
signals may be inherited transgenerationally with DNA
sequence4 and may account for heritability of some traits
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Psychiatric diseases place a tremendous burden on
affected individuals, their caregivers, and the health care
system. Although evidence exists for a strong inherited
component to many of these conditions, dedicated efforts
to identify DNA sequence-based causes have not been
exceptionally productive, and very few pharmacologic
treatment options are clinically available. Many features
of psychiatric diseases are consistent with an epigenetic
dysregulation, such as discordance of monozygotic twins,
late age of onset, parent-of-origin and sex effects, and
fluctuating disease course. In recent years, experimental
technologies have significantly advanced, permitting in-
depth studies of the epigenome and its role in mainte-
nance of normal genomic functions, as well as disease
etiopathogenesis. Here, we present an epigenetic expla-
nation for many characteristics of psychiatric disease,
review the current literature on the epigenetic mecha-
nisms involved in major psychosis, Alzheimer’s disease, and
autism spectrum disorders, and describe some future
directions in the field of psychiatric epigenomics.  
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and diseases.5 Thirdly, epigenetic regulation is required
in the maintenance of proper genomic function, for
example, regulation of gene activity, inactivation of par-
asitic DNA elements, and chromosomal segregation.6
Epigenetic factors greatly affect phenotype—even genes
that are free of mutations may become harmful if they
are not expressed at the appropriate time and at the
required level. Combined, these points provide a solid,
mechanistic basis for a cohesive interpretation of vari-
ous epidemiological, clinical, and molecular features of
complex diseases. 
The molecular epigenetic mechanisms are complex and
highly intertwined. At the most basic level, methyl
groups may be bound to cytosines at the C5 carbon, usu-
ally within cytosine/guanine dinucleotides (CpG), which
are established and maintained by the DNA methyl-
transferase (DNMT) family of enzymes. This is believed
to be the most stable epigenetic mark, due to the cova-
lent nature of the modification.7 Additionally, another
DNA modification, hydroxymethylcytosine, has very
recently been discovered in Purkinje neurons and other
cells of the brain, and it may also play a role in epige-
netic regulation of neural function.8
DNA is wrapped around octamers of basic histone pro-
teins, each consisting of a core and N-terminus, to form
nucleosomes. Numerous modifications of these proteins
influence the condensation of chromatin, which can be
open (transcriptionally active) or closed (inactive).
Histone acetyltransferases (HATs) acetylate lysine
residues on the N-terminal tail of histone proteins, neu-
tralizing the positive charge of the protein and decreas-
ing its affinity for DNA. As a result, the chromatin
relaxes and the transcription machinery gains access to
previously restricted sites.9 Acetyl groups can be
removed by histone deacetylases (HDACs), resulting in
chromatin condensation and transcriptional inactiva-
tion.10 The presence of an N-terminal methyl-CpG-
binding domain (MBD) allows proteins, such as methyl-
CpG-binding protein 2 (MeCP2), to bind methylated
sites on DNA and complex with HDACs and the core-
pressor SIN3A. The complex facilitates histone deacety-
lation and downstream gene silencing from the methy-
lated CpG site. Histone methylation can result in either
gene activation or repression, depending on the specific
lysine or arginine that is modified.11 Another family of
enzymes, the histone demethylases, such as lysine-spe-
cific demethylase 1 (LSD1), are capable of removing this
methyl group from the lysine residues of histone and
nonhistone proteins.12
A hallmark of non-Mendelian disease, discordance of
monozygotic (MZ) twins, has traditionally been attrib-
uted to differential environmental factors activating a
disease state in one of the genetically predisposed co-
twins13; however, very few of these factors have been
identified. Alternately, MZ twin discordance may be due
to the partial stability of epigenetic factors, as disease-
relevant epigenetic dissimilarity can accumulate quite
readily between cotwins.5,14,15 Another non-Mendelian
peculiarity, sexual dimorphism, is the differential sus-
ceptibility to a disease between males and females. It is
observed in many psychiatric conditions, such as
Alzheimer's disease, schizophrenia, alcoholism, and
mood and anxiety disorders.16 Although the exact mech-
anism by which they predispose or protect from a dis-
ease is currently unknown, there is a great deal of evi-
dence that sex hormones exert control of gene
expression via epigenetic modifications; thus it is hypoth-
esized that sexual dimorphism in many disease states
may be the result of sex hormone-induced differences in
the epigenetic status of key genes.17,18 Furthermore, the
degree of risk for acquiring certain complex diseases
may depend on the sex of the affected parent, as in
schizophrenia,19 Alzheimer's disease (AD),20 autism,21
and bipolar disorder (BD).22 Genomic imprinting, an epi-
genetic mechanism in which differential epigenetic mod-
ification of genes occurs depending on their parental ori-
gin,23 is thought to be the source of such parent-of-origin
effects. Diseases affecting cell growth, development, and
behavior may result from disruption of the normal
imprinting pattern.24
In the epigenetic model of complex disease, it is assumed
that a primary epigenetic disruption takes place during
the maturation of the germline, and this pre-epimutation
increases an organism's risk of acquiring a disease. The
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pre-epimutation may be tolerated and it may not be suf-
ficient to cause the disease itself, but with time, perhaps
even decades, small misregulations add up until a thresh-
old is crossed and the individual experiences phenotypic
changes that meet diagnostic criteria for a clinical disor-
der. The age of disease onset may depend on the effects
of tissue differentiation, stochastic factors, hormones, and
likely some external environmental factors (nutrition,
infections, medications, addictions, etc).6,25,26 Severity of
epimutations may fluctuate over time, due to their
reversible nature, known to clinicians as “remission” and
“relapse.” It is also possible that epimutations may
regress back to the norm with aging, which presents par-
tial recovery, eg, reduction of psychopathology in elderly
psychiatric patients.
Although there are very few studies investigating the
role of epigenetic factors in psychiatric diseases, there is
an increasing body of experimental evidence that epi-
genetic signals play a critical role in neuronal develop-
ment, differentiation, and communication, as well as
synaptic plasticity in general27; these processes are fun-
damental for normal brain activity, such as learning and
memory.28,29 The known epigenetic modifiers, Polycomb
(PcG), and Trithorax (TrxG) proteins, have been shown
to influence synaptic plasticity,30,31 and cascade activation
during memory formation in the mitogen activated pro-
tein kinase (MAPK) pathway appears to trigger H3K14
acetylation.32 Additionally, pharmacologic inhibitors of
epigenetic processes have had documented effects on
long-term potentiation (LTP), an increase in efficiency
of synaptic transmission, in the mammalian brain.
DNMT inhibitors, such as zebularine, impair induction
of LTP in mouse hippocampus,33 while HDAC inhibitors
(HDACi), such as sodium butyrate and trichostatin A
(TSA), have been shown to enhance LTP in rat hip-
pocampus32 and amygdala.34 Taken together, this theo-
retical and experimental evidence suggest that epige-
netic regulation is essential for neural and brain
functioning, and putative epimutations may play a role
in etiopathogenesis of complex psychiatric disease. 
Psychiatric epigenetics and epigenomics
Major psychosis
Major psychosis is a classification that encompasses both
schizophrenia (SZ) and BD—two conditions that seem
to be related etiologically.35 SZ is a multifactorial disease
characterized by disordered thinking and concentration
that results in psychotic thoughts (delusions and hallu-
cinations), inappropriate emotional responses, erratic
behavior, as well as social and occupational deteriora-
tion,36 while BD represents a category of mood disorders,
in which affected individuals experience episodes of
mania or hypomania interspersed with periods of
depression, and may also suffer from delusions and hal-
lucinations. Thus far, traditional gene- and environment-
based approaches have not been very successful in deci-
phering the clinical, molecular, and epidemiological
aspects of psychosis, such as MZ discordance (41% to
65% for SZ,37 ~60% BD38), sexual dimorphism, parent-
of-origin effects, fluctuating disease course with periods
of remission and relapse, and peaks of susceptibility to
the disease that correspond to periods of major hor-
monal changes in the organism.25 Classically, psychosis
research was aimed at defining genetic and environ-
mental risk factors, but despite significant evidence of
a heritable component derived from twin and adoption
studies,39,40 many molecular genetic findings have not
been replicated, and significant heterogeneity and small
effect sizes are thought to plague genetic association
studies.41
Recently, the first epigenomic study of major psychosis
utilizing CpG-island microarrays was released by Mill et
al,42 providing a large-scale overview of DNA methylation
differences in the brain associated with SZ and BD. DNA
extracted from the frontal cortex was subjected to enrich-
ment of the unmethylated fraction using the methylation-
sensitive restriction enzymes, and adaptor ligation cou-
pled with PCR amplification. The amplicons (multiple
copies of the unmethylated genomic DNA) were interro-
gated on 12 192 feature CpG-island microarrays. The data
was normalized, assigned raw P values based on a t sta-
tistic, and then converted to false discovery rates (FDR).
Indeed, in cortex they discovered differences at loci
involved in glutamatergic and γ-aminobutyric acid
(GABA)-ergic neurotransmission, brain development,
mitochondrial function, stress response, and other disease-
related functions, many of which correspond to psychosis-
related changes in steady-state mRNA. In relation to the
glutamatergic hypothesis, a lower degree of DNA methy-
lation was observed in SZ and combined male psychosis
(SZ and BD) samples at two glutamate receptor genes,
NR3B and the α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid receptor (AMPA) receptor-sub-
unit gene GRIA2; the dysregulation of AMPA and N-
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methyl-D-aspartic acid (NMDA) receptors is an etiolog-
ical component of major psychosis, and it has been shown
that GRIA2 expression is altered in the prefrontal cortex
and striatum of SZ patients.43 Hypomethylation was also
detected at the vesicular glutamate transporter
(VGLUT2) in SZ females, and at secretogranin II
(SCG2), which encodes a neuronal vesicle protein that
stimulates glutamate release. A higher degree of methy-
lation was observed in SZ females at VGLUT1, a trans-
porter protein that is downregulated in SZ brains,44 and
the glutaminase enzyme, GLS2, in SZ males, which has
previously been shown to exhibit altered expression in
cases of SZ.45 In synergy with glutamatergic pathways,
GABAergic pathways also show dysregulation in cases of
major psychosis. Detected disruptions in such pathways
included hypermethylation at the RNA-binding regula-
tor of GABA(B) receptors, MARLIN-1, in SZ, BD, and
psychosis females, the G protein-coupled inwardly recti-
fying potassium channel linked to GABA neurotrans-
mission, KCNJ6, in SZ and psychosis males, as well as the
HELT locus in SZ and BD females, which is known to
determine GABAergic over glutamatergic neuronal fate
in the mesencephalon. Several other intriguing loci were
highlighted, such as the hypermethylation at WNT1, a
gene critical for neurodevelopment that is differentially
expressed in SZ brains,46 in females affected with major
psychosis, and at AUTS2 in SZ males, which spans a
translocation breakpoint associated with autism and men-
tal retardation. A highly significant hypermethylation was
detected in both male and female samples at two loci:
RPP21, which encodes a component of ribonuclease P, a
complex that forms t-RNA molecules via 5’-end cleavage,
and KEL, which encodes the Kell blood-group glycopro-
tein and causes McLeod Syndrome when incorrectly
expressed; SZ symptoms are manifested as part of
McLeod Syndrome. Network and gene ontology (GO)
analyses were performed in order to determine relation-
ships between the functionally linked pathways from the
microarray dataset. The network analysis revealed a lower
degree of modularity of DNA methylation “nodes” in the
major psychosis samples, indicating that there is some
degree of systemic epigenetic dysregulation involved in
the disorder. From the GO analysis, several categories
were highlighted, including those involved in epigenetic
processes, transcription, and development, as well as brain
development in female BD and SZ samples, and in those
related to stress response in male BD samples.46 To date,
this is the largest and most comprehensive epigenomic
study of major psychosis—the data presented supports
epigenetic mechanisms underlying broader hypotheses of
major psychosis and uncovers some new avenues for
future exploration.
Both SZ and BD have also been examined using the
candidate gene approach, as epigenetic downregulation
of genes is emerging as a possible underlying mechanism
of the GABAergic neuronal dysfunction in SZ. One of
the more intensively investigated SZ-related genes is
RELN, which is involved in neuronal development and
cell signaling, and has been found to be hypermethylated
in cases of SZ.47 However, no differences were observed
at this locus in a replication attempt,46,48 and the focus
seems to be shifting to other candidate genes, namely the
67 kDa glutamate decarboxylase (GAD67, aka GAD1)
and DNMT1. GAD67 catalyzes the conversion of glu-
tamic acid to GABA. In cases of SZ, the levels of this
enzyme and several others involved in GABAergic neu-
rotransmission, such as GAD65 and GABA plasma
membrane transporter-1 (GAT-1), display decreased
mRNA levels, as determined by real-time quantitative
polymerase chain reaction (qPCR) and in situ hybridiza-
tion.49-52 In addition to aberrant methylation at this locus,
an analysis of the microarray collection of the National
Brain Databank (USA) has shown that decreased
GAD67 mRNA levels strongly correlated with upregu-
lated HDAC1 in the prefrontal cortices of SZ subjects.53
Oddly enough, at the GAD67 promoter, SZ patients
have been shown to display an ~8-fold deficit in repres-
sive chromatin-associated DNA methylation.54 In the
prefrontal cortex of 41 SZ patients, another histone
modification, H3-(methyl)arginine 17 (H3meR17) was
found to exceed control levels by 30%, and this was
associated with downregulated metabolic gene expres-
sion.55 So, while it is apparent that histone modifications
are involved in the development of SZ, their exact mech-
anism is not entirely clear. Hypermethylation of GAD67
is believed to occur via DNMT1,56,57 a maintenance
methyltransferase enzyme that is upregulated in the
GABAergic neurons and peripheral blood lymphocytes
of SZ patients, along with the de novo methyltransferase,
DNMT3a.56,58 Interestingly, nicotine has been shown to
decrease DNMT1 mRNA expression in cortical and hip-
pocampal GABAergic neurons in mice—this decrease
results in GAD67 promoter demethylation, and is
inversely related to an upregulation of cortical GAD67
protein.59 This information is highly relevant, as SZ
patients tend to smoke tobacco at a rate that is 2- to 4-
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fold higher than in the general population,60 and are pos-
sibly drawn to the nicotine content for its effects on the
aforementioned pathway.
Less information is available on BD; genomic imprinting
has been suggested by statistical genetics, but molecular
approaches have not yielded the imprinted disease
genes.61 A recent study applied methylation-sensitive rep-
resentational difference analysis (MS-RDA) to lym-
phoblastoid cells derived from twins discordant for BD.62
One detected gene, named peptidylprolyl isomerase E-
like (PPIEL), was hypomethylated in BD-affected twins,
while a region of the spermine synthase (SMS) gene was
hypermethylated versus unaffected twins; it has yet to be
determined if either of these regions are biologically and
functionally significant. In combined studies of epige-
netics and DNA sequence, some interesting develop-
ments have been observed. It has recently been shown
that rare G variants of a G/A polymorphism in the potas-
sium chloride co-transporter 3 gene (SLC12A6) may rep-
resent risk factors for BD.63 Eventually, it was discovered
that variants containing the G allele were methylated at
the adjacent cytosine, and this accompanied a decrease
in gene expression in human lymphocytes.64 This hints at
a functional link between epigenetics and genetic varia-
tion, and the association with BD is believable, as
SLC12A6 mutations underlie another psychiatric disor-
der, Andermann syndrome, which is an autosomal reces-
sive motor-sensory neuropathy associated with develop-
mental and neurodegenerative defects.65 It is interesting
to note that BD provides a unique opportunity to inves-
tigate epigenetic variation between two extreme forms
of the same disease—depression and mania. A study
design of this variety would unfortunately be limited to
the use of peripheral blood, buccal epithelial cells, and
fibroblasts as experimental tissues, but nonetheless, it
would be incredibly interesting to determine the state of
the epigenome during manic and depressive states, in the
same individual when the same genetic and environ-
mental impacts are present.
Alzheimer’s disease
AD is a neurodegenerative disorder and the most com-
mon form of dementia in the elderly; it is characterized
by the accumulation of intracellular neurofibrillary tan-
gles (NFT) and extracellular amyloid plaques in the
brain.66 AD often presents with psychiatric symptoms
such as memory loss, mood swings, and irritability that
increase in severity as the disease progresses. While the
phenotype of this condition is well documented, the mol-
ecular mechanisms largely remain unknown. The major-
ity of AD research focuses on dysregulation of fibers and
proteins, such as epsilon4 allele of apolipoprotein E
(APOE), but little ground has been gained in regards to
determining the actual origins of their dysfunction.67 In
the rare early-onset form of AD (EOAD), genetic fac-
tors play a more defined role, with mutations in amyloid-
beta precursor protein (APP) and the presenilin genes
(PSEN1, PSEN2) showing a clear connection to the dis-
ease.68 However, since EOAD does not represent the
majority of all cases, accounting for only ~5% of the
total,69 this genetic model is not normally applicable.
Similar to other complex diseases, late-onset AD
(LOAD), the more common form of the illness that
affects individuals over 65 years of age, demonstrates a
considerable number of non-Mendelian features. Some
of these anomalies include dominance of sporadic over
familial cases,70 discordance of MZ twins,71 differential
susceptibility and course of illness in males and
females,16,18 parent-of-origin effects72 and, clearly, the late
age of onset that is not easily explained by genetic causes
alone. Consistent with the epigenetic hypothesis, abnor-
mal levels of folate and homocysteine, signs of dysreg-
ulated methylation maintenance, have been detected in
the brain of AD subjects. LOAD is a particularly inter-
esting target from the epigenetics of aging perspective,
as the epigenome may become deregulated in old age.73
Using a MethyLight approach, it was shown that a large
number of genes increase in methylation with age in
control subjects, including several implicated in AD and
SZ (GAD1, PSEN1, BDNF, DRD2, GABRA2, HOXA1,
NTF3, LDLR, and S100A2), whereas Alu and other
repetitive elements showed a significant decrease in
DNA methylation that was limited to the first decade of
life.74 Of the fifty loci investigated, two displayed signif-
icant changes in methylation status with age in AD sub-
jects: SORBS3 gained methylation over time and is
more likely to be methylated in AD patients, while
S100A2 displays a complex chronology, but results in a
slow, stochastic methylation decrease later in life (ibid).
SORBS3 encodes a neuronal/glial cell adhesion mole-
cule and S100A2 encodes a calcium binding protein from
the S100 family. As part of normal brain aging, S100A2
protein accumulates in corpora amylacea, or polyglu-
cosan bodies; subjects with neurodegenerative disorders
experience a much greater accumulation of corpora
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amylacea,75 and this is consistent with the eventual
decrease in S100A2 methylation.74
In a study dedicated to DNA methylation analysis of AD
candidate genes, it was found that the twelve analyzed loci
were epigenetically different in the brains of LOAD cases
versus controls, particularly at the locus for transcription
factor A (TFAM), a key activator of mitochondrial tran-
scription in mammals. Other candidates, such as PSEN1,
APOE, DNMT1, and MTHFR, displayed an enhanced
“distance” in LOAD subjects.76 This concept of distance is
part of the theory of “epigenetic drift,” in which an affected
individual has an epigenetic status at some gene(s) that is
distanced from the norm, and this distance increases with
age.76 Of the CpG-rich regions analyzed, the majority were
unmethylated, and it appears possible that very small alter-
ations in methylation level could accumulate over time,
ultimately affecting gene regulatory functions and causing
disease. Age-related alteration of methylation status is a
global phenomenon, not necessarily limited to particular
disease susceptibility genes. Another study examined the
methylation changes in 807 arbitrarily selected genes from
two cohorts from Utah and Iceland, taking DNA samples
at two timepoints from each subject, spaced either 11 or
16 years apart. In these two populations, they observed
time-dependent changes in global DNA methylation
within the same individual, with 8% to 10% of individuals
in showing changes that were greater than 20 percent; both
gains and losses of methylation were detected.77 Similarly,
the Boston Normative Aging Study measured DNA
methylation in the blood of 718 elderly subjects (55 to 92
years of age) over a span of 8 years. A progressive loss of
DNA methylation in repetitive elements was found, par-
ticularly in Alu repeats, and this linear decline highly cor-
related with time since the first measurement.78 A seem-
ingly innocuous early-life epigenetic change in some
critical gene involved in AD etiology, for example, the
amyloid precursor protein (APP) locus, could potentially
become pathologic when subjected to epigenetic drift as
the subject ages. Although the molecular mechanisms
leading to early-life methylation disturbances have not yet
been identified, the possibility of early epimutation and
epigenetic drift should not be ignored as an etiological can-
didate for LOAD. 
Autism spectrum disorders
Autism and related developmental disorders, such as
Asperger’s and Rett syndromes, fall under the broader
class of autism spectrum disorders (ASD), where “spec-
trum” reflects the observed continuum of severity or
impairment experienced. These disorders become appar-
ent in young children and persist into adulthood, with
deficits in social cognition regarded as the most charac-
teristic feature of ASD, leading to restrictions in social
communication.79 While autism itself is believed to have
a particularly strong inherited basis relative to other
developmental psychiatric syndromes,80 DNA sequence
factors in the etiology of ASD are still largely unknown.81
Evidence supports a contribution of imprinted genes in
ASD, as well as paternal transmission (reviewed in ref
82), and perhaps the combination of this information
and the lack of identified genetic markers will stimulate
future epigenetic and epigenomic studies of ASD. 
Rett syndrome (RTT), a division of ASD, has been
extensively studied and arises from loss of function
mutations at the locus for methyl-CpG-binding protein-
2 (MeCP2), a transcriptional repressor that silences
methylated genes83 and may participate in RNA splic-
ing.84 Mouse models have been very useful in delineat-
ing the relationship between disturbances to MeCP2 and
the disease.85 In mice, deletion of MeCP2 mimics RTT
syndrome, leading to locomotor impairments and reduc-
tions in brain size.86,87 Mice with a truncated MeCP2 pro-
tein, similar to that of RTT patients, developed many
features of RTT, such as tremors, motor impairments,
hypoactivity, increased anxiety-related behavior,
seizures, kyphosis, and stereotypic forelimb motions;
these mice also presented hyperacetylation on histone
H3,88 illustrating that chromatin abnormalities exist in
this disorder. In astrocytes cultured from a mouse model
of RTT, MeCP2 deficiency causes significant abnormal-
ities in BDNF regulation, cytokine production, and neu-
ronal dendritic induction. Whereas previous experiments
have only focused on neurons, this evidence suggests
that astrocytes may also represent therapeutic targets for
RTT.89
The classic form of autism also appears to be connected
to MeCP2 expression. Coding mutations affecting the
protein are rarely detected in autism, but significantly
increased MeCP2 promoter methylation has been found
in autistic male frontal cortex compared with controls,
and this inversely correlated with protein expression90;
aberrant promoter methylation at MeCP2 has also been
detected in female brain DNA.91 Similarly, loss of
methyl-CpG binding protein 1 (MBD1), leads to autism-
like behavioral deficits in mice, namely reduced social
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interaction, learning deficits, anxiety, defective sensory
motor gating, depression, and abnormal brain serotonin
activity.92 Also, a novel mutation has been discovered in
the Jumonji AT-rich interactive domain 1C (JARID1C)
gene of a child with autism. While very preliminary, this
discovery is interesting, as JARID1C is believed to be a
histone demethylase specific for di- and trimethylated
histone 3 lysine 4 (H3K4), as well as a transcriptional
repressor for the ASD-associated genes SCN2A,
CACNA1H, BDNF, and SLC18A1.93 Finally, another
interesting hypothesis relating epigenetics to ASD con-
cerns the observation that autistic children exhibit
improved behavior communication during febrile
episodes.94 It may be the case that fever restores the
modulatory functions of the intact, but dysregulated
locus coeruleus-noradrenergic (LC-NA) system that is
present in ASD. The fact that the state of the LC-NA
system can be switched back and forth, combined with
evidence that imprinted genes within the LC-NA are
tightly epigenetically regulated and susceptible to envi-
ronmental interference,95 suggests that dynamic epige-
netic remodeling processes may regulate the malfunc-
tioning pathways in ASD.96
Epigenetic treatment opportunities
Epigenetic drug strategies are currently employed to
treat a collection of cancer subtypes, and these medica-
tions are now being considered in the treatment of psy-
chiatric disease, as well. The DNMT inhibitor, doxoru-
bicin, has been used to increase reelin and GAD67
expression in neuronal precursor cells, and it was shown
that reelin gene expression correlated with the dissocia-
tion of DNMT1 and MeCP2 from its promoter, as well as
an increased level of histone H3 acetylation.97 Other stud-
ies have shown that HDAC inhibition enhances learning
and memory following neurodegeneration induced by
traumatic brain injury,98 and also shows some therapeu-
tic efficacy in rodent models of neurodegenerative con-
ditions, such as Huntington’s disease,99 multiple sclero-
sis,100 and Parkinson’s disease.101 One of the downstream
effects of HDAC inhibition is upregulation of p21,102 a
cyclin-dependent kinase inhibitor that appears to play an
important protective role against oxidative stress and
DNA damage.103 Valproate, a compound utilized for its
anticonvulsant and mood-stabilizing properties, also
exhibits HDAC activity and has been successfully imple-
mented as a treatment for epilepsy,104 BD,105 and, less
commonly, SZ.106 Like valproate, it has been discovered
that several drugs have previously unknown epigenetic
modifying properties, and the list continues to grow.
While such medications are promising, their pleiotropy,
transient effects, and nonspecific alterations to the entire
epigenome limit them for the time being. 
A substantial challenge to the field of epigenomics of
psychiatric and other diseases involves the identification
and verification of inhibitors for specific histone-modi-
fying enzymes. Once developed, these compounds should
provide higher therapeutic efficiency versus the nonspe-
cific therapeutics that are currently in use, such as
suberoylanilide hydroxamic acid (SAHA). The develop-
ment of small, targeted molecules to specific disease-
causing epimutations may resolve some of these issues
but, of course, the molecules themselves must first be
identified. Alternately, discovery of the downstream
effects of epimutations in vivo may nominate particular
proteins, to which drug interventions can be applied in
a more traditional style, using molecules to exert agonis-
tic and antagonistic effects on the protein products of epi-
genetically misregulated genes. Knowledge of the three
dimensional structures of DNA- and histone-modifying
enzymes is mounting and, through the use of fragment-
based drug design and ligand motif-based libraries,107 vir-
tual screening technologies may soon become a feasible
option. In the search for target-specific ligands, high-
throughput screening of small organic molecule libraries
is a useful tool.108 A recent study utilized a 125 000 small
molecule library to screen for specific inhibitors against
histone lysine methyltransferases (HMTases). The com-
pound discovered was BIX-01294 (diazepinquinazolin-
amine derivative), an incredibly specific inhibitor of the
target enzyme, euchromatic G9a HMTase, that was able
to significantly lower promoter-proximal H3K9me2
marks in mouse embryonic stem cells.109
In addition to small molecules, RNA and proteins may
also be utilized in the design of effective epigenetic
drugs. One strategy focuses on RNA interference
(RNAi), in which endogenously produced small inter-
fering RNAs (siRNAs) are incorporated into an RNA-
induced silencing complex (RISC) that targets and
destroys homologous mRNA, thus preventing protein
production.110 A siRNA with the ability to knock down
beta-secretase (BACE1) in Huntington’s and AD has
been developed, as has one against the SCA1 gene in
spinocerebellar ataxia.111 However, before these RNAs
can become effective treatment options, the issues of
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nonspecific silencing of partially homologous genes, safe
delivery, and inhibition of microRNA (miRNA) must
first be resolved. Although the exact mechanisms by
which RNAi affects local chromatin structure, gene
silencing, and heterochromatin assembly is unknown,112
it still holds much promise as a therapeutic technique.
Another promising technology utilizes zinc-finger pro-
teins (ZFPs), which can recognize specific DNA
sequences and bind to short stretches of DNA (~9–18
basepairs), depending on their particular domains.113 This
feature could theoretically allow targeted ZFPs, attached
to a DNA- or histone-modifying enzyme,114 to bind an
epimutated site and permit the enzyme to correct the
misregulation at that location alone. The damaging
global epigenetic effects observed with current drugs
would not occur, in this case.
The ability to target etiological disease epimutations and
identify epigenetic biomarkers for psychiatric diseases
would be another incredibly beneficial development.
Biotechnologies are advancing at an amazing rate, and
already allow for genome-wide detection of the patterns
of DNA methylation and histone modifications. Fully
mapped epigenomes in different tissues and cells will
facilitate the discovery of disease epimutations and the
mechanisms of their pathological action, thus providing
the basis for etiological treatment. 
Concluding remarks
The role of epigenetic mechanisms in psychiatric diseases
is only beginning to solidify, but it is already evident in
major psychosis, AD, ASD, and several other conditions
not described in this review, such as Rubinstein-Taybi
syndrome,115 addiction,116,117 Huntington’s disease,118 and
Fragile X syndrome.119 Maintenance of DNA methylation
and histone modifications is crucial for normal neurode-
velopment and functioning of the brain—dysregulation
of these components is highly deleterious to the subject
and can predispose to any of the aforementioned disease
phenotypes. Previous studies of psychiatric conditions
have concentrated on the contributions of genetic and
environmental factors but, while DNA sequence and
external influences may play an important role in disease
etiology, the impact of gene regulation via epigenetic
mechanisms on neural function also cannot be ignored.
Rather, the interplay between epigenetics, DNA
sequences, and environment should become the focus of
future work, adopting such concepts as differentially
methylated “epi-alleles”120 and environmental effects on
DNA methylation and chromatin modifications.2 As tech-
nologies advance, next-generation sequencing and com-
prehensive microarrays will become much more afford-
able, allowing researchers to perform larger, more
in-depth epigenomic studies. Perhaps, in the near future,
identification of epigenetic biomarkers and operational-
ization of new, effective diagnostics and treatments will
become feasible for psychiatric and various other com-
plex diseases. ❏
Acknowledgements: This project was supported by the National Institute
of Mental Health (R01 MH074127; R01 MH088413), and the Canadian
Institutes for Health and Research (CIHR). CP is a CIHR Graduate Fellow, and
AP is Senior Fellow, of the Ontario Mental Health Foundation.
B a s i c  r e s e a r c h
REFERENCES
1. Henikoff S, Matzke MA. Exploring and explaining epigenetic effects.
Trends Genet. 1997;13:293-295.
2. Weaver IC, Cervoni N, Champagne FA, et al. Epigenetic programming
by maternal behavior. Nat Neurosci. 2004;7:847-854.
3. Riggs AD, Xiong Z, Wang L, LeBon JM. Methylation dynamics, epige-
netic fidelity and X chromosome structure. Novartis Found Symp.
1998;214:214-25; discussion 25-32.
4. Richards EJ. Inherited epigenetic variation--revisiting soft inheritance.
Nat Rev Genet. 2006;7:395-401.
5. Kaminsky ZA, Tang T, Wang SC, et al. DNA methylation profiles in
monozygotic and dizygotic twins. Nat Genet. 2009;41:240-245.
6. Jaenisch R, Bird A. Epigenetic regulation of gene expression: how the
genome integrates intrinsic and environmental signals. Nat Genet.
2003;33(suppl):245-254.
7. Davey CA, Sargent DF, Luger K, Maeder AW, Richmond TJ. Solvent
mediated interactions in the structure of the nucleosome core particle at
1.9 a resolution. J Mol Biol. 2002;319:1097-1113.
8. Kriaucionis S, Heintz N. The nuclear DNA base 5-hydroxymethylcyto-
sine is present in Purkinje neurons and the brain. Science. 2009;324:929-930.
9. Margueron R, Trojer P, Reinberg D. The key to development: inter-
preting the histone code? Curr Opin Genet Dev. 2005;15:163-176.
10. Thiagalingam S, Cheng KH, Lee HJ, et al. Histone deacetylases: unique
players in shaping the epigenetic histone code. Ann N Y Acad Sci.
2003;983:84-100.
11. Klose RJ, Zhang Y. Regulation of histone methylation by demethylim-
ination and demethylation. Nat Rev Mol Cell Biol. 2007;8:307-318.
12. Nicholson TB, Chen T. LSD1 demethylates histone and non-histone pro-
teins. Epigenetics. 2009;4:129-132.
13. Reiss D, Plomin R, Hetherington EM. Genetics and psychiatry: an unher-
alded window on the environment. Am J Psychiatry. 1991;148:283-291.
14. Petronis A, Gottesman II, Kan P, et al. Monozygotic twins exhibit
numerous epigenetic differences: clues to twin discordance? Schizophr Bull.
2003;29:169-178.
15. Fraga MF, Ballestar E, Paz MF, et al. Epigenetic differences arise during the
lifetime of monozygotic twins. Proc Natl Acad Sci U S A. 2005;102:10604-10609.
16. Seeman MV. Psychopathology in women and men: focus on female
hormones. Am J Psychiatry. 1997;154:1641-1647.
17. Auger AP, Jessen HM. Corepressors, nuclear receptors, and epigenetic
factors on DNA: a tail of repression. Psychoneuroendocrinology. 2009;34 (suppl
1):S39-S47.
DCNS_44_5.qxd:DCNS#44  10/03/10  1:44  Page 32
Epigenetic approaches to psychiatric disorders - Ptak and Petronis Dialogues in Clinical Neuroscience - Vol 12 . No. 1 . 2010
Aproximaciones epigenéticas a los 
trastornos psiquiátricos
Las enfermedades psiquiátricas determinan un
enorme costo para los individuos afectados, sus cui-
dadores y el sistema de atención de salud. Aunque
existe evidencia de un fuerte componente heredita-
rio para muchas de estas condiciones, los esfuerzos
dedicados a identificar las causas en base a las
secuencias de ADN no han resultado especialmente
productivos y son muy pocas las opciones de trata-
mientos farmacológicos que están clínicamente dis-
ponibles. Muchas características de las enfermedades
psiquiátricas son concordantes con una falta de regu-
lación epigenética, como la discordancia de los
gemelos monocigóticos, la edad tardía de aparición,
los efectos del sexo y de los padres biológicos y el
curso fluctuante de la enfermedad. Recientemente
las tecnologías experimentales han avanzado de
manera significativa, permitiendo estudios a fondo
del epigenoma y de su papel en el mantenimiento
de las funciones genómicas normales, como también
en la etiopatogenia de las enfermedades. En este
artículo se presenta una explicación epigenética para
muchas características de la enfermedad psiquiátrica,
se revisa la literatura actual acerca de los mecanismos
epigenéticos involucrados en las principales psicosis,
la Enfermedad de Alzheimer, y los trastornos del
espectro autístico, y se describen algunas líneas a
futuro en el campo de la epigenómica psiquiátrica. 
Approches épigénétiques des troubles 
psychiatriques
Les maladies psychiatriques pèsent considérable-
ment sur les individus atteints, leurs soignants et sur
le système de santé. Même s’il existe des arguments
pour une forte héritabilité de beaucoup de ces
troubles, les efforts portés sur l’identification des
causes liées à une séquence ADN n’ont pas été très
productifs et très peu de traitements pharmacolo-
giques sont disponibles. De nombreuses caractéris-
tiques des maladies psychiatriques concordent avec
une dysrégulation épigénétique, comme une dis-
cordance entre jumeaux monozygotes, un début
tardif, des effets liés au sexe et aux origines paren-
tales et une évolution fluctuante de la maladie. Ces
dernières années, des avancées significatives des
technologies expérimentales ont permis d’étudier
en profondeur l’épigénome et son rôle dans le
maintien des fonctions génomiques normales
comme dans l’étiopathogenèse de la maladie. Nous
présentons dans cet article une explication épigé-
nétique pour de nombreuses caractéristiques des
maladies psychiatriques, nous analysons la littéra-
ture actuelle sur les mécanismes épigénétiques
impliqués dans les psychoses majeures, la maladie
d’Alzheimer et les troubles autistiques et nous don-
nons quelques perspectives dans le domaine de
l’épigénomique psychiatrique.
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n recent years, hundreds of genetic association
studies have sought to explore the relationship between
common genetic variation and disease, biological char-
acteristics, or drug response. The basic premise of these
studies is that the diseases (or traits) are not caused by
single gene variants of strong effect, such as, for instance,
sickle-cell anemia or cystic fibrosis, but rather that some
“manageable” number of common variants have an
important influence on the trait under question. Part of
the motivation for this perspective is the “common dis-
ease, common variant” (CDCV) theory.1,2 Once a genetic
variant has been found to be associated, there are a
number of possible uses for the information. If the effect
of the genetic variant is strong enough, perhaps in com-
bination with lifestyle or other environmental factors,
it might be used to predict risk of the disease.
Alternatively, the associated variant(s) may be used to
try to predict response to a particular medication. Finally,
if the effect size of the genetic variant is very small and
thus not useful for either of these purposes, it may still
be of use in identifying a disease-associated gene or
genetic pathway that could illuminate disease patho-
physiology or implicate new therapeutic targets. Here we
review the current status of genome-wide association
studies, with a particular focus on neuropsychiatric dis-
orders.
Genome-wide association studies
Genome-wide association studies (GWAS), are a way of
performing genetic association studies without prior
B a s i c  r e s e a r c h
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Hundreds of genome-wide association studies have been
performed in recent years in order to try to identify com-
mon variants that associate with complex disease. These
have met with varying success. Some of the strongest
effects of common variants have been found in late-
onset diseases and in drug response. The major histo-
compatibility complex has also shown very strong asso-
ciation with a variety of disorders. Although there have
been some notable success stories in neuropsychiatric
genetics, on the whole, common variation has explained
little of the high heritability of these traits. In contrast,
early studies of rare copy number variants have led
rapidly to a number of genes and loci that strongly asso-
ciate with neuropsychiatric disorders. It is likely that the
use of whole-genome sequencing to extend the study of
rare variation in neuropsychiatry will greatly advance our
understanding of neuropsychiatric genetics. 
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hypotheses about which genes are likely to be involved.
To do this, arrays of single-nucleotide polymorphisms
(SNPs) that cover the whole genome are used. Although
there are thought to be approximately 10 million com-
mon SNPs in the genome,3 it is not necessary to geno-
type each one of these individually to get information
about most of them. This is because, due to the way that
human populations have migrated and genetic variants
have arisen, many of the variants are associated with
each other or “linked.” Thus, in European and Asian
populations, if you genotype one variant, you are gain-
ing information about 10 to 20 other variants simulta-
neously. This is called “tagging” (the genotyped variants
“tag” the ungenotyped, linked variants), and was
brought to the genome-wide scale by the HapMap pro-
ject, which has genotyped millions of common SNPs in
four populations to create a detailed map of how com-
mon genetic variants relate to one another.3-5 A signifi-
cant motivation for the HapMap project was the idea
that common variants make up an important part of the
genetic contribution to common diseases (the CDCV
hypothesis). While some theoretical arguments were
marshaled in support of this hypothesis—and indeed,
even before the HapMap project a handful of examples
were known—there was no way to know a priori how
general the CDCV hypothesis might turn out to be. For
this reason, a systematic investigation of common varia-
tion was judged by much of the community (including
these authors) but not all6 to be a sensible beginning to
the study of human disease genetics. The result is that a
true genome-wide study can be performed by actually
genotyping as few as 300 000 to 1 million SNPs.7,8
However, because so many tests are being performed, it
is necessary to obtain a very strongly significant P value
to be sure that the result is really significant. This is
known as “genome-wide significance” and the consen-
sus is that this should be about 10-8 or less.9 Because the
effects sizes of common variants are generally small, it is
usually necessary to include a large number of subjects
in the study in order to have the power to detect a
genome-wide significant P value (Figure 1).
Major discoveries with GWAS
The success of GWAS has been very variable for differ-
ent disease areas. Some diseases have found common
variants with very strong effects, and managed to track
these down to the causal variant. An inspiring example
is an intronic variant in BCL11A that was found in two
GWAS studies to associate with fetal hemoglobin (HbF)
levels in healthy adults,10,11 and also to modify the pre-
sentation of β-thalassemia, and associate with HbF lev-
els in patients with sickle-cell disease.11 This finding was
soon followed up with a functional study that showed
that the variant associated with high HbF12 reduced the
expression of BCL11A,13 and that reduction of BCL11A
expression caused increase in levels of gamma-globin in
adult human red blood progenitor cells, which led to
increased levels of HbF.13 These findings clearly suggest
that BCL11A serves as an inhibitor of HbF production
and that directed repression of BCL11A could be devel-
oped as a clinical tool to ameliorate the presentation of
thalassemias and sickle-cell disease. These findings in
turn have led to further understanding of developmen-
tal and species-specific changes in globin regulation.14
On the less inspirational side, however, other diseases,
like hypertension, have been thoroughly and carefully
investigated using huge numbers of patients and controls
with very little progress.15 Here we outline some of the
highest impact findings of GWAS and where (if any-
where) they have led us. 
As might be expected by the laws of natural selection,
there are not many common genetic variants that con-
fer a strong predisposition to common diseases. Such
variants would be expected to have been selected
against, and thus maintained at low population frequen-
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Figure 1. The power to detect a causal variant that is perfectly tagged
by a genotyped marker (assuming dominant model, minor
allele frequency=0.2, frequency of disease is 1% and equal
numbers of cases and controls). To have a good chance of
detecting a variant with a relative risk of 1.2, about 2000 cases
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cies. However, there are some phenotypes that might be
expected to have dodged the purifying effects of selec-
tion. These include common diseases that do not onset
until old age, and response to drugs that the body has
not historically had to interact with. Accordingly, some
of the strongest effects of common variants on disease
have been found in association with ailments with an
onset during the postreproductive years, and with drug
response. 
Genetic variants that affect late-onset diseases
One of the most well-known genetic risk factors is the
E4 variant of the apolipoprotein E gene, ApoE, which
greatly increases the risk of Alzheimer’s disease (AD)
and reduces the age of onset in a dose-dependent man-
ner.16-18 The effect of this variant is so strong that it was,
in fact, discovered before the GWAS era, but it has since
been confirmed as the most important predictor of late-
onset AD in a number of genome-wide analyses,19-22 one
with fewer than 500 cases and controls reporting a P
value of 1 x 10-40.21 However, despite the definitive effects
of this genetic variant on AD and the length of time that
we have known about it, it is still not clear how the vari-
ant mediates its effects,23 and it has not yet led to
improved treatment. 
One of the very earliest novel discoveries of GWAS was
the association of an amino acid substitution in the com-
plement factor H gene, CFH, with age-related macular
degeneration, a very common form of blindness that
affects the elderly. This genetic association was found
with a tiny sample size: 96 cases and 50 controls, and car-
rying two copies of the risk variant increases the risk of
illness up to 7 times.24 The associated variant does itself
seem to be functional, changing the binding properties
of the protein, although it is not yet exactly understood
how the variant contributes to disease,25 nor how this can
be utilized in novel treatments.
A third very strong disease-associated common genetic
variant is in the LOXL1 gene in exfoliation glaucoma,
another very common form of age-related blindness. The
associated variant was discovered in a set of only 75
cases, and individuals homozygous for the risk haplo-
types are thought to be at 700-fold increased risk of
exfoliation glaucoma when compared with homozygotes
of the low-risk haplotype. However, because the risk
haplotype is so common, this translates to just a 2.5-fold
increase risk from the population average.26 The two
variants contributing to the risk haplotype are both pro-
tein-coding changes, and the same variants have now
been associated with disease in multiple populations,27-40
suggesting that these are the causal variants, although
the degree of penetrance, and the risk haplotype, have
been reported to differ in Australia and Japan.28,29,35,37,38,41,42
Unfortunately, the very high frequency of the risk hap-
lotype in the general population currently precludes
these markers from being used to predict disease, but it
is hoped that a better understanding of the role of
LOXL1 in optical pathophysiology may lead to
advances in treatment.40
Genetic variants that affect drug response
Genetic variants affecting drug response can have very
strong effects, and often occur in the genes that would
be most expected to be involved.43 Thus, pharmacoge-
netics was one of the more successful areas of genomics
before the GWAS area, and a number of strong genetic
influencers of drug response have been known for some
time.44 GWAS have added at least three pharmacoge-
netic associations of considerable strength and impor-
tance.
Flucloxacillin-induced liver injury
Idiosyncratic drug reactions are the most common cause
of liver failure in the US.45 Flucloxacillin is an antibiotic
drug commonly used to treat Staphylococcus aureus
infections, but it has a relatively high incidence of caus-
ing liver injury (6.1 per 100 000 users) in comparison
with other antibiotics such as penicillin.46 This has previ-
ously led to restrictions on its use.46 A GWAS was per-
formed on 51 patients with flucloxacillin-induced liver
injury and 487 controls, in which a huge signal was seen
for a missense polymorphism in the HCP5 gene (P= 8.7
10-33).47 Through linkage disequilibrium, the association
was traced to the HLA-B*5701 allele, the presence of
which increased the likelihood of flucloxacillin-induced
liver injury by 80 times.47 Since the general frequency of
the associated allele in the European population is only
about 5%, and it was present in 84% of cases, this vari-
ant could potentially be used to screen out people at
high risk of liver injury before flucloxacillin is prescribed.
However, due to the rarity of the hepatoxicity, this would
result in a high false-positive rate. A proposed alterna-
tive is to use the genotyping of this variant as a diagnos-
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tic marker in suspected cases of hepatoxicity so that the
patient can be rapidly switched to alternative antibi-
otics.47
Statin-induced myopathy
Taking statin therapy to reduce the levels of low-density
lipoprotein cholesterol has been shown to reduce the
likelihood of cardiovascular events, such as heart attack
and stroke.48 Occasionally, however, statins, particularly
at high doses, can cause serious myopathy, which may
lead to hospitalization or death.49 In August 2008 a
GWAS that included only 85 cases and 90 controls
revealed a SNP in the SLCO1B1 gene, which accounted
for more than 60% of cases of myopathy.50 Carrying one
C at this locus increases the risk of statin-induced
myopathy by 4.5 times, and CC homozygotes have a 17-
fold greater risk than TT homozygotes. This has been
suggested as a genetic test to identify vulnerable indi-
viduals before offering high-dose simvastatin therapy.51
Hepatitis-C treatment response
One of the most recent, and perhaps the most clinically
significant, of any GWAS to date is the association of a
SNP close to the IL28B gene with response to treat-
ment for hepatitis C.52 In this study, Ge et al focused on
who is cured by treatment, and found that the good
response genotype is associated with a greater than
80% chance of clearance in European-Americans, while
the poor response genotype is associated with only
about a 30% chance. A follow-up study found that the
polymorphism also influences natural clearance of
hepatitis C and shows very sharp geographic differenti-
ation.53 This suggests that the variant may be common
in the population because the “good response” allele
conferred protection against one or more viruses and
hence was positively selected. This variant is a very good
candidate to use as a pharmacogenetic predictor of
treatment response before beginning hepatitis C treat-
ment, since the procedure is long and often associated
with adverse effects.54
The major histocompatibility complex
Setting aside the old-age or pharmacogenetic associa-
tions, many of the strongest reported GWAS associa-
tions of common variants with common disease involve
markers in the major histocompatibility complex
(MHC). These associations are too extensive to discuss
in detail in this review, but include autoimmune diseases,
infectious diseases, neuropsychiatric disorders, and vari-
ability in normal traits such as height.55 A number of
hypotheses have been put forward to explain why vari-
ants conferring disease risk at this locus have been main-
tained at high frequency in the population. One sugges-
tion is that the disease-associated variants have been
selected for because they confer resistance to particular
infectious agents, either now or historically. An alterna-
tive hypothesis is that each locus that confers risk for
one common disease is maintained at high frequency
because it confers protection against one or more other
common diseases. For example, the HLA gene
DQB1*0602, which encodes the β chain for the HLA
class II molecule DQ6, is protective against diabetes,56
but a strong risk factor for narcolepsy57 and multiple
sclerosis.58
GWAS in neuropsychiatry
Neuropsychiatric traits have been among the most dis-
appointing GWAS results. Despite many GWAS, most
associated variants have either not withstood signifi-
cance correction for multiple testing, or else have failed
to replicate. In general, where replicable effects have
been found, they have required very large sample sizes
and the effects have been small.
There have been some notable success stories, however.
Two GWAS have revealed strong and replicable genetic
influences on restless legs syndrome (RLS), a condition
characterized by an unpleasant and irresistible urge to
move the legs, particularly while resting and during the
evening and night. Both studies, one on Icelandic indi-
viduals and one on a more mixed European cohort,
implicated BTBD9.59,60 The European study also found
an association with two other loci: MEIS1 and a locus
encompassing MAP2K5/LBXCOR1.60 The associations
with MEIS1 and BTBD9 were quickly replicated in two
subsequent studies,61,62 but the MAP2K5/LBXCOR1
appears to be weaker, showing a borderline significance
in one study only.62 Although the risk associated with
MEIS1 and BTBD9 (ranging from 1.5 to 3.759,60,62,63) is
substantially lower than those described above, they do
appear to be real and highly significant risk factors for
RLS. Nevertheless, the biology underlying the associa-
tions remains unclear. The associated variants do not
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appear to have any obvious function, and a thorough
search for putative functional variants in all coding
exons and across intron-exon boundaries revealed no
obviously causal variant.64
Another positive GWAS finding in neuropsychiatry is
with narcolepsy, a disorder that causes disrupted sleep
patterns, with the patient often feeling excessively tired
during the day, and suffering sudden sleep attacks. Pre-
GWAS studies had connected the disorder to an MHC
class II antigen called HLA-DQB1*0602, and about 85%
of narcoleptics carry this antigen.65 However, there
remained unexplained heritability. Very recently, a
GWAS study was done on 807 cases and 1074 controls,
all positive for HLA-DQB1*0602. A significant associa-
tion of three SNPs in the T cell receptor alpha locus was
found, which was then replicated in the same study in
1057 further cases and 1104 controls.66 Further analysis
showed a single SNP was responsible for the association,
although it is not clear whether this variant is itself
causal or how it may contribute to disease. This associa-
tion is of particular interest because it adds considerable
weight to the view that narcolepsy is an autoimmune dis-
ease, and as such, it would be the first autoimmune dis-
ease to be associated with a T-cell receptor locus. This
finding also opens up the possibility of immunotherapy
as a future treatment for narcolepsy. 
Other neuropsychiatric diseases for which definite, repli-
cated effects of common SNPs have been found include
schizophrenia, associated with MHC markers, NRGN
and TCF4 (12 945 cases and 34 591 controls, ORs=1.24,
1.15,1.23),67,68 bipolar disorder, associated with ANK3 and
CACNA1C (4 387 cases and 6 209 controls, ORs=1.45
and 1.18)69, and autism, associated with SNPs at 5p14.1 (3
101 family members, 204 cases and 6 941 controls,
OR=1.19).70,71 However, all of these were discovered with
very large sample sizes and account for very little of the
very high heritability of these conditions.
Rare variants
Although studies of common variation in neuropsychi-
atric disease may be underwhelming, the opposite is true
for rare variation. Although the SNP chips used for
GWAS comprise only polymorphisms that are reason-
ably common (~≥5%), their data can be used to find
other types of non-SNP variants—specifically copy num-
ber variants (CNVs)—with much lower frequency.
CNVs are duplications or deletions of large stretches of
DNA—ranging in size from just a few hundred base
pairs to many megabases. To detect such variants, the
intensity data from the SNP chips is examined to deter-
mine whether particular stretches of SNPs are less
intense than expected (or absent), which would indicate
a deletion, or more intense than expected, which sug-
gests a duplication.72 Because the CNVs are identified
on an individual-by-individual basis, very rare CNVs,
even those present in a single individual, can be found.
This has allowed us for the first time to examine the role
of rare variation in common disease (albeit just a tiny
fraction of the total amount of rare variant in a cohort).
The majority of investigations of copy number variation
to date have been in neuropsychiatric disease and, hap-
pily, they have led immediately to real, replicable and
very strong associations. A summary of CNVs recently
strongly associated with neuropsychiatric disease is
shown in Table I. 
These variants confer considerable risk, but they are
not completely penetrant. Although the specific vari-
ants are very rare in the general population, they are
occasionally seen in controls (Table I), and where fam-
ilies have been examined, the variants are often inher-
ited from unaffected or only mildly affected parents.73-77
Additionally, as can be seen in Table I, many of the
variants have been associated with more than one neuro-
psychiatric condition. This is consistent with the char-
acteristics of neuropsychiatrically-associated rare vari-
ants that were found before the GWAS era, such as
DISC1 in schizophrenia, which associated with a
range of phenotypes from psychiatrically normal to
suicide, recurrent major depression, and schizophre-
nia.78 It seems that these variants, rather than predis-
posing to a specific neuropsychiatric condition, may
strongly confer some sort of “neural vulnerability,” the
ultimate manifestation of which depends on other
interacting genetic and environmental factors.
Because, to date, the only rare variants that we have
been able to associate with neuropsychiatric illness
are very large deletions and duplications, it is not clear
whether this lack of specificity will be a general rule,
or is somehow related to the size of the lesion.
However, there is some evidence from the associa-
tions with common SNPs that this is a characteristic
of the disease rather than the size of the associated
variant. For instance, bipolar-associated common vari-
ants in CACNA1C may also confer risk of depression
and schizophrenia.79
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The future for neuropsychiatric genetics
There are two, not incompatible, possible directions for
neuropsychiatric genetics research. One approach is to
continue searching for common variants of small effect
size using much larger cohorts in the tens or hundreds of
thousands. This has been suggested as a future direction
for schizophrenia genetics.80 Although this will require a
considerable effort, there are already established world-
wide collaborations for schizophrenia,68,80 so very large
collections should be achievable in the relatively near
future. The disadvantages of this approach are that if such
huge sample sizes are needed to discover them, the effect
sizes of the associated variants must be very small (Figure
1), and they will be present at a similar frequency in unaf-
fected controls. This makes further study of the effects of
the variants very difficult or impossible. However, pro-
ponents of this approach correctly suggest that although
the associated variant may have a very small effect, the
gene it is in may have a big impact on disease when tar-
geted by novel pharmaceuticals. 
A second argument in favor of proceeding with GWAS
in very large samples is that neuropsychiatric researchers
have long expressed concern that clinical diagnostic cri-
teria do not reflect the biological underpinnings of the
disease, and that diseases such as schizophrenia may in
fact represent multiple different disorders with different
genetic contributors. Thus, only with very large sample
sizes would one expect to obtain sufficient numbers of
any one genetically homogenous subgroup to obtain a
genome-wide significant association. However, as dis-
cussed above, all genetic variants that have been associ-
ated with neuropsychiatric disease so far seem to be very
nonspecific. Where they are found in multiple patients
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CNV Copy # Seen in Seen in Seen in Seen in Other Reported in Lead candidate
linked to schizophrenia autism epilepsy patients disorders controls*? genes
disease patients? patients? patients? with mental
retardation?
1q21.1 Deletion and Deletion Yes75,94 Yes77,83,95, Yes95,96 Congenital heart Deletion, HYDIN
duplication (0.23-0.29%)82-84 unpublished data disease77,97,98, micro- 0.02% paralog77;
and macrocephaly,75,77 (8/41,199),84 GJA884
neuroblastoma,99 frequency for
other75 dup unclear
15q11 Deletion Yes (0.61%)84,100 Yes101 No Yes102 Deletions of this region Yes, (0.19%) CYFIP184
cause Angelman and (79/41,194)
Prader Willi syndrome  (0.19%)
15q13.1 Duplication Yes81,83,84, 103 NR NR NR NR no data APBA2 
and deletion
15q13.3 Deletion Yes (0.17%- Yes Yes Yes73,106 Various including mild Yes, 0.02% CHRNA783,84
0.27%)83,84 (0.31%)84,86,104 (1-1.3%)73,74,110 developmental delay, (8/39,800)74,84
heart defects73
16p11.2 Deletion and Yes94 Yes (0.6%, Yes110,111 Yes76,108 Various neuropsychiatric Yes, 0.01% del, SEZ6L2110,111
duplication del only,107 and developmental76,108 0,03% dup94
1% dup + del94)
16p13.11 Deletion Yes81 Yes112 Yes (0.6%) Yes NR NR (0/3313),87,96 NDEI81
unpublished data (0.5%)87,111 unpublished data but inherited 
from unaffected parents87
CNTN4 Deletion and NR Yes85,114,115 NR NR NR no data
duplication
NRXN1 Deletion Yes Yes85,116-118 NR Yes122,123 NR Yes, 0.04%
(0.19%)81-83,104,120-122 (17/42054)115
Table I. Copy number variants (CNV) strongly associated with neuropsychiatric disorders.. Frequencies are given only when the CNV was found in a
large case-control study design. *Controls may not have been carefully screened for neuropsychiatric illness. NR, not reported; Dup, dupli-
cation; Del, Deletion
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with a single diagnosis (eg, schizophrenia), they do not
segregate patients into any clear diagnostic categories
either by disease presentation or drug response.
Additionally, they tend to associate with multiple neu-
ropsychiatric conditions (Table I). 
The alternative approach is to further investigate the
role of rare variants in neuropsychiatric disease. To date,
the only type of rare variation that has been identifiable
on a genome-wide scale has been large CNVs, and
already we have found many strong associations.81-87 It is
likely that when we can identify the totality of rare vari-
ation in an individual using whole-genome sequencing,
many more rare variants will be found to be definitely
associated with neuropsychiatric illness. Fortunately, this
is rapidly becoming a reality, and the first sequencing
studies in neuropsychiatric illness are already underway.
For confirmation and follow-up, this approach will defi-
nitely benefit from very large cohorts collected for
GWAS, but the ideal discovery samples will be rather dif-
ferent. With this approach, we hope to find variants with
very large effect sizes and high penetrance. This means
that it will be much more straightforward to understand
how the variants exert their effects and what genetic and
environmental factors influence them. To do this, the pri-
ority will be patients and relatives that can be reap-
proached for further study after potentially causal vari-
ants have been identified. Additionally, since initial
sequencing attempts will be expensive, it is worth, at first
at least, selecting patients who are most likely to carry
highly penetrant genetic variants. These include severely
ill, treatment-resistant patients88 and patients with a
strong family history of mental illness. Thus, this approach
benefits from close collaboration between geneticists and
psychiatrists and a thorough understanding of each
sequenced patient and his or her relatives.
Although it is hoped that whole-genome sequencing will
lead swiftly to a clearer understanding of neuropsychi-
atric disease, there are many challenges ahead. Not least
is a very well-characterized psychiatrically normal con-
trol cohort. And, as with any new technology, there are
considerable technical challenges, such as the use of
whole-genome data to identify copy number variation.
However, software is constantly developing and it is
doubtful that these will be limiting factors for long.89-92
There are also “genomic” challenges: there are many
regions of the genome on which we tend not to focus,
such as remote enhancer regions, upstream open read-
ing frames, and chromatin binding sites, which are likely
to be functional and affected by rare variation. However,
using Mendelian diseases as a model, it is reasonable to
expect that many of the most important variants will be
in or very close to exons.93 Thus, neuropsychiatric geneti-
cists should be able to gorge themselves on the low-
hanging fruit for some time to come.
In summary, there have been many GWAS success sto-
ries in which common variants have been found to asso-
ciate definitely with complex diseases. In most cases,
however, the mechanism underlying the association is
not well understood, and they have not yet led to strong
predictive tests or to novel treatments. Neuropsychiatric
disease, in particular, has so far benefited little from
large-scale analysis of common variants. Use of GWAS
data to examine rare copy number variants, however,
rapidly led to multiple strong and highly penetrant asso-
ciations with neuropsychiatric illness. However, the asso-
ciated variants are not completely penetrant and tend to
be associated with multiple neuropsychiatric conditions.
Detailed studies of patients and their relatives will be
necessary to understand what factors affect the mani-
festation of the phenotype. Despite this recent success,
we can still only account for a very small amount of the
heritability of neuropsychiatric conditions. Further inves-
tigation of rare variation using whole-genome sequenc-
ing is likely to significantly advance the field.
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he dawning of a new decade is an appropriate
time to reflect on the tremendous progress that has been
made in human genomic research. In 2010, with whole-
genome sequencing becoming increasingly affordable,
the promise of large-scale human genomic research stud-
ies involving hundreds, thousands, and even hundreds of
thousands of individuals is rapidly becoming a reality.
The next generation of human genomic research will
occur on a scale that would have been nearly unfath-
omable at the start of the last decade, when the publica-
tion of the Human Genome Project’s first draft results
was still pending.
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The cost of a diploid human genome sequence has dropped from about $70M to $2000 since 2007—even as the standards
for redundancy have increased from 7x to 40x in order to improve call rates. Coupled with the low return on investment
for common single-nucleotide polylmorphisms, this has caused a significant rise in interest in correlating genome sequences
with comprehensive environmental and trait data (GET). The cost of electronic health records, imaging, and microbial,
immunological, and behavioral data are also dropping quickly. Sharing such integrated GET datasets and their interpre-
tations with a diversity of researchers and research subjects highlights the need for informed-consent models capable of
addressing novel privacy and other issues, as well as for flexible data-sharing resources that make materials and data avail-
able with minimum restrictions on use. This article examines the Personal Genome Project’s effort to develop a GET data-
base as a public genomics resource broadly accessible to both researchers and research participants, while pursuing the
highest standards in research ethics. 
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When the Human Genome Project published its draft
results on June 26, 2000, it published a compound human
genome sequence containing genetic information from sev-
eral volunteers. Seventy percent of the final sequence was
obtained from one anonymous individual, while the remain-
ing 30% came from a number of different individuals. From
the first amalgamated human genome sequence—which
was refined in 2003 and continues to be updated and refined
to this day—private and public research efforts have gone
on to sequence numerous individual human genomes with
increasing speed and detail and decreasing time and cost.
The acceleration of whole-genome sequencing in the
research context necessitates new perspectives and models
that enable scientists and society to learn as much as pos-
sible from this rapidly expanding dataset while still respect-
ing important ethical, legal, and social norms.
The Personal Genome Project (PGP),1 an ambitious
research study directed by faculty members in the
Department of Genetics at Harvard Medical School, aims
to recruit as many as 100 000 informed participants to con-
tribute genomic sequence data, tissues, and extensive envi-
ronmental, trait, and other information to a publicly acces-
sible and identifiable research database.
In this review we describe the Personal Genome Project
itself, focusing on its unique structural features and the
rationale behind the project’s design. We also elucidate the
changing scientific and social landscape that makes the
PGP’s model of open consent and public data access
increasingly important to the furtherance of human
genomic research.
The PGP’s mission
In contrast to research studies that focus on small sub-
sets of traits within narrowly defined human populations
exhibiting single diseases, the PGP was conceived with
an expansive mission. From the outset, the mission of the
project (Table I) has been to develop a broad-based, lon-
gitudinal, and participatory research study that will facil-
itate a comprehensive understanding of the project’s
participants at the genomic level and beyond. 
The PGP is constructed with the recognition that our
desire to truly understand the genesis of most complex
human traits—from dread diseases to the talents and
quirks that make us each uniquely human—could only
be satisfied by examining genomic information in con-
text and by surrounding it with the richest possible data
from the widest possible array of supplemental sources.
By supplementing genomic sequence data with the col-
lection and analysis of tissues and extensive environ-
mental and trait data, and by making these data publicly
accessible to researchers worldwide, the PGP aims to
improve understanding of the ways in which genomes
plus environments ultimately equal traits (Figure 1).
The PGP is more than just a research repository. In addi-
tion to its publicly accessible research database, the PGP,
which is supported by the nonprofit PersonalGenomes.org,
also works to disseminate genomic technology and knowl-
edge at a global level, thereby producing tangible and
widely available improvements in the understanding and
management of human health and disease. The PGP also
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The Personal Genome Project’s Mission Statement
The mission of the Personal Genome Project is to encourage the development of personal genomics technology and practices that: 
• are effective, informative, and responsible 
• yield identifiable and improvable benefits at manageable levels of risk 
• are broadly available for the good of the general public 
To achieve this mission we will build a framework for prototyping and evaluating personal genomics technology and practices at increasing 
scales. In support of this goal, we will: 
• develop a broad vision for how personal genomes may be used to improve the understanding and management of human health and 
disease 
• provide educational and informational resources for improving general understanding of personal genomics and its potential 
• recruit individuals interested in obtaining and openly sharing their genome sequences, related health and physical information, and 
reporting their experiences as a participant of the project on an ongoing basis 
• develop technologies to improve the accessibility of personal genome sequencing 
• foster dialog with research communities, industries, and public and governmental bodies with interests in personal genomics, and related 
ethical, legal, and social issues (ELSI)
• develop tools for interpreting genomic information and correlating it with personal medical and biological information
Table I. PGP’s Mission Statement, available at: htttp://www.personalgenomes.org/mission.html.1
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finds itself at the forefront of discourse surrounding the
ethical, legal, and social issues (ELSI) associated with
large-scale whole-genome sequencing, particularly in the
areas of privacy, informed consent, and data accessibility.
The PGP is, and is intended to be, a research project that
is constantly in progress, exploring the boundaries of
human genomic research in a way that produces maxi-
mal advances in scientific understanding and public
understanding and well-being, while striving to reach
beyond what is minimally required to satisfy its ethical,
legal, and social obligations to its participants. In the sec-
tions that follow we report on unique aspects of the PGP
relating to technology development, integrative
genomics, and human subject research protocols, as well
as describe the development and current state of the
PGP.
Key developments in 
human genome sequencing
The PGP derives its impetus and importance from his-
toric breakthroughs in understanding and analysis of
DNA. DNA comprises only a very small fraction of a
cell (~3% dry weight E. coli), and its role as the mole-
cule primarily responsible for transmission of genetic
traits was not recognized until a series of discoveries
beginning in the 1940s. The emergence in 1953 of a clear
concept of DNA as a double-helical structure compris-
ing a pair of complementary strings of four elementary
bases (the nucleotides A, C, G, and T) crystallized inter-
est in determining the DNA sequences of genes and the
sequence differences responsible for disease, and set the
stage for over four decades of development of ever more
efficient and comprehensive sequencing methods. Table
II describes this history by a set of milestones that take
one from the early beginnings of DNA sequencing up
through delivery of draft human genome sequences in
2001 to 2003. In the 38 years between 1965, when Robert
Holley and colleagues at Cornell and the US
Department of Agriculture sequenced a 77 nt RNA
gene after 4 years of effort, and 2003, when the public
Human Genome Project (HGP) declared that it had met
its goals regarding delivery of a ~3Gbp human genome
sequence, the size of DNA sequence that could be




Notably, the HGP had delivered only a single human
genome sequence that was a composite built from a small
number of deidentified individuals, while the competing
nonpublic human genome project merged in data from an
identified individual (Craig Venter); both were haploid
estimates. As recognized from the beginning of the HGP,
many additional resources would be needed to under-
stand the functions of the genes laid out in these “refer-
ence” human genomes, and to identify the sequence dif-
ferences between individuals that contribute to individual
traits, health, and disease. Indeed, as the HGP ended, pro-
jects were already under way to identify large numbers of
genetic differences from the HGP-derived reference
genome in different human populations that could sub-
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Figure 1. Genome + Environment = Traits (GET) equation. Envirome: the totality of environmental influences; VDJ-ome: the DNA sequences of the entire
repertoire of an individual’s immunoglobulin and T-cell receptors, which reflect a lifetime of antigenic exposures; Microbiome: the billions of
commensal, symbiotic, and pathogenic micro-organisms that share our body space; Epigenome: the totality of programmed biochemical and
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sequently be analyzed using low-cost array methods in
large numbers of individuals, a strategy that has since
given rise to more than 480 published genome-wide asso-
ciation studies.16,17 At the same time, however, interest was
rising in the second approach: to significantly improve
DNA sequencing technology to a point where an indi-
vidual’s entire genome could be sequenced at very low
cost. A combination of two kinds of arguments were
advanced supporting this approach, focusing on functional
utility and economics, respectively. 
The gist of the functional arguments was that sequenc-
ing of individuals is intrinsically more informative and
flexible than array-based interrogation of known sites of
variation and that, variation aside, any improvements in
sequencing cost and capability could be quickly applied
to numerous general aspects of biology that are critical
to understanding gene function, traits, and health and
disease.18,19 The relative advantages of sequencing have
long been recognized. Unlike array analyses, sequenc-
ing: (i) does not require variations to be preidentified;
(ii) can more readily accommodate more complex vari-
ations than single nucleotide changes and very short
inserts or deletions; and (iii) need not focus on variations
that are common in large populations vs rare or unique
variations. In consequence, as sequencing technology has
improved, it has increasingly been integrated into asso-
ciation studies of variation.20-23
However, these advantages of sequencing were coun-
terbalanced by their high cost, a situation well illustrated
by the $3 billion US cost of the HGP itself. It is here that
economic arguments were advanced suggesting that dra-
matic improvements in sequencing were feasible that
might ultimately enable an individual’s genome to be
sequenced for 1000 to 10 000 USD.18 On an empirical
level, sequencing technology has appeared to exhibit a
historical trend of exponentially decreasing costs with
time as measured by sequenced base pairs per dollar at
a given error rate, a situation frequently compared with
“Moore’s Law” in computing,24 which noted that com-
puting power measured by the integrated circuit tran-
sistor density doubled roughly every 2 years at constant
cost (Figure 2).18,25 To get genome sequencing costs down
to $1000 would require cost and throughput improve-
ments of an additional 4 to 5 orders of magnitude, so the
question of economic feasibility ultimately turned on
whether new methods could enable this very large
improvement. 
Here, the HGP again gave grounds for optimism, for
even though the HGP itself only achieved 100-fold
improvements, it achieved this largely by refining, minia-
turizing, and robotically scaling up, but not fundamen-
tally changing, a Sanger sequencing method initially
developed over 20 years earlier (Table II). If such meth-
ods were capable of 100-fold improvement, considerably
greater improvements might be expected from more rad-
ically changing sequencing chemistry, signal generation
and detection, and instrumentation in ways that could
integrate some of the vast advances in chemistry and
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Date Event Size of sequence (bp) Reference
1957 First sequence mutation identified responsible for disease 1 amino acid (Ingram 19572) 
(sickle cell vs normal hemoglobin)
1965 First sequence of a single complete gene 77 bases (Holley, Apgar et al 19653)
1976-1977 Sequencing of first viral genomes 3562 bases (MS2 RNA phage) (Fiers, Contreras et al 19764;
5375 bases (φ X174 DNA phage) Sanger, Air et al 19775)
1975-1977 Maxam/Gilbert and Sanger DNA sequencing methods (Sanger and Coulson 19756; 
Maxam and Gilbert 19777;
Sanger, Nicklen et al 19778)
1994 First commercial bacterial genome sequence 1.7Mbp (Helicobacter pylori) (Nature Genetics, May 19969)
1995 First published bacterial genome sequence 1.83Mbp (Haemophilus influenzae) (Fleischmann, Adams et al 199510)
1998-2000 Genome sequences of first animals 100Mbp (Caenorhabditis elegans) (C. elegans Sequencing
120Mbp (Drosophila melanogaster) Consortium 1998,11 Adams, 
Celniker et al 200012)
2001 Two draft sequences of human genome ~3Gbp (Lander, Linton et al 2001,13
Venter, Adams et al 200114)
2003 Completion of public Human Genome Project (Collins, Morgan et al 200315)
Table II. Development of DNA sequencing. 
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enzymology, optics and electronics, materials science,
microfabrication, and process control that had accrued
over the preceding 20 years and been put to good use in
many other fields. The HGP also directly provided an
important resource for realizing this strategy: the refer-
ence human genome sequence itself, as this could serve
as a template against which reads obtained by new tech-
nologies could be located, allowing new human genomes
to be assembled at least initially by “resequencing” vs de
novo assembly. This reduces the burden on new sequenc-
ing methods by allowing them to generate useful data
with shorter reads and higher base call error rates than
would generally be needed for de novo assembly,
although de novo assembly of genomes using new
sequencing technology remains an important goal.
Next-generation sequencing
Researchers were quick to work out sequencing
approaches along the lines indicated in these arguments,
and commercial products emerged soon, giving rise to
next-generation sequencing (NGS). Soon granting agen-
cies promised funding for support, and a ~10M USD
competition was announced for rapid, accurate genomic
sequencing, generating increased coalescence around
target goals for dramatic improvements to sequencing
technology.26,27,28 Detailed reviews and comparisons of
NGS approaches have been published.18,29,30
Among the earliest NGS methods were polony sequenc-
ing (the Polonator) and 454 Life Sciences.31,32,33 Both meth-
ods amplify DNA templates onto microbeads that are
packed onto two-dimensional arrays for sequencing,
thereby achieving enormous economies of scale com-
pared with Sanger sequencing, and each achieved ~25-
fold better cost per bp compared with HGP (Figure 2).
However, each uses different sequencing chemistry and
arraying technology, giving rise to many technical trade-
offs. Together they proved the general point that great
improvements in sequencing efficiency were indeed
within reach, but also that the precise character and
degree of improvement would depend closely on the
novel technologies employed and the ingenuity with
which they could be integrated. A second wave of devel-
opment introduced methods by Illumina and ABI that, by
very different means, have improved the utility and costs,
(Figure 2)34,35 and hence use of these systems is becoming
widespread for both large scale and “deep” sequencing
applications, and both are under continuous development.
Two complete cancer genomes were recently sequenced,
one with each platform.36,37 Further rounds of innovation
have yielded a diverse set of newer NGS methods. For
instance, a number of “single-molecule” sequencing meth-
ods are now available or in development. These methods
avoid the need to make thousands to millions of copies of
DNA template molecules on microbeads or surfaces to
assure that sequencing operations generate sufficient sig-
nal to read individual bases accurately, and instead use
highly sensitive optics to detect bases at the single mole-
cule level; this allows even denser packing of DNA tem-
plates and further efficiencies in sequencing chemistry.
While Helicos Biosciences has commercialized a single-
molecule system that simply arrays single template mol-
ecules on a surface and uses sequencing cycle similar to
the methods above, Pacific Biosciences is developing a
system in which enzymes and templates are tethered to
the bottom of nanofabricated wells and which monitors
the signals generated by sequencing chemistry in real-
time vs artificial cycles.38,39 Here, the nanofabricated wells
enable substantially increased accuracy of single molecule
base incorporation events. Finally, on another track, the
company Complete Genomics, Inc has developed a
method whereby very compact self-assembling amplicons
of template DNAs called “nanoballs” are flowed onto a
nanofabricated grid of ~300nm spots at 700 to 1300 nm
center-to-center distances. Three complete human
genomes were sequenced with this method (as of January
2010) with an average consumable cost of $4400 and as
low as $1500 for 40X coverage.40
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Figure 2. Exponential trend of sequencing costs in base pairs per USD
(bp/$), a trend often compared with Moore's Law (see text). See
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Towards affordable personal genomes
These developments suggest that technology capable of
meeting the cost target of $1000 or less for a diploid
human genome sequence is within reach. Indeed, the in-
depth resequencing of individual human genomes has now
been demonstrated several times by NGS developers to
demonstrate that their methods have come of age. There
are now published full genome sequences for at least
seven individuals,40 with some having been sequenced by
more than one method. There are also tens—and perhaps
hundreds—of additional unpublished or partly published
genomes (see, eg, refs 36,37),while the lower-coverage 1000
Genomes Project20,21 continues. Clearly, the age of personal
genomics is now close at hand. 
The PGP
As described in the first section, one of the PGP’s central
aims is to develop a publicly available, fully consented
database containing comprehensive human genome and
phenome data for its research participants. Such inte-
grated datasets are fundamental drivers of progress in
functional genomics and enable systems biology-based
insights into the mechanisms of human health and dis-
ease.41 PGP studies will look beyond inherited genomes
to include somatic and epigenetic variation data, as well
as relevant microbiome, transcriptome, immunity-reflect-
ing “VDJ-ome” and phenome data to develop compre-
hensive profiles. By developing high-resolution data pro-
files for each participant, and multiplying that by a large
(up to 100 000) participant population, the PGP will also
generate valuable data describing the kinds and distrib-
utions of variation that exist in populations. Although an
improved understanding of human health and disease is
a central aim of the PGP, its focus is considerably broader
and will enable research into the social and behavioral
sciences using personal genomic data. Finally, the PGP’s
flexible study protocol and public and distributed
approach to research enables it to keep pace with
sequencing and other technological advances while
simultaneously driving these developments.
Integrated personal genomes: inherited, somatic, envi-
ronmental genomics 
If the PGP is to fulfill its mission to address the multidi-
mensional complexity of human biology, it must encom-
pass multiple interacting “-omes.” For example, a per-
son’s diet will have a profound influence upon her or his
somatic gene expression as well as the genomic and pro-
teomic activity of the person’s microbiome. It will also
affect the metabolome. Similarly, an individual’s envi-
ronmental exposures to pollutants will have a direct
bearing on her or his immunological response and there-
fore, on the VDJ-ome. Germline alleles will affect how
one metabolizes drugs, which will have myriad effects on
an individual’s physiological and behavioral phenotypes.
Genomes (vs exomes)
In its early phase, given the then-current cost of genomic
sequencing, the PGP planned to focus on exomes rather
than whole genomes as a way to affordably expand the
project to large numbers of participants. Despite repre-
senting only 1% to 2% of the 6 billion base pairs in a
human genome, the exome contains all protein-coding
exons and therefore provides access to the majority of
known functional variants.48,49,50 However, continued
improvements in genomic sequencing have produced
price declines that have rendered whole-genome
sequencing significantly cheaper per base pair than
exome sequencing. The PGP, as a result, has determined
that whole-genome sequencing is cost-justified given the
relatively high price of exomes and the additional infor-
mation supplied by whole-genome sequences of PGP
participants.51 See also Table III for the various “omes.”
Phenomes
Detailed phenotype data is required to categorize and,
ultimately, understand the phenotypes that the PGP
seeks to explore. However, the vastness of the human
phenome, defined as the physical totality of human traits
at all levels, from the molecular to the behavioral, will
require new strategies that permit high-throughput trait
collection while yielding accurate and standardized phe-
notypic data. With regard to the cellular and molecular
phenotypes, the PGP collects participant tissue samples
and develops cell lines that are then deposited and pub-
licly accessible through established biobanks.52,53
As the PGP expands it is exploring Web-based, high-
throughput behavioral phenotype data-collection mod-
els pioneered by leading public and private researchers.
While the reliability and validity of self-reported traits
is a concern, particularly for phenome research con-
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ducted online,54,55 Web-based assessments provide dis-
tinct opportunities for “dynamic phenotyping” based on
a particular individual’s prior genotype-phenotype asso-
ciations.56 The multimodal capabilities of Web-based trait
collection instruments, combined with their low cost of
implementation at large scales, seem likely to accelerate
the ability of studies like the PGP to effectively explore
new corners of the human phenome.
The PGP is also taking advantage of recent advance-
ments in health information technologies to assist par-
ticipants and researchers alike in structuring and access-
ing the massive amounts of personalized data generated
by the project. The emergence of online Personally
Controlled Health Record (PCHR) platforms and other
novel tools enables individuals to collect and manage
their own health data—including health history, med-
ication, allergy, immunization, biometric and other data
types57,58,59—and can be developed for integrated data
entry, access and dissemination by both the individual
and third-party researchers or data providers, including
health care providers.
Enviromes
The picture of genome and phenome is incomplete with-
out the envirome. The envirome can be described as the
totality of equivalent environmental influences con-
tributing to all disorders and organisms.60 The mode of
response of an organism to the environment that is
reflected in its phenotype is constrained by its unique set
of genetic variations and the environmental influences on
gene expression. Therefore, a comprehensive approach is
required to describe the envirome systematically in con-
junction with genome and phenome information. The rel-
evant envirome data is too large and complex to be
reported, managed, or analyzed manually. The creation of
phenome-genome and genome-envirome networks has
been suggested in order to relate phenome and envirome
information to potential disease-associated genes.61
Microbiomes
Even though microbial cells are estimated to outnumber
human cells in a single individual by a factor of ten, we
know very little about the microbes that live in and on us,
including what mixture of bacteria, viruses, and other
micro-organisms constitute a “normal” human micro-
biome and how those organisms impact different biolog-
ical states.62 Major efforts such as the Human Microbiome
Project are under way to characterize the microbiota at
different body sites in humans and to assess how variation
in microbial communities is associated with states of
health and disease.63 The PGP takes advantage of the
unique availability of comprehensive participant profiles
and uses them to explore interactions between host
genetic and phenotypic variability alongside the genomic
variation in the microbes that colonize them.64
The VDJ-ome
The Church Lab at Harvard Medical School is develop-
ing techniques for characterizing the repertoires of B-
and T-cell receptors in individual humans from blood
samples and correlated across time with personal expo-
sure histories, with an ultimate goal of characterizing
individuals repertoires of linked VDJ and VJ sequences.
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Personal genome: Entire diploid human genome of a single individual representing 6 billion base pairs.
Exome: All exons, representing 1% to 2% of the entire human genome.
Phenome: Set of all traits in an organism, at all levels, or one of its subsystems, including morphology, physiology, and behavior.42,43
Envirome: The totality of equivalent environmental influences contributing to all disorders and organisms.44
Microbiome (human): The ecological community of commensal, symbiotic, and pathogenic microorganisms that share our body space.45
VDJ-ome: The repertoire of rearranged V, D, and J genome segments present in an individuals's B and T immune cells at any given time (see 
Table IV).
Transcriptome: The set of all RNA molecules, including mRNA, rRNA, tRNA, and noncoding RNA produced in one or a population of cells.46
Epigenome: The totality of programmed biochemical and structural modifications to genomic DNA that regulate organism or phenotype 
development.
Metabolome: Total set of metabolites generated by an organism, or subsystem.
Proteome: The entire set of proteins expressed by a genome, cell, tissue or organism at a given time under defined conditions. There are 
more proteins than genes.47
Table III. The “omes.”
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These techniques will be directly applicable to PGP par-
ticipants and their self-reported data, and will yield a
database of unprecedented depth describing the diver-
sity and time development of human immune responses
of large numbers of individuals in their life contexts.
Tissue reprogramming
The PGP also applies advances in tissue reprogramming
techniques to tissue samples collected from PGP partic-
ipants. Cells from collected somatic tissues are repro-
grammed into induced pluripotent stem (iPS) cells68 and
made to differentiate into the cell types that are targeted
for functional analysis. These methods enable experi-
mental access to diverse tissue types that would other-
wise be unobtainable from human subjects but are rou-
tinely analyzed in model organisms, and thus, PGP
participants can effectively serve as human model organ-
isms. By examining multiple cell types from a single indi-
vidual, differences in physiological states within and
between tissues can be compared within a single PGP
participant and/or across the entire PGP cohort. This
approach also permits researchers to elucidate connec-
tions between genetic variation and variation in other
molecular traits, such as gene expression or epigenetic
modifications.69 Stored fibroblast cell lines provide
researchers with access to renewable supplies of differ-
ent tissue types from PGP participants. 
The PGP: from personal to public genomes
The potential benefits arising from large-scale and inte-
grated human genomic datasets are immense.70 The util-
ity of such research, however, depends upon the respon-
sible development and widespread availability of such
comprehensive datasets, which in turn depends on
describing and addressing the various ethical, legal and
social challenges. Those challenges include a standard set
that are inherent to any research involving human sub-
jects, as well as certain challenges that are unique to
“public genomics”71 research involving publicly available,
identifiable whole-genome sequence data, such as the
model pioneered by the PGP. We use the term “public
genomics” to denote research studies that possess the
following three critical attributes.
Integrated data
The various data types, including genomic and phenomic
or trait data, are accessible in a linked format, such as a
PCHR or other integrated data structure. Through this
explicit linkage of data it is possible to ascertain the
complete list of available traits and genetic variants for
any given participant. Integration also facilitates partic-
ipant-researcher interactions, longitudinal study and
recontact and, crucially, simultaneous investigation of the
full range of complex trait associations. Although par-
ticipants need not be explicitly identified, integrated data
sets that include both genomic and phenomic data will
be identifiable in most cases. For this reason, participants
must be made explicitly aware of the probability that
they will be identified with their publicly available data,
rendering promises of perfect privacy, anonymity, or con-
fidentiality impermissible within the public genomics
model. However, the promise of privacy need not give
way to a promise of publicity.
Open access
Data sets and tissues are made publicly available with
minimal or no access restrictions (including researcher
qualifications and cost), and are generally transferable
outside the original research study to be utilized by and
combined with data from third parties. Well-developed
data structures and intellectual property licenses are
important components of this characteristic. Developing
datasets that are not only publicly available but also eas-
ily portable fosters the development of a genomic com-
mons, allows data validation by third parties, and enables
the use and application of data in novel contexts that
may not be foreseeable at the time of collection, thereby
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The adaptive immune system 
The adaptive immune system enables individuals to respond to 
their unique exposure histories to pathogens and environmental 
antigens, and possibly to cancerous mutations in their own cells, by
generating and modulating expression of >1012 unique antibodies
from B cells and T cell receptors.65 Antibody diversity derives from
programmed stochastic rearrangements in maturing B cells of ~40
V, 23 D, and ~5 J functional genomic segments into VDJ heavy
chains, and ~35 V and ~5 J segments into VJ light chains (κ or λ) in
B cells, that are further randomized by somatic hypermutation; a
similar process occurs in T cells.66 NGS methods are now allowing
researchers to identify and analyze expressed VDJ sequences in
depth.67
Table IV. The adaptive immune system and the VDJ-ome.
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facilitating hypothesis generation, encouraging serendip-
ity and broadening the genomic research community.
Voluntary and informed participation
Satisfaction of the first two criteria publication of an inte-
grated dataset in an open-access format necessitates that
a premium be placed on receiving truly voluntary and
informed consent from participants in public genomics
research projects. Given the yet-unknown outcomes and
the potential personal, familial, and social risks associated
with such research, enrollment is only acceptable under
an informed consent protocol that is specially designed
to meet the highest standards of human research subjects
protection in view of these conditions.
The study protocol
The PGP aims to produce public genomics research—
and to develop and evaluate associated technologies
and research—on a large and expanding scale. In
October of 2008, the PGP published the first inte-
grated set of DNA sequences, traits, and tissues col-
lected from ten participants (the “PGP-10”) enrolled
in a pilot study initiated in 2005. Today, the PGP is
incrementally expanding its cohort toward 100 000
participants. More than 12 000 individuals had regis-
tered to participate in the PGP as of February 2010. In
the following section we highlight significant features
of the PGP study protocol as it is implemented for the
enrollment of the first 100 participants (“PGP-100”)
and summarized in Table V. 
Public genomes: adding to ELSI
The practice of public genomics poses its own challenges,
especially for the organization and governance of human
subjects’ research, forcing us to critically reassess current
frameworks and practices. In order to pursue innovative
research in a responsible manner, the PGP has devel-
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Table V. Overview of PGP study protocol. 
Adapted from ref 52: Angrist M. Eyes wide open: the personal genome project, citizen science and veracity in informed consent. Pers Med. 2009;6:691-699.
Copyright © Future Medicine 2009
• Review and sign “mini-consent” form.
• Eligibility questionnaire about family circumstances and privacy preferences.
• Entrance exam to ensure informed consent; includes potential risks of participating, project protocols, and basic
   genetics.
• Review of full PGP consent form.
• Submit information or delete account.
• Consent to participate.
• Collection of baseline trait data via questionnaire and a personal health record. Includes allergies, 
   immunizations, medical history, medications, physical traits and measurements, diet, ethnicity/ancestry, lifestyle, 
   and environmental exposures.
• Participants asked to make a financial pledge (does not impact enrollment decisions).
• Identity verification and provision of mailing address.
• Submission of application for enrollment. Individuals selected to continue the enrollment process will receive an 
   enrolment kit by mail, including saliva collection materials.
• Participants may be interviewed by one or more PGP staff to verify identity and consent, confirm familiarity with 
   study protocols, and/or review trait questionnaire responses. Blood samples, saliva sample, and/or skin cells may 
   be collected.
• Tissue samples prepared for DNA sequencing and other biological analyses.
• Participants opt-in to have their profiles made available on a publicly accessible Web site, or withdraw from the 
   study.
• Establishment, distribution and analysis of cell lines for research.
• Information collected for 25 years. Participants can leave the study at any time.
• Data Safety Monitoring Board monitors the impacts of the PGP on enrolled participants. Quarterly emails 
   inquire about adverse events.
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oped a number of project-specific tools and resources
relevant to ELSI. 
Open consent 
The “open consent” model developed by the PGP is
designed to address the set of challenges associated with
the creation of datasets where it may be possible to iden-
tify individual participants with their genomic and other
data. The open consent model assumes that, in such a
context, conventional assurances of anonymity, privacy
and confidentially are impossible and should not serve
as any part of the foundation for the informed consent
protocol.72,73 Due to the structure of public genomics pro-
jects such as the PGP, and their associated datasets, while
privacy and confidentiality can be protected they cannot
and should not be guaranteed to participants. This prac-
tice ensures veracity, which we regard as a necessary—
though not sufficient—prerequisite for the exertion of
substantive autonomy. It is only through veracity that the
criteria underlying truly informed consent can be satis-
fied.
Open consent is therefore based on complete openness
and transparency with regard to all aspects of participa-
tion, including the potential for reidentification and the
reality that there may be other risks that are unidenti-
fiable at the time of consent. Predicting all potential risks
is by definition impossible and even a list of known pos-
sible risks is unlikely ever to be comprehensive.
Data sharing—and the risks of public genomes
The PGP’s informed consent process begins with an
extensive pre-enrollment educational examination
designed to ensure a potential participant’s ability to
understand the specific nature of the data collected and
the risks presented by public genomics research. For indi-
viduals who demonstrate the needed proficiency, the spe-
cific informed consent agreement that follows includes a
lengthy but “noncomprehensive list of hypothetical sce-
narios that could pose risks” for participants and their
families (Table VI). Participants are warned that “the com-
plete set and magnitude of the risks that the public avail-
ability of [your genomic data] poses to you and your rel-
atives is not known at this time.” It is crucial that
participants understand that once identifying genetic and
trait data and tissues are released into the public domain
for the express intent of broad dissemination and use by
third parties it will be, in all likelihood, impossible to effect
a meaningful retraction at a later date.
The PGP’s informed consent agreements and broader
study protocol are developed in continuous close interac-
tion with the Harvard Medical School Committee on
Human Studies. The project is also overseen by an inde-
pendent Data Safety Monitoring Board. Removing poten-
tially disingenuous promises of anonymity, privacy, and
confidentiality, while seeking to comprehensively and
openly describe both known and unknown risks of partic-
ipation, helps to ensure that research participants are as
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Potential risks of participation in the PGP as described in the consent form (Abbreviated) 
• The risks of public disclosure of your genetic and trait information could affect your employment, insurance and financial well-being and 
social interactions for you and your family. 
• Anyone with sufficient knowledge and resources could take your DNA sequence data and/or posted trait information and use that data, 
with or without modification, to: (i) infer paternity or other features of your genealogy; (ii) claim statistical evidence that could affect your 
employment, insurance or ability to obtain financial services; (iii) claim relatedness to criminals or incriminate relatives; (iv) make synthetic 
DNA and plant it at a crime scene, or otherwise use it to falsely identify you; or (v) reveal the possibility of a disease or unknown propensity 
for a disease.
• Whether or not it is lawful to do so, you could be subject to actual or attempted employment, insurance, financial, or other forms of 
discrimination or negative treatment on the basis of the public disclosure of your genetic and trait information by the PGP or by a third party.
• The distribution of your cell lines could result in the creation and further distribution by a third party of additional cell lines, organs, or 
tissues containing your DNA for research, commercial, clinical, or other uses, including certain forms of assisted reproduction, some of which 
you may find objectionable or upsetting.
• If you have previously made available or intend to make available genetic information in a confidential setting, for example in another 
research study or in a clinical trial, the data that you provide as part of the PGP may be used, on its own or in combination with your 
previously shared data, to identify you as a participant in otherwise confidential genetic research or trials.
Table VI. Potential risks of participation.
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informed as possible about the nature of public genomics
research and, simultaneously, safeguards the trustworthi-
ness of scientists and of scientific research in general.
Return of research data to participants
Research volunteers have been traditionally treated as
“objects” of study who have no intrinsic rights to the
data generated by their participation.74 Today, we see
that study participants are increasingly asking for access
to their data75 and that available information and com-
munication technologies have turned the return of
research results into a feasible option. While some
researchers adhere to the traditional viewpoint that
research subjects should not or cannot receive identifi-
able research data, some have suggested legal and ethi-
cal grounds for finding that researchers possess the
obligation to inform their participants of certain results,
particularly when they are clinically actionable.76
However, defining the scenarios in which research
results should be reported—and how to report such
results—remains a challenging issue. The medical, finan-
cial, and psychosocial risks of disclosing variants of
known and unknown clinical significance require that a
careful distinction be made between those variants in
which convincing clinical observational data exists and
those in which disease association is less robust; a dis-
tinction that can influence both when and how to return
results. Other concerns that have been voiced include
the uncertainty surrounding regulations governing the
return of genomics research results directly to partici-
pants, the impact of false-positive and/or false-negative
results, as well as the “incidentalome,”77 and in the con-
text of commercial direct-to-consumer testing, the con-
cern that obtaining results could lead to a “raiding of the
medical commons.”78
As new models of genomic research and commerce
emerge, new mechanisms for communicating results to
participants are also being explored. Many of these new
models embrace a high level of involvement from their
participants and, in return, may rely on some combina-
tion of education, informed consent, and intermediation
to return data in a responsible fashion.79
The public genomics model adopted by the PGP utilizes
the first two approaches while foregoing the third, opting
to return data directly to research participants without
the required intervention of an intermediary. The advan-
tages of direct data return and participant communica-
tion are blunted by the partial shifting of the interpreta-
tive burden from the clinician to the researcher. The PGP
has approached this issue by focusing on data disclosure
via the Preliminary Research Report (PRR), which con-
tains a noncomprehensive list of genetic variants present
in the participant’s DNA sequence data currently
thought to have a likelihood of clinical relevance among
individuals possessing such variants.
This preliminary identification of potentially significant
variants is not intended to substitute in any way for pro-
fessional medical advice, diagnosis or treatment. It lever-
ages current knowledge by combining an evolving set of
filtering algorithms and the use of existing variant data-
bases— neither of which can be expected to have 100%
accuracy in identifying truly pathogenic variants given
the gaps in current scientific understanding. Participants
are specifically instructed to confirm any potentially sig-
nificant findings in consultation with their health care
provider. It is possible that the increased rate of data
return from public genomics research—as well as from
commercial providers of personal genomic data—will
help speed the creation of universal standards for clini-
cal genomic interpretation that will help shift some of
the interpretative burden back away from public
genomics researchers.
Outlook: the PGP from 10 to 100 000
After publishing initial data from its first 10 participants
in 2008, the PGP has continued to broaden the scope of
the information it is collecting and publishing while
simultaneously commencing the next stages of partici-
pant enrollment. From exome to whole-genome
sequence data, the development and release of the GET-
EvidenceBase tool80 for generation of Preliminary
Research Reports, and the publication of substantial
scholarship based on the PGP data generated to date,
the project’s progress has been substantial. The PGP is
now supported by PersonalGenomes.org, a 501(c)(3)
non-profit charity that coordinates the international
efforts of the PGP with other collaborative public
genomics research projects around the world. Both the
PGP and PersonalGenomes.org continue to strive to
develop and disseminate genomic technologies, pheno-
typing strategies, and knowledge on a global scale and
to produce tangible and widely available improvements
in the understanding and management of human health
in a responsible fashion. 
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Avances en el genoma personal: 
desde el Proyecto Genoma Humano al
Proyecto Genoma Personal
El costo de una secuencia del genoma humano diploide se ha
reducido desde cerca de 70 millones de dólares a 2000 dólares
desde 2007, aunque los estándares de la redundancia han
aumentado de 7 a 40 veces para mejorar los índices de
demanda de genotipo. Junto con el bajo retorno de inversión
para los polimorfismos de nucleótidos únicos comunes, esta
situación ha causado un aumento significativo del interés en
correlacionar las secuencias genómicas con una completa
información ambiental y de rasgos (GAR). El costo de las fichas
médicas electrónicas, de las imágenes y de la información
microbiológica, inmunológica y conductual también está
reduciéndose rápidamente. El compartir tal conjunto de infor-
mación y sus interpretaciones con una diversidad de investi-
gadores y sujetos de investigación pone de relieve la necesi-
dad de contar con modelos de consentimiento informado
capaces de estar orientados hacia nuevos temas de privacidad
y otros, además de flexibilizar los recursos de datos compar-
tidos que permitan disponer de materiales e información con
mínimas restricciones de uso. Este artículo examina el esfuerzo
del Proyecto de Genoma Personal para desarrollar una base
de datos de GAR como un recurso de genómica pública
ampliamente accesible tanto a investigadores como a parti-
cipantes de las investigaciones, respetando los estándares más
elevados de la ética de la investigación. 
Les progrès du génome personnel : 
de l’étude du génome humain à l’étude du
génome personnel
Le coût de séquençage d'un génome diploïde humain a
chuté de 70 millions de dollars à 2 000 dollars depuis 2007,
bien que les standards de redondance aient augmenté de 7
à 40 fois afin d'améliorer le taux d'identification des bases.
Associé au faible retour sur investissement des polymor-
phismes de simples nucléotides (SNP), cette situation explique
l’intérêt accru pour la corrélation des séquences des génomes
avec des données complètes environnementales et de traits
(GET). Les coûts des enregistrements numériques médicaux,
de l’imagerie et des données microbiennes, immunologiques
et comportementales chutent aussi rapidement. Le partage
de telles bases de données GET intégrées et de leurs inter-
prétations avec un grand nombre de chercheurs et de sujets
de recherche souligne la nécessité de modèles de consente-
ment éclairé nécessaires à cette nouvelle protection des don-
nées personnelles et autres problématiques, en plus des
besoins de flexibilité des ressources requises pour le partage
des données, permettant en plus une utilisation peu restric-
tive de ces matériels et données. Cet article analyse les efforts
du Projet du Génome Personnel afin de développer une base
de données GET en tant que ressource génomique publique,
largement accessible à la fois aux chercheurs et aux partici-
pants à la recherche, tout en respectant les standards les plus
élevés de l’éthique de la recherche.
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A surge of discoveries in the 
genetics of disease
he past 4 years have yielded an unparalleled
number of discoveries in the field of the genetics of
human disease. In particular, huge strides have been
made in the discovery of DNA sequence variants that
are associated with risk of common complex diseases,
such as type 2 diabetes, myocardial infarction, Crohn’s
disease, breast cancer, and prostate cancer. Prior to 2006,
in spite of huge efforts by dedicated researchers, only a
few sequence variants had been found to be associated
with these diseases that had been adequately verified by
replication in well-powered studies. By October of 2009,
according to the Catalog of Genome-Wide Association
Studies,1,2 the number of replicated associations of
sequence variants with these diseases was 44, 10, 59, 14,
and 28, respectively (obtained by counting unique vari-
ants reported as statistically significant in more than one
study, or in at least two population samples from the
same study). Figure 1 shows the total count of replicated
disease associations by year of publication, based on the
same criteria, as reported by this database. These num-
bers will almost certainly continue to rise at a rapid rate. 
This sudden progress is due to the advent of genome-
wide association studies (GWAS), made possible by a
combination of at least four key developments. The first
is the wealth of knowledge that has been produced
about sequence variation in the human genome, in large
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Technological advances in the field of human genetics
have resulted in a wave of discoveries of common DNA
sequence variants that are associated with a risk of com-
mon complex diseases, such as heart attack, that account
for a substantial proportion of morbidity, mortality, and
health care costs in most contemporary populations. The
overall predictive power of these sequence variants can
be considerable, due to the high incidence of these dis-
eases and the sheer number of associations that have
been discovered. Health care providers have been slow
to utilize this knowledge for preventative medicine.
However, several companies have taken on a transla-
tional role by offering genetic tests based on these dis-
coveries direct to consumers. In this paper, we review the
current state and future prospects of such genetic tests,
as scientists involved both in the discovery of disease
associations and the development of genetic tests.
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part due to the Human Genome Project6 and the ensu-
ing HapMap project.7 The second is the development of
high-throughput microarray genotyping technologies,
that now enable researchers to simultaneously and rel-
atively cheaply assess genotypes at hundreds of thou-
sands of single-nucleotide polymorphisms (SNPs) across
the genome. The third is the availability of collections of
DNA samples from large numbers of individuals who
suffer from the diseases of interest and controls from the
same populations. Another factor that has contributed
to the success of GWAS is the close and fruitful cooper-
ation between research groups and journals in defining
conservative and robust standards for the verification of
disease association signals obtained using this approach. 
The recent discoveries of sequence variants associated
with the risk of complex diseases represent an important
step in the task of understanding their biology, of which
we are still remarkably ignorant. While some of the
newly discovered associations were found in genes
already suspected of playing a role in etiology, most are
in, or close to, genes with no prior connection to the dis-
ease in question. These latter discoveries, in particular,
represent important new points of departure for more
focused research into the biology and etiology of these
diseases. 
While the discovery rate of new disease-associated vari-
ants shows no signs of decline, there is good reason to
believe that much of the lowest-hanging fruit has already
been picked. These are the common sequence variants
that have an easily detected impact on disease risk, given
the existing sample sizes of cases and controls (ie, with an
odds ratio of more than 1.1) and that are covered by the
existing microarray genotyping platforms. Some
researchers argue for continuation of the GWAS
approach, with larger sample sizes to detect more com-
mon variants with small effect.8 Others argue for a
change of strategy, pointing out that the combined effects
of variants that are likely to be found with more GWAS
only account for a part of the overall heritability of the
diseases concerned.9 Proposals have been made to pay
greater attention to rare variants, copy number variants,
epigenetic factors, or epistatic effects between unlinked
sequence variants. At least some of these aims will be
achieved in the near future, as further technological
developments make full genome sequencing and more
comprehensive microarray genotyping platforms realis-
tic options for large-scale disease studies. 
Translation of disease association 
findings for public use
Clearly, there is more to be found, and it seems obvious
to us that all of the aforementioned lines of research
should be pursued. However, at the same time as geneti-
cists continue their hunt for new disease-associated
sequence variants and attempt to determine the func-
tional relevance of the variants they have already dis-
covered, they must address an equally pressing issue of
practical concern in relation to existing knowledge. To
date, more than 1000 sequence variants have been dis-
covered with robustly verified disease associations to
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Figure 1. The number of replicated sequence variants associated with dis-
eases and medically relevant traits by publication year of first
report in genome-wide association studies according to the
Catalog of Genome-Wide Association Studies on October 20th
2009. Counts were obtained by counting unique variants
reported as statistically significant (at the level of P< 1.0 x 10-5)
in more than one study or in at least two population samples
from the same study. They represent a total of 1108 replicated
associations to sequence variants based on 132 diseases and
medically relevant traits. Note that in some cases the Catalog of
Genome-Wide Association Studies reports multiple correlated
single-nucleotide polymorphisms (SNPs) from the same genomic
region, and thus the numbers shown are likely to be overesti-
mates. However, the 1108 associated SNPs belong to 871 dif-
ferent genomic regions, and this latter number is likely to be an
underestimate of the overall number of associations discovered.
This is because some regions are known to contain multiple
independent associations to the same trait—for example, region
8q24 and prostate cancer.3 Also, not all bona fide disease-asso-
ciated sequence variants are included in the catalog, for exam-
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tens of major complex diseases.1 These diseases account
for a substantial proportion of morbidity, mortality, and
health care costs in most contemporary populations.
Even though the functional impact of most of these vari-
ants is not yet understood, their association with disease
imbues them with intrinsic value for both the general
public and health care practitioners. This is because the
strength of their association in a population reflects the
degree to which they can be used to improve predictions
of disease risk for individuals. 
Disease risk stratification (by age, sex, weight, and other
biological markers) forms the cornerstone of effective
screening programs. It also serves an important role in
increasing the health awareness of individuals, thereby
promoting the adoption of preventative measures and
leading to earlier diagnosis. The overall result is not only
a healthier population, but a reduction in the burgeon-
ing cost of health care, much of which stems from late
treatment of preventable diseases. It follows that con-
siderable additional health benefit and cost-effectiveness
could be achieved through the addition of recently dis-
covered genetic factors. Although such genetic tests are
available, they have yet to be routinely adopted by major
health care providers. This may be partly due to a lack
of familiarity with such tests, or with their scientific basis,
or due to an inherent resistance that stems from finan-
cial or organizational concerns. However, genetic tests
are also available directly to the public through the
Internet, where they have been positively received
through a combination of health concerns, curiosity, and
recreational interest in genetics and ancestry. 
The authors of this article are members of a research
team at deCODE Genetics that has contributed to the
ongoing wave of discoveries in the genetics of complex
disease and intends to remain at the forefront of this
field in the coming years. However, from 2007 deCODE
Genetics has also been a leader in using this knowledge
to develop tests to evaluate genetic risk, both in the form
of diagnostic products aimed at health care providers,
and a personal genome scan, under the name of
deCODEme, which is sold directly to consumers via the
Internet. In what follows, we will outline the nature of
the genetic tests provided by deCODE Genetics and
others, and the value we believe they can bring by
informing individuals about their health prospects and
motivating them to take preventative measures where
possible or to seek early diagnosis. We will also discuss
some of the concerns raised by such genetic tests.
The nature of the genome and 
possibilities of genetic testing
Before moving on to a description of the kinds of
genetic tests that are currently available to health care
providers and the general public, it may be helpful to
consider the nature of the genome. This can help us to
understand what kind of information the genome can
offer and thereby what kind of genetic tests are possible.
The genome constitutes an extremely complex set of
instructions for the assembly and maintenance of an
organism, within some normal range of environmental
conditions. For humans these instructions are almost
exclusively encoded in the sequence of the roughly 3 bil-
lion nucleotides that make up the genome. 
We may consider a human being as a vast collection of
phenotypic traits, ranging from, for example, height and
skin pigmentation to less perceptible features such as
blood insulin levels or the build-up of amyloid plaques
in brain tissue. All such traits are the outcome of an
interaction between instructions from one or more parts
of the genome and some set of environmental factors.
Most phenotypic traits exhibit some variation among
individuals that reflects underlying differences in DNA
sequence and differences in exposure to environmen-
tal conditions. In some cases, differences between indi-
viduals exposed to normal environmental conditions are
solely due to DNA sequence variants from a single gene.
An example of a trait that is fully determined by
sequence variants, and is inherited in accordance with
simple Mendelian rules of inheritance, is the capacity to
metabolize the amino acid phenylalanine, that when
lacking, results in the disease phenylketonuria. More
often, however, trait variation among individuals can be
traced to many DNA sequence variants and environ-
mental factors. 
The power to correctly predict traits such as the devel-
opment of disease for individuals using a genetic test
(that is, the clinical validity of the test) depends on the
nature of the relationship between genotype and phe-
notype. Many of the key human diseases, the so-called
common complex diseases, are substantially affected by
environmental factors. This means that the predictive
power of genetic tests for these diseases will be less than
for “simple” traits such as phenylketonuria (although the
validity for such tests could be boosted by including
known environmental risk factors). Nonetheless, the
potential health and economic rewards gained from
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improving risk predictions for diseases that affect large
numbers of individuals in a population are substantial.
No matter how many sequence variants and environ-
mental factors contribute to a given phenotypic trait, all
other things being equal, the accuracy of prediction is
always increased by the inclusion of just one truly asso-
ciated sequence variant. 
Diseases may be defined as the fraction of variation in
physiological function that lies outside the normal range,
such that either the quality of life is impaired, or the
probability of untimely death is raised to an unacceptable
level. It is no coincidence that diseases are the focus of
most existing genetic tests, because they have been the
primary focus to date of research into genotype-pheno-
type associations in humans. However, once reliable
information has been gathered about an association
between any phenotypic trait and a set of sequence vari-
ants, it becomes possible to develop a genetic test to esti-
mate genetic propensity for that trait. In fact, there are
already several genetic tests on the market that include
nondisease traits such as eye color, male-pattern baldness,
bitter taste perception, and drug metabolism. Such traits
are often ignored by commentators on genetic testing,
but they are likely to play a larger role in this field as our
understanding of the functional impact of sequence vari-
ants on normal human phenotypic variation advances. 
In addition to enabling the assessment of genetic pre-
dispositions to particular phenotypic traits, the genome
holds a record of ancestry and genealogical relationships
between all people. This information is inscribed into the
genome as it is replicated and transmitted from parents
to offspring with a small number of changes in the form
of mutations and recombination events. In the world of
consumer genetic tests, ancestry has been a leading area
of interest, with considerable sales of tests based on the
uniparentally inherited genetic material from mito-
chondria and Y chromosomes.10
The use of genetic markers to verify the existence of
close family relationships between individuals is a rela-
tively trivial task that is routinely performed in forensic
laboratories and in tests that are already available to the
public. The introduction of microarray genotyping plat-
forms with hundreds of thousands of SNPs is likely to
facilitate the development of more powerful algorithms
to explicitly test for more distant genealogical relation-
ships between individuals. Such data are already used in
genetic tests in conjunction with recently developed sta-
tistical methods from population genetics to provide
detailed assessments of ancestry and admixture. The
results from these analyses are in effect summary analy-
ses of the genealogical relationship of an individual to
different populations from around the world. As the
magnitude of comparative data from such populations
grows and the number of sequence variants assessed
increases (for example, through full genome sequenc-
ing), there will be considerable improvements in the
detail and accuracy of ancestry assessments and
genealogical testing.
Genetic tests of ancestry are typically defined as recre-
ational by commentators, and somehow qualitatively dif-
ferent from tests that evaluate disease risk.11,12 However,
it is important to bear in mind that in the genome, infor-
mation about function and ancestry is inexorably inter-
twined. Sequence variants that are used in an ancestry
test today, on the basis of having no known function,
may well be found to be associated with a disease or
medically relevant traits tomorrow. Moreover, to the
extent that disease risks vary between populations due
to differing frequencies of the underlying associated
sequence variants, it follows that tests of ancestry are in
effect tests, albeit low-powered tests, of genetic risk of
disease.
The past and present of genetic testing
At present, a wide range of genetic tests are available
either through health care providers or by companies
direct to the consumer (DTC). Indeed, there are now so
many that it is impossible to provide a comprehensive
overview of them all. To begin with, most tests were per-
formed by university or hospital laboratories within the
scope of health care provision. They were based on rare
and highly penetrant sequence variants that are strongly
associated with a particular disease. Included in this cat-
egory are tests used for prenatal and newborn screening,
diagnostic testing for chromosome abnormalities, carrier
testing, and predictive testing for particular conditions
such as Huntington’s disease and hemochromatosis. In
time, companies offering such tests emerged, in some
cases established by people from the aforementioned
universities or hospitals. An early example is the com-
pany Myriad Genetics, that patented and marketed pre-
dictive tests for breast cancer based on variants in the
BRCA genes (that confer a roughly fivefold risk of
developing this disease). 
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One thing the tests available through health care
providers have in common is that the variants tested are
rare and highly penetrant (ie, their clinical validity is
high). Consequently, very few individuals from the gen-
eral population would be expected to receive positive
results from such tests—as is the case, for example, in
population screening for phenylketonuria mutations. In
many cases, however, such tests are provided on the
basis of clinical diagnosis or familial risk, which increases
the fraction of positive results from the tests. For indi-
viduals who receive positive results, the implications
tend to be a very high probability of disease. Thus, test-
takers often meet a genetic counselor prior to tests and
after in light of a positive result (with treatment if applic-
able). The use of tests for rare and highly penetrant
sequence variants is widespread among health care
providers in most countries. Many have also adopted
predictive tests for breast cancer (using variants in the
BRCA gene), and Alzheimer’s disease, based on more
common variants in the APOE gene that confer a four-
fold risk. However, they have been slow or reluctant to
take advantage of the recent wave of robustly replicated
GWAS discoveries of variants associated with increased
disease risk ranging from 1.05-fold to 7-fold. 
In spite of the reluctance of health care providers to
adopt genetic tests for common diseases, a growing num-
ber of companies have been harnessing findings from
GWAS and other genetic studies to design tests that are
sold DTC, mainly through the Internet. Most currently
available DTC tests are based on a handful of sequence
variants and focus on a specific application, such as
ancestry, family relationships, or the testing of genetic
risk for particular diseases. Often a particular company
will offer several such small tests covering one or more
of these areas. On top of this, a few companies are now
offering DTC personal genome scans. These products
are mostly based on large-scale and cost-effective
microarray genotyping platforms that test 500 000 to 1
million SNPs from across the entire genome, but in a few
cases on more expensive full-genome sequencing. The
four best-known providers of DTC personal genome
scans are, in order of appearance on the market,
deCODEme (the product the authors are involved
with), 23 and me, Navigenics, and Knome. Such products
typically provide consumers with estimates of risk or
predispositions to many diseases or traits, in addition to
a range of tests of ancestry and family relationships
through a secure personal Web site account. Aside from
the breadth of tests that such a large number of SNPs
can offer, one advantage of the personal genome scans
for consumers is that they can (at least in principle)
obtain updated estimates for all tests as new discoveries
are made. Thus, the initial purchase of the test may be
viewed as an investment that yields interest in the form
of accumulating knowledge from new discoveries. To
date, the companies providing DTC personal genome
scans have been fairly active in updating the tests
offered on their Web sites. In addition, customers can
download their genotypes onto their own computers and
analyze the data for themselves (for example, by upload-
ing genotypes on Web sites such as SNPedia or seeking
advice on layman Web sites such as DNA-forums.org).
Addressing the concerns of some scientists
about DTC genetic tests
Many of the recent commentaries about DTC genetic
testing in the scientific literature have focused on the
personal genome scans11-17 and in particular on concerns
about the disease risk estimates they provide to cus-
tomers. These concerns may be divided into two main
themes. 
First, there are questions about the validity of the tests.
The most common criticism here is that because the risk
conferred by each variant used in these tests tends to be
low (odds ratio <2), then the accuracy in predicting risk
of disease for individuals (ie, their clinical validity) will
also be low.11-13,15,18 Such comments either explicitly or
implicitly compare the new tests with older tests that are
already in use by health care providers in a way that is
highly misleading. If we take a multifactorial disease
such as heart attack, then it is self-evident that one can-
not design a genetic test with predictive power as great
as that for Huntington’s disease, which is rarer, solely
caused by mutations in one gene, and is negligibly
affected by environmental factors. However, it is wrong
to think that the predictive power of genetic tests based
on GWAS findings is insignificant and not clinically rel-
evant. Take, for example, the test for heart attack in the
deCODEme personal genome scan, which includes eight
independent SNPs with strong evidence for association
to this disease19-23 at the time of writing. This test alone
can allow for the identification of 10% of people of
European decent who have at least 1.4 times greater risk
of developing a heart attack than the average person in
the population. The average relative risk in this group is
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1.6. Since the lifetime risk of suffering a heart attack is
42% for men over the age of 40,24 it follows that this test
can identify men who have, on average, a lifetime risk of
67% of developing the most lethal disease of man.25
There is a dramatic difference between 42% and 67%
lifetime risk. For example, individuals who are in the top
quintile of the concentration of LDL cholesterol have
only 1.3 times the population average risk of having a
heart attack. Hence, a genetic test based on recently dis-
covered sequence variants can identify people with
added risk of heart attack that is twice that of those who
are at the top of the cholesterol curve. In this context,
it is important to keep in mind that the ability to assess
risk of the heart attack by measuring serum cholesterol
has transformed cardiology into the most important field
of preventive medicine. Given the rather high lifetime
risk of heart attack in most industrialized populations,
then it follows that even a small increase in predictive
power for each individual can be valuable. 
Comparable estimates of average relative risk in the top
10% of people for other diseases included in the
deCODEme genome scan are, for example, 5.2 for age-
related macular degeneration, 1.8 for type 2 diabetes and
3.0 for Crohn’s disease. There is good reason to believe
that the predictive power of these genetic tests will
increase in the near future. On the one hand, we expect
additional associated sequence variants to be discovered.
On the other hand, because risk estimates in current
tests are typically only stratified by sex and ethnicity,
advances can be made through the inclusion of other rel-
evant background variables (for example, the waist-to-
hip ratio and smoking history in the case of heart
attack). In both cases, further epidemiological research
is needed. However, contrary to the views of some com-
mentators,11,13 these are not grounds for delay. The value
of the discoveries so far, as reflected in the aforemen-
tioned example of heart attack, unequivocally warrants
their use in genetic tests. 
The second main theme of concern raised by commen-
tators relates to the capacity of consumers to understand
and cope with disease risk estimates from tests.8,9,12-14
Underlying these concerns is a somewhat paternalistic
and patronizing view that information about disease risk
is dangerous to the general public unless mediated in
person by medical experts. Among the alleged dangers
to the public are anxieties from overinterpreting risk
estimates, which could lead to increased demands on
health care providers and unnecessary medical proce-
dures. We are not aware of any evidence that has been
reported in support of this view, but there is at least
some indirect evidence against it.26
However, even if such information were to provoke anx-
iety, the right of regulators or medical experts to prevent
access to it is questionable. Consider the following anal-
ogy of a hypothetical company that provides individuals
with reliable estimates of their risk of being mugged,
murdered, run over, or burgled based on their age, sex,
and address. There is no question that someone living in
a rough inner-city area with limited economic means
would have considerably greater risk on all counts than
people living in more affluent areas. Would this be a
legitimate reason for preventing individuals from seek-
ing such potentially anxiety-provoking information? 
Another issue raised by commentators is that of clinical
utility,10,13 that is, the extent to which knowledge of
increased risk can reduce the burden of a disease
through prevention or treatment. Although frequently
raised in discussions of DTC genetic tests, this issue is
really only relevant within the scope of health care pro-
vision (for example in the case of Huntington’s disease).
Thus, for DTC genetic tests, clinical utility is a secondary
issue when balanced against peoples’ right to seek infor-
mation about themselves at their own cost. Given that
such tests are in accordance with the accepted scientific
literature and adhere to consumer laws (ie, that they
deliver what their providers promise), then it is hard to
see how regulators could prevent the public from buy-
ing them. 
The challenge for providers of 
DTC genetic tests
In our opinion, the key to the success of DTC genetic
tests for consumers, the companies that provide them,
and regulators, is clarity and transparency. Whether tests
report disease risk estimates, ancestry analyses, or eval-
uation of genealogical relationships, the information
used to motivate consumers to buy tests and then
explain the results should be as clear and accurate as
possible. In particular, the probabilistic rather than
deterministic nature of disease risk estimation must be
unambiguous and comprehensible to the layman (and to
medical experts). A key task is also to use the scientific
literature in an accurate and responsible manner, for
example by including only sequence variants with asso-
ciations to disease that have been robustly replicated.
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One way to uphold such standards is through trans-
parency, ie, by providing information about all the
sequence variants used and the parameter values for risk
models and their sources in the scientific literature. Most
of the current providers of DTC personal genome scans
have followed this approach, to a greater or lesser
extent. 
If such basic ground rules are adhered to, we believe that
DTC genetic tests can provide considerable value to the
general public, in particular while tests based on disease-
associated variants discovered through GWAS are not
available through health care providers. From a public
health perspective, there is real preventative value to be
gained from making people aware of their health and
the risks posed to it. It is true that many of the lifestyle
changes recommended for prevention through the appli-
cation of DTC genetic tests could benefit many individ-
uals, regardless of whether they take such tests.
However, as most health care providers know, people
are generally reluctant to change their lifestyle, even in
the face of stern advice from medical experts. We would
argue that when genetic risk factors are added on to con-
ventional lifestyle risk factors in motivating people to
take preventative measures, the outcome provides a
greater impetus to act. Of course, from the perspective
of personal autonomy, even if people choose to disre-
gard advice about disease prevention, their right to seek
information about genetic risk should prevail. 
It is also important to highlight the educational nature
of the Web sites of many companies that offer DTC
genetic tests. They usually contain detailed information
on hundreds of Web pages about diseases, ancestry, and
genetic discoveries and methods that are used to provide
results. This information is typically available to anyone
through various front-end Web pages, where potential
buyers can explore the kind of information they would
receive as customers. Anyone can therefore learn a great
deal about diseases, ancestry, and genetics without pay-
ing for a test. Whether the decision to buy a test is moti-
vated by health concerns, recreational curiosity, or van-
ity, the consumer is almost certain to gain not only an
increased understanding of genetics in general, but also
what the recent wave of discoveries in the human genet-
ics of disease and ancestry mean for them personally.
Conclusion
We believe that DTC genetic tests play a key transla-
tional role for the science of genetics, democratizing and
disseminating privileged knowledge to the public. No
matter how clichéd it sounds, knowledge is power. While
some medical experts may complain about patients
armed with results from DTC genetic tests or informa-
tion about disease symptoms from the internet,13 we
believe that a knowledgeable public is an empowered
public. 
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Pasado, presente y futuro de las pruebas
genéticas dirigidas a los usuarios
Los avances tecnológicos en el campo de la gené-
tica humana han producido una ola de descubri-
mientos de variantes de la secuencia común del
ADN que están asociadas con un riesgo de enfer-
medades comunes y complejas, como el ataque car-
díaco, que dan cuenta de un porcentaje significa-
tivo de morbilidad, mortalidad y costos de salud en
la mayoría de las poblaciones actuales. El poder pre-
dictor en conjunto de estas variantes de la secuen-
cia puede ser considerable, debido a la alta inci-
dencia de estas enfermedades y al reducido número
de asociaciones que se han descubierto. Los prove-
edores de atención de salud han utilizado lenta-
mente este conocimiento para la medicina preven-
tiva. Sin embargo, algunas empresas han asumido
un papel translacional al ofrecer pruebas genéticas
basadas en estos descubrimientos dirigidas a los
usuarios. En este artículo se revisa tanto el estado
actual y las perspectivas futuras de tales pruebas
genéticas, como a los científicos involucrados en el
descubrimiento de las asociaciones de enfermeda-
des y en el desarrollo de las pruebas genéticas.  
Les tests génétiques en vente libre : 
passé, présent, futur
Les avancées technologiques en génétique humaine
ont permis une série de découvertes de variants fré-
quents de séquence d’ADN associés à un risque de
maladies complexes courantes, comme la crise car-
diaque, responsables d’une morbi-mortalité et de
coûts liés à la santé très importants chez la plupart
de nos contemporains. La puissance prédictive glo-
bale de ces variants génétiques peut être considé-
rable en raison de la fréquence élevée de ces mala-
dies et du seul nombre d’associations découvertes.
Les acteurs du système de santé ont mis du temps à
utiliser ces données en médecine préventive.
Plusieurs laboratoires ont néanmoins accepté de
servir d’intermédiaire en proposant directement au
grand public des tests génétiques basés sur ces
découvertes. En tant que scientifiques impliqués à
la fois dans la découverte d’associations de mala-
dies et dans le développement de tests génétiques,
nous analysons dans cet article l’état actuel et le
devenir de tels tests.
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linical pharmacogenomics consists of the appli-
cation of research that links measurable genetic variants
with the prediction of drug response.1 Every medical
specialty can utilize the results of pharmacogenomic
probe studies to inform the adoption of individualized
pharmacotherapy. However, psychiatric pharmacother-
apy is particularly likely to benefit from the introduction
of pharmacogenomic testing, because there are many
psychotropic agents available for selection that target
specific symptoms.
The terms pharmacogenetics and pharmacogenomics
are currently used interchangeably. However, with the
growing understanding that multiple intragenic varia-
tions should be considered in making predictions related
to medication response, the use of the term pharma-
cogenomics has become more frequently chosen to des-
ignate the process of using documented genetic variation
to guide medication selection and dosing.
Historically, psychiatrists have used empirical strategies
to select medications. In the best practices, the choice of
medications has evolved based on a rational trial-and-
error process that has used clinical indicators to select
medications and then relied on documenting treatment
responses to titrate the optimal dose for a particular
patient. Psychiatrists learn to “start low and go slow” in
order to minimize side effects. They also know that it is
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The clinical adoption of psychiatric pharmacogenomic
testing has taken place rapidly over the past 7 years.
Initially, drug-metabolizing enzyme genes, such as the
cytochrome P450 2D6 gene (CYP2D6), were identified.
Genotyping the highly variable cytochrome P450 2D6
gene now provides clinicians with the opportunity to iden-
tify both poor metabolizers and ultrarapid metabolizers
of 2D6 substrate medications. Subsequently, genes influ-
encing the pharmacodynamic response of medications
have been made available for clinical practice. Among the
earliest “target genes” was the serotonin transporter
gene (SLC6A4) which has variants that have been shown
to influence the clinical response of patients of European
ancestry when they are treated with selective serotonin
reuptake inhibitors. Genotyping of some of the serotonin
receptor genes is also available to guide clinical practice.
The quantification of the clinical utility of pharmacoge-
nomic testing is evolving, and ethical considerations for
testing have been established. Given the increasingly clear
cost-effectiveness of genotyping, it has recently been pre-
dicted that pharmacogenomic testing will routinely be
ordered to guide the selection and dosing of psychotropic
medications.  
© 2010, LLS SAS Dialogues Clin Neurosci. 2010;12:69-76.
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necessary to provide their patients with an “adequate”
trial of each medication. Unfortunately, these strategies
can result in a 3- to 4-week interval during which the
patient continues to experience symptoms. In recent
years, the potential iatrogenic harm associated with psy-
chotropic medications has become increasingly obvious,
with “black-box warnings” being attached to antide-
pressants, antipsychotic medications, stimulants, and
mood stabilizers.
Despite a growing awareness of this potential harm,
there are powerful pressures to try to accelerate the
achievement of therapeutic benefit. At the most basic
level, patients are impatient. They do not want to wait a
month to achieve symptom relief. Additionally, with an
increasing focus on the relief of specific symptoms,
strategies using multiple psychotropic medications have
become a standard of practice. Research supports the
common practice of augmenting an initial medication
with a second psychotropic drug.2 However, there is no
scientifically available evidence to support the practice
of using four or five psychotropic medications simulta-
neously. Nevertheless, patients routinely receive multi-
ple psychotropic medications in an attempt to identify
the “right combination.” While some patients do achieve
a good therapeutic response using this trial-and-error
approach to individualized medicine, it is also true that
others become overmedicated or suffer from iatrogenic
side effects.
Pharmacogenomic testing provides an innovative strat-
egy to improve the likelihood of selecting an effective
psychotropic medication. The earliest medical texts rec-
ognize that individual patients experience quite dra-
matically different responses to the same drug. There is
also a longstanding observation that unusual drug
responses can occur in members of the same family. The
identification of specific gene variants associated with
idiosyncratic responses is about 50 years old,3 and the
recognition that some psychiatric patients metabolize
antidepressants at dramatically different rates has been
documented for several decades.4 However, with the use
of newer antidepressant medications that rarely have
life-threatening complications, the relatively expensive
practice of monitoring the serum levels of newer anti-
depressant medications has become uncommon in the
United States. This change has occurred despite the fact
that serum levels of these newer agents also have dra-
matic variations based on the metabolic capacity of each
patient.
A decade ago, the cost of genotyping began to become
more affordable, and individual laboratories initiated
pharmacogenomic testing that would provide genotyping
of individual cytochrome P450 genes. However, there was
no standard or well-validated methodology for the geno-
typing of these informative genes. There was also consid-
erable variability in the interpretation of the results. In
2004, the US Food and Drug Administration (FDA)
approved the use of a new product, the AmpliChip.5 The
introduction of the AmpliChip provided reference labo-
ratories with a standard method for identifying variations
in two of the cytochrome P450 genes: cytochrome P450
2D6 (CYP2D6) and cytochrome P450 2C19 (CYP2C19).
The approval of the AmpliChip was an important land-
mark in the history of psychiatric pharmacogenomic test-
ing, and within 3 years, CYP2D6 and CYP2C19 were
being genotyped by every reference laboratory in the
country. However, this advance also highlighted some of
the challenges associated with the introduction of clinical
testing. One of the most obvious challenges that must be
addressed is how to begin to assess new variants of these
two genes in updated versions of the assay. Ideally, the
methodology for establishing drug-metabolizing pheno-
types should be updated regularly based on new molecu-
lar genetic findings showing how new genotypic variants
influence gene function. Also, the clarification of the pre-
dictive capacity of previously identified gene variants
influencing gene function is similarly evolving, and newly
identified associations between gene structure and func-
tion should ideally be incorporated into algorithms that
define the metabolic capacity of psychiatric patients.
The evolution of pharmacogenomic research should
inform modifications in pharmacogenomic testing.
However, an implication of the rapid increase in our
knowledge base is that these new studies demonstrate
limitations in the accuracy of older genotyping method-
ologies that were designed prior to the discovery of
more recent variants. What is often not well appreciated
is that even older pharmacogenomic methods provided
important information for many patients, as these early
innovations were a major advance over psychopharma-
cological practice without pharmacogenomic insights.
However, as newer methodologies have further
improved the accuracy of the prediction of medication
response, the clinical utility of pharmacogenomic testing
continues to increase.
Pharmacogenomic testing in psychiatric practice initially
focused on identifying pharmacokinetic variability that
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would influence the responses of patients who had atyp-
ical genotypes. Pharmacokinetic variation influences 
the concentration of a drug at its sites of action.
Pharmacogenomic testing of drug-metabolizing enzyme
genes provides a prediction of how an individual patient
will metabolize a specific psychotropic medication. More
recently, the focus of pharmacogenomic testing has
expanded to include determining variability in the phar-
macodynamic response of a patient to a specific med-
ication. This variability reflects the capacity of the indi-
vidual patient to respond to adequate exposure to the
drug. Prediction of response is estimated based on the
documentation of variations in “target genes” that code
for receptors and transporters that influence the
response of the patient to a particular medication. 
This review will first identify the most widely genotyped
drug-metabolizing enzyme genes that influence the
pharmacokinetic metabolic capacity of a patient. Then,
it will focus on genes that influence the pharmacody-
namic responses of individual patients, before conclud-
ing with a brief discussion of the clinical utility of phar-
macogenomic testing and some of the ethical
considerations related to its routine use.
Pharmacogenomic testing to establish the
metabolic capacity of psychiatric patients
Many genes code for enzymes that influence drug
response. However, only the clinical implications of geno-
typing four of the most commonly tested cytochrome
P450 genes will be reviewed. The focus of this discussion
will be the clinical benefit for the patient of identifying
individualized molecular variations, and the implications
for those patients who have a quite significant decrement
in their capacity to metabolize specific psychotropic med-
ications. Identifying these individual patients provides
clinicians with a clear method of minimizing side effects.
This determination of decreased metabolic capacity is the
most obvious benefit of pharmacogenomic testing, but
implications of the pharmacogenomic testing for patients
with increased metabolic capacity will also be discussed,
as these patients are less likely to respond to specific psy-
chotropic medications.
The cytochrome P450 2D6 gene (CYP2D6)
CYP2D6 was the first drug-metabolizing enzyme gene
that was genotyped to identify psychiatric patients with
increased or decreased metabolic capacity. It is located
on chromosome 22 and consists of 4382 nucleotides.
CYP2D6 codes for an enzyme that is composed of 497
amino acids.
The CYP2D6 enzyme plays a primary role in the metab-
olism of more than 70 substrate medications, including
twelve psychotropic medications. CYP2D6 is one of the
most highly variable drug-metabolizing enzyme genes.
However, many of the other 29 P450 drug-metabolizing
enzyme genes are also highly variable. The specific
genetic variations that define variable phenotypes can
be located on a Web site maintained by the Karolinska
Institute (http://www.cypalleles.ki.se/). Each newly iden-
tified variant is included on the Web site after confir-
mation that it is unique.
There are currently 75 distinct CYP2D6 alleles posted
on this site, as well as an additional 55 CYP2D6 variants
that closely resemble one of the primary variants.
Traditionally, these variants have been classified as being
normal, deficient, or inactive drug-metabolizing alleles.
Additionally, some alleles have more recently been
demonstrated to code for an increased amount of
enzyme which enhances the metabolic activity of the
patient. Furthermore, patients can have a variable num-
ber of copies of CYP2D6. The most common number of
copies of CYP2D6 that patients carry is two. However,
some patients have only one copy and, rarely, none at all.
It is also possible to have more than two copies, and one
patient has been reported to have 13 copies.4 The devel-
opment of several different classification systems to cat-
egorize 2D6 substrate metabolic capacity of patients into
four phenotypic categories has been problematic. The
use of alternative methodologies by different research
teams has made it more difficult to study the implica-
tions of this variability.
The most important CYP2D6 phenotype to identify is
the poor 2D6 substrate metabolizer phenotype. Patients
who are poor metabolizers are at increased risk for
adverse events when they are prescribed 2D6 substrate
medications, because of their low metabolic capacity.
Patients are now classified as poor metabolizers if they
have two inactive alleles, or one inactive allele and one
deficient allele. 
The second most clinically important CYP2D6 pheno-
type is the ultrarapid metabolizer phenotype. Patients
are ultrarapid metabolizers if they have either three or
more active copies of CYP2D6 or two or more enhanced
copies of CYP2D6. They are unlikely to respond to 2D6
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substrate medications at standard doses because their
ability to rapidly metabolize these medications makes it
difficult to sustain therapeutic serum levels.
The third clinically important CYP2D6 phenotype is the
intermediate metabolizer phenotype. These patients
have one normal copy of CYP2D6, and one copy that is
either deficient or inactive. While these patients can nor-
mally benefit from 2D6 substrate medications at low-to-
moderate doses, they are at increased risk for the devel-
opment of side effects at higher doses because of their
decreased metabolic capacity, and they are more at risk
for enzyme inhibition as a consequence of drug-drug
interactions. When intermediate metabolizers are
exposed to powerful 2D6 inhibitors such as paroxetine
or fluoxetine, their metabolic capacity can be further
decreased to the level of a poor metabolizer.6
There are many psychotropic medications metabolized
by the 2D6 enzyme. Specifically, this enzyme:
• primarily metabolizes five antidepressants: fluoxetine,
paroxetine, venlafaxine, desipramine, and nortriptyline 
• substantially metabolizes amitriptyline, imipramine,
doxepin, duloxetine, trazodone, and mirtazapine
• primarily metabolizes risperidone and four of the typ-
ical antipsychotic medications: chlorpromazine, thior-
idazine, perphenazine, and haloperidol 
• has substantial involvement in the metabolism of arip-
iprazole and olanzapine
• primarily metabolizes atomoxetine and dextroam-
phetamine.
Beyond the prescription of psychotropic medications,
psychiatric patients are given many other 2D6 substrate
medications. Specifically, dextromethorphan is a cough
suppressant that is metabolized by the 2D6 enzyme.
Patients who are poor metabolizers of 2D6 substrate
medications are at increased risk for cognitive side effects
if taking standard doses of preparations that contain dex-
tromethorphan. Another example is codeine, which is a
prodrug. A prodrug must be converted to an active
metabolite in order to have a therapeutic effect. Patients
who are poor 2D6 metabolizers do not receive analgesic
benefit from codeine because they do not metabolize
codeine to morphine. Tamoxifen is also a prodrug that is
the most frequently prescribed treatment for breast can-
cer. Poor metabolizers have little or no benefit from
tamoxifen because they are not able to metabolize
tamoxifen to endoxifen.7,8 Additionally, paroxetine, flu-
oxetine, or bupropion should not be given to patients
who are receiving tamoxifen because they inhibit the
2D6 enzyme. Giving these inhibitors to intermediate
metabolizers can convert them to functional poor metab-
olizers. Consequently, they become unable to produce
endoxifen.9
The cytochrome P450 2C19 gene (CYP2C19)
CYP2C19 was the second drug-metabolizing enzyme
gene that was widely genotyped to identify patients with
increased or decreased metabolic capacity. It is a large
gene located on chromosome 10. It consists of 90 209
nucleotides, but codes for an enzyme that contains only
490 amino acids.
The identification of patients with low 2C19 metabolic
capacity is clinically important because it allows clini-
cians to decrease the risk of iatrogenic side effects. 
The 2C19 enzyme:
• primarily metabolizes citalopram, escitalopram,
clomipramine, and amitriptyline 
• has substantial involvement in the metabolism of ser-
traline, imipramine, nortriptyline, and doxepin
• plays an important role in the metabolism of clozapine
and a minimal role in the metabolism of thioridazine
• is the primary enzyme involved in the metabolism of
diazepam. 
Recently, a new variant of CYP2C19 has been identified
which has enhanced function.10 Patients who are
homozygous for this new allele are less likely to respond
to 2C19 substrate medications at standard doses. The
identification of ultrarapid 2C19 metabolizers can be
helpful in evaluating patients who do not respond to
standard doses of any of these psychotropic medications.
The cytochrome P450 2C9 gene (CYP2C9)
CYP2C9 is located on chromosome 10 in relative close
proximity to CYP2C19. However, it is only about half
the size of CYP2C9 as it consists of 50 708 nucleotides.
Like CYP2C19, CYP2C9 codes for an enzyme that con-
tains 490 amino acids.
CYP2C9 is a drug-metabolizing enzyme gene that is less
routinely genotyped to identify the increased or
decreased metabolic capacity of psychiatric patients for
2C9 substrate medications. It does not play a primary
role in the metabolism of any currently prescribed psy-
chotropic medications. However, the 2C9 enzyme pro-
vides the only secondary pathway for the metabolism of
fluoxetine, so patients who are poor metabolizers of
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both 2D6 substrates and 2C9 substrates are at very high
risk for adverse effects if treated with standard dose of
fluoxetine.
The cytochrome P450 1A2 gene (CYP1A2)
CYP1A2 is a less well-studied drug-metabolizing
enzyme gene, but it codes for an enzyme that plays an
important role in the metabolism of fluvoxamine. It is
also involved in the metabolism of duloxetine and olan-
zapine. CYP1A2 is located on chromosome 15 and con-
sists of 7758 nucleotides. CYP1A2 codes for an enzyme
that is composed of 516 amino acids.
A somewhat atypical aspect of the CYP1A2 gene is that
there are alleles of this gene that are inducible by smok-
ing tobacco or consuming cruciferous vegetables, such
as cabbage or Brussels sprouts. Consequently, patients
who smoke tobacco and have two alleles of CYP1A2
that are inducible by their smoking can be difficult to
maintain on 1A2 substrate medications. A relatively
common problem occurs when these patients are treated
with olanzapine or clozapine on an inpatient psychiatric
unit that does not allow them to smoke. When they
begin to smoke after they are discharged, their serum
level drops and their psychotic symptoms often reoccur.
In some populations of European ancestry, as many as
25% of the population can have an inducible ultrarapid
CYP1A2 phenotype.
Pharmacogenomic testing to identify 
variability in pharmacodynamic responses
A goal of individualized molecular psychopharmacology
is to identify medications for an individual patient that
will not only be safe, but will be effective. Progress in
making predictions of medication response has occurred,
and while the goal of being able to predict this response
with certainty has not been achieved, we can make
increasingly accurate probabilistic predictions of the
likelihood of response. Psychiatrists are familiar with this
limitation. While hundreds of randomized clinical trials
of psychotropic medications have been conducted to
identify effective psychotropic drugs, the results of these
trials only provide assurance that for a sample of
patients there is reasonable likelihood that the medica-
tion will be of more benefit than a placebo. While selec-
tive serotonin reuptake blockers are among the most
widely prescribed medications in the world, many
patients do not respond. Specifically, the largest clinical
effectiveness study of citalopram reported that less than
30% of the entire sample of patients experienced a com-
plete remission of their symptoms.11 While the ultimate
goal of pharmacodynamically designed pharmacoge-
nomic testing is to identify a drug for a specific patient
that will definitely be effective, at the current stage of
our understanding, it is only possible to identify a med-
ication that is more likely to be effective.
The serotonin transporter gene (SLC6A4)
SLC6A4 is located on chromosome 17 and consists of 37
800 nucleotides. It codes for an enzyme that is composed
of 630 amino acids.
SLC6A4 is the most widely genotyped pharmacoge-
nomic “target” gene. A meta-analysis of studies of the
relationship between the more active long form of the
indel promoter variant of this gene and responses to
selective serotonin reuptake inhibitors12 confirmed the
early finding that the long form is associated with a more
rapid and better response.13 However, this has not con-
sistently been demonstrated in patients of Asian ances-
try.14,15 The importance of ancestral heritage has been fur-
ther demonstrated by multiple analyses of the large
STAR*D effective treatment study.
Analyses that did not consider ancestral background did
not demonstrate a significant association,16 while those
that focused on patients who identified themselves as
“white” but not “Hispanic” did confirm the relationship
that patients who were homozygous for the more active
long form of the indel promoter polymorphism were
more likely to respond to citalopram. Other variants,
such as rs2553117 and the second intronic VNTR18 are
likely to influence the activity level of the gene and, con-
sequently, its response to medications that block its abil-
ity to reuptake serotonin in the synapses of the central
nervous system.
The serotonin receptor 2A gene (HTR2A)
HTR2A is located on chromosome 13 and consists of 62
663 nucleotides. Despite its large size, it codes for an
enzyme that is composed of only 471 amino acids.
There have been a series of studies examining the asso-
ciation between variants of HTR2A and antidepressant
response. A large study examining the response of
depressed patients of European ancestry to citalopram
DCNS_44_5.qxd:DCNS#44  10/03/10  1:44  Page 73
found that a positive response to citalopram was associ-
ated with having a copy of the adenine allele of
rs7997012.19
Another study examining a different HTR2A variant,
rs6313, reported that patients who were homozygous for
the cytosine allele were less likely to tolerate taking
paroxetine than those who had one or more copies of
the thymine allele.20
A series of studies have reported a better response to
clozapine in patients who had the thymine allele of
rs6313. The thymine allele of rs6313 has also been asso-
ciated with a lower risk for the development of
extrapyramidal side effects when taking antipsychotic
medications.21-23
The serotonin receptor 2C gene (HTR2C)
HTR2C is a very large gene that is located on the X
chromosome and consists of 326 074 nucleotides.
However, it codes for a protein product that is composed
of only 458 amino acids.
Variations in the HTR2C gene have been associated
with a better clinical response to clozapine. Specifically,
patients with schizophrenia who have a copy of the cyto-
sine allele of rs6318 have achieved better control of their
psychotic symptoms than patients with the guanine
allele.24,25 However, this same variant has been associated
with a higher risk for the development of extrapyrami-
dal side effects in patients who are taking typical antipsy-
chotic medications.26
An increased risk for the development of weight gain
has been linked to a different HTR2C variant.
Specifically, the cytosine allele of rs518147 is associated
with increased weight gain, while the thymine allele is
conceptualized as providing protection against weight
gain.27-29
The clinical utility of pharmacogenomic 
testing in psychiatric practice
Assessing the clinical utility of pharmacogenomic test-
ing is an ongoing process, given that the accuracy of
genotyping is continually improving, and new research
is identifying additional genetic variants that influence
medication responses. Reports of adverse responses to
2D6 substrate medications in patients with decreased
2D6 metabolic capacity support the use of testing at this
most basic level. Specifically, poor 2D6 metabolizers
have had quite dramatic side effects to 2D6 substrate
medications3 and some toxic reactions have been
lethal.30,31 However, there have been no large random-
ized clinical trials to demonstrate the clinical utility of
pharmacogenomic testing. Such trials would reinforce
the use of testing. However, it is unlikely that these tri-
als will ever be conducted because, by definition, they
are not designed to concentrate on those patients who
are the most likely to benefit from pharmacogenomic
testing. Trials that screen vulnerable populations and
identify patients at risk for suboptimal responses to med-
ications are a more efficient method to address the clin-
ical usefulness of testing patients with decreased meta-
bolic capacity. These screened patients could then be
enrolled in protocols designed to provide optimal
response for their specific genotypes and predicted phar-
macogenomic phenotypes.
Ethical considerations for pharmacogenomic
testing in psychiatric practice
The provision of pharmacogenomic testing involves rel-
atively few risks, but ethical safeguards are still impor-
tant to consider. These are essentially the same consid-
erations that are important to think through when
ordering any laboratory test that has the potential to
direct a treatment decision.
First, clinical pharmacogenomic testing requires obtain-
ing appropriate consent. This has become a guiding prin-
ciple for all diagnostic and therapeutic procedures.
Clinicians should provide the basic rationale for pro-
ceeding with pharmacogenomic testing so that their
patients have the opportunity to provide explicit
informed consent. 
Secondly, as a component of obtaining clinical consent,
it must be clear that clinical testing is a voluntary proce-
dure. This is true for virtually all clinical laboratory test-
ing with the relatively rare exceptions of mandatory test-
ing that can identify a condition with a potential
negative influence on the public health of the commu-
nity. A common example of compulsory testing is the
monitoring of infections in order to prevent contagion. 
A third principle is that clinicians must insure the confi-
dentiality of sensitive medical information that becomes
a part of the medical record of the patient. This is true
whether the information is derived from a pathological
specimen that reveals a malignant carcinoma or from
magnetic resonance imaging that demonstrates atrophy
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of the hippocampus. The security of the medical record
is the responsibility of the clinician.
Finally, any diagnostic medical procedure must have an
acceptable level of reliability. The degree of accuracy of
any clinical laboratory testing is dependent on a number
of key variables. Two of these variables are the serious-
ness of the prognosis for the patient if the test is positive
and the efficacy of available treatments. In designing the
treatment plan for a potentially lethal condition that is
likely to respond well to a relatively benign intervention
if it is administered early in the course of the illness, a
laboratory test with high sensitivity is desirable. The
most important objective in this situation is to identify
as quickly as possible those patients who will benefit
from treatment.
Future developments that will influence 
pharmacogenomic testing in 
psychiatric practice
In the 2009 presidential lecture of the American
Psychiatric Association, it was predicted that pharma-
cogenomic testing would become a part of everyday psy-
chiatric practice.32 Ironically, in many academic health
centers, pharmacogenomic testing has been utilized since
2004—the time of the introduction of the AmpliChip.
Over the intervening years, early adopters have inte-
grated pharmacogenomic testing into their inpatient
protocols and ultimately into their outpatient practices.
However, this testing has not yet been included in many
clinical guidelines. 
Pharmacogenomic testing is an innovation, and it takes
time for innovations to become integrated into standard
practice. While it is difficult to predict with accuracy just
how quickly pharmacogenomic testing will become an
essential component of clinical psychopharmacological
practice, there is no question that this will happen.
Ironically, given advances in our ability to sequence genes
both rapidly and inexpensively, there will come a time in
the near future when most patients will know their 2D6
phenotype in the same way as today they know their
blood type. However, well before we reach a state of uni-
versal awareness of our informative genotypes, our
patients will no longer accept avoidable side effects, and
will demand basic pharmacogenomic testing prior to tak-
ing antidepressant or antipsychotic medications.
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Pruebas farmacogenómicas en la práctica 
clínica psiquiátrica
La incorporación en psiquiatría clínica de las prue-
bas farmacogenómicas ha ocurrido rápidamente en
los últimos siete años. Inicialmente se identificaron
genes de enzimas metabolizadoras de fármacos,
como el gen del citocromo P450 2D6. La tipificación
del gen del citocromo P450 2D6 que es altamente
variable da la oportunidad actualmente a los clíni-
cos de identificar a los metabolizadores pobres y los
ultrarrápidos para las sustancias que son sustrato
del 2D6. Con posterioridad se ha podido disponer
en la práctica clínica de genes que influyen en la
respuesta farmacodinámica de los medicamentos.
Entre los primeros “genes blanco” estuvo el gen del
transportador de serotonina (SLC6A4), el cual tiene
variantes que han demostrado que influyen en la
respuesta clínica de los pacientes con ancestros
europeos cuando son tratados con inhibidores
selectivos de la recaptura de serotonina. La tipifi-
cación de algunos de los genes del receptor de sero-
tonina también está disponible para guiar la prác-
tica clínica. La cuantificación de la utilidad clínica de
las pruebas farmacogenómicas está en desarrollo y
se han establecido las consideraciones éticas para
su realización. Considerando la cada vez más clara
costo-eficacia de la tipificación génica, reciente-
mente se ha pronosticado que las pruebas farma-
cogenómicas se solicitarán de rutina para orientar
la selección y dosificación de los fármacos psicotró-
picos.  
Évaluation pharmacogénomique 
psychiatrique en pratique clinique
L’évaluation pharmacogénomique psychiatrique
s’est rapidement imposée en pratique clinique au
cours de ces 7 dernières années. Les gènes d’en-
zymes métabolisant les médicaments, comme le
cytochrome P450 2D6 (CYP2D6), ont d’abord été
identifiés. Le génotypage de ce gène très variable
permet maintenant aux cliniciens d’identifier des
métaboliseurs lents et des métaboliseurs ultrara-
pides des substrats du 2D6.  Des gènes influant sur
la réponse pharmacodynamique des médicaments
sont ensuite devenus disponibles en pratique cli-
nique. Parmi les premiers « gènes cibles », le gène
du transporteur de la sérotonine (SLC6A4) possède
des variants qui influent sur la réponse clinique des
patients d’ascendance européenne lorsqu’ils sont
traités avec des inhibiteurs sélectifs de la recapture
de la sérotonine. Le génotypage de certains gènes
du récepteur de la sérotonine est également dis-
ponible pour  guider la réponse clinique. La quan-
tification de l’utilité clinique de l’évaluation phar-
macogénomique évolue et fait l’objet de
considérations éthiques. Il a été  récemment prédit
qu’en raison de l’évidente rentabilité croissante du
génotypage, l’évaluation pharmacogénomique
devrait faire partie des examens de routine pour
sélectionner et ajuster la posologie des médica-
ments psychotropes.
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t is well established that risk for many sub-
stance-dependence traits is genetically influenced; this is
the case for each specific substance that has been stud-
ied. This has been determined using the methods of
genetic epidemiology, the most relevant of which, for this
purpose, are twin and adoption studies. We discuss rel-
evant findings from genetic epidemiologic studies of
drug use and use disorders below.
In considering drug dependence, we include the most
commonly used illegal substances (primarily cocaine,
opioids, marijuana, and methamphetamine) and also
nicotine, a legal drug that is the dependence-causing sub-
stance in tobacco. Alcohol dependence (AD) shares
many risk genes with the drug-dependence disorders, but
is beyond the scope of the present article. We have
recently reviewed AD genetics elsewhere.1
As is usual for complex traits, risk for drug dependence is
influenced by both genetic and environmental factors.
Compared with most other kinds of traits though, envi-
ronmental factors, most obviously exposure to the sub-
stance, are crucial—you cannot become heroin-dependent,
for example, if you live in an environment with no access
to heroin. Because the availability of illegal substances of
abuse varies over the world (to a much greater extent than
the availability of either alcohol or tobacco), and also
varies with time as a function of secular trends in substance
use that are determined by fads, trends in law enforcement,
and other factors, patterns of substance dependence are
very different across the globe. Genetic epidemiologic
studies have helped to clarify the important implications
of this environmental variation for genetic studies.
Family studies have shown substantially higher rates of
drug abuse among siblings (particularly those whose par-
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Drug-dependence disorders (we focus here on cocaine,
opioid, and nicotine dependence) are genetically influ-
enced. Risk genes have been located based primarily on
genetic linkage studies, and identified primarily based on
genetic association studies. In this article we review salient
results from linkage, association, and genome-wide asso-
ciation study methodologies, and discuss future prospects
for risk allele identification based on these, and on newer,
methodologies. Although considerable progress has been
made, it is likely that the application of more extensive
sequencing than has previously been practical will be
required to identify a fuller range of risk variants.  
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ents were positive for substance abuse) than among indi-
viduals in the community.2-5 Such studies have also pro-
vided evidence for both general familial aggregation for
substance-use disorders and substance-specific aggrega-
tion across a wide range of drugs, including nicotine, opi-
oids, cocaine, and cannabis.6,7 However, while these designs
demonstrate that drug-dependence disorders are familial,
they cannot distinguish between genetic and environmen-
tal contributions to this familiality. A demonstration of
genetic contributions to these and other disorders requires
other designs, prominently twin and adoption studies.
Two adoption studies conducted by Cadoret et al8,9
showed that the only biological factor that was signifi-
cantly associated with drug abuse in the proband was an
alcohol problem in first-degree relatives. However,
Tsuang et al,10 studying a sample of more than 3000 twin
pairs, found a significantly greater pairwise concordance
rate for monozygotic (MZ) than dizygotic (DZ) twins
for abuse of marijuana, stimulants, cocaine, and for all
drugs combined. Using twin pairs ascertained through
the Virginia Twin Registry, Kendler et al examined con-
cordance rates for drug use and dependence among
more than 800 female-female pairs.11-13 Model fitting
showed that twin resemblance for liability to the use of
cocaine, cannabis, hallucinogens, opioids, and sedatives
was due to both genetic and family environmental fac-
tors. Liability to abuse or dependence on cocaine and
cannabis was due only to genetic factors. In contrast,
however, in another study by Kendler et al14 of the use
and misuse of six classes of illicit drugs by nearly 1200
male-male twin pairs, model fitting revealed that one
common genetic factor exerted a potent influence on
risk for both substance use and misuse for all six sub-
stances. There was a modest effect on risk of substance-
specific genetic factors seen for substance use, but in
contrast to other studies cited above, not for abuse or
dependence. A single common shared environmental
factor was also found to exert an effect on risk of sub-
stance use, and to a lesser extent, on risk of abuse depen-
dence. 
Despite some contradictory findings, overall, the data
from adoption, twin, and family studies support a sub-
stantial genetic contribution to drug dependence, includ-
ing the existence of genetic factors specific to each of
these disorders, and factors common to these disorders
and other forms of substance dependence.
It is only common genetic factors (that is, those that
influence more than one substance) that are likely to be
important worldwide (genetic factors specific to sub-
stances will vary because the specific substances vary).
Whether genes relevant to drugs of abuse that have
some similarities in their mechanisms of action, such as
cocaine (important, eg, in the US) and methampheta-
mine (predominant, eg, in Thailand, and important in
certain regions in the US) will prove to overlap, is still
an open question. Further, different risk factors may be
important in different populations (discussed in ref 1).
In the small number of instances where similar SD traits
have been studied in different populations, the genetic
factors uncovered have not been identical.
Thus, gene mapping for substance-dependence (SD)
traits is complicated. Some risk alleles identified may be
important only for specific substances of abuse and oth-
ers, only for certain populations. So why try to map
genes for SD traits? First, SD is a huge cause of mor-
bidity and mortality worldwide; that is, it is a very impor-
tant problem that deserves to be studied despite its com-
plexity. Second, despite all of the a priori reasons to
believe that it would be exceedingly difficult to identify
genes and validate the findings, the track record for SD
genetics as a field is really very good. Below, we will
review some recent results that support this claim.
Linkage studies
Genome-wide linkage studies, the traditional approach
to identifying risk loci, provide chromosomal locations
for risk-influencing loci based on the observation of
coinheritance of marker alleles and the disease trait in
families. To be comprehensive, linkage studies employ
markers that map throughout the entire genome. This
approach has been used for cocaine, opioid, and nicotine
dependence, and for related traits. 
We are aware of only one linkage study of cocaine
dependence (CD); we studied a sample of small families
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each with at least one subject affected with CD, which
included 528 full and 155 half sibpairs and was 45.5%
European-American (EA) and 54.5% African-
American (AA).15 We completed an autosomal genome-
wide linkage scan for the CD diagnosis, cocaine-induced
paranoia, and cocaine-related subphenotypes derived
using cluster analytic methods. The subtyping procedure
was used to identify more genetically homogeneous sub-
groups of subjects in which the effects of individual risk
loci might be more prominent. For CD, we found “sug-
gestive” linkage signals on chromosome 10, in the full
sample, and on chromosome 3, in the EA part of the
sample. Much stronger results were obtained for the
cluster-derived subtypes, including genome-wide-
significant lod scores for membership in the “Heavy Use,
Cocaine Predominant” cluster on chromosome 12 and
for membership in the “Moderate Cocaine and Opioid
Abuse” cluster on chromosome 18. In AA families only,
we observed a genome-wide-significant lod score on
chromosome 9 for the trait of cocaine-induced paranoia.
Genome-wide significance was defined on the basis of
Lander and Kruglyak's 1995 criteria.16
There have been three independent genome-wide link-
age studies of opioid dependence (OD). We studied 393
small families each with at least one individual affected
with OD.17 We completed a genome-wide linkage scan for
DSM-IV OD, and, as for the CD study, for cluster-
defined phenotypes, a heavy-opioid-use cluster, and a
non-opioid-using cluster. The strongest results were,
again, seen with the cluster-defined traits: for the “heavy
opioid users” cluster there was a genome-wide-
significant linkage for EA and AA subjects combined, on
chromosome 17. For the “nonopioid users” cluster, there
was a genome-wide-significant linkage elsewhere on
chromosome 17, for EA subjects only. Lachman et al18
studied a mixed US sample of 305 OD-affected sibling
pairs, and identified evidence for linkage on a region of
chromosome 14 overlying the neurexin 3 gene (NRXN3).
They also identified a male-specific linkage peak on chro-
mosome 10q. Finally, Glatt et al19 studied a sample of
nearly 400 independent affected sibling pairs ascertained
in China near the Golden Triangle, one of Asia's largest
illicit opium-producing areas, but did not identify any
strongly-supported linkage signals, despite the presumed
genetic homogeneity of the sample. The strongest signal
they observed was on chromosome 4q.
There have been numerous genome-wide linkage scans for
smoking and related phenotypes, reviewed in ref 20. Han
et al21 completed genome scan meta-analysis (GSMA) of
genome-wide linkage scans for nicotine dependence (ND)
and related traits, pooling all available independent
genome scan results on smoking behavior. To minimize
locus heterogeneity, subgroup analyses of the smoking
behavior assessed by the Fagerstrom Test for Nicotine
dependence (FTND) and maximum number of cigarettes
smoked in a 24-hour period (MaxCigs24) were also car-
ried out. Fifteen genome scan results were available for
analysis, including 10 253 subjects in 3 404 families. The pri-
mary GSMA across all smoking behavior identified a
genome-wide “suggestive” linkage in chromosome
17q24.3-q25.3. But the strongest result derived from the
subgroup analysis of MaxCigs24 (including 966 families
with 3 273 subjects), which identified a genome-wide sig-
nificant linkage in 20q13.12-q13.32. CHRNA4, a strongly
supported ND candidate gene, is located in this interval;
Li et al22 previously reported on association of CHRNA4
variants to ND.
A high level of statistical support for a genetic linkage is
very valuable, but the ultimate proof that a disease-influ-
encing locus underlies a statistical linkage peak is the
identification of a risk gene in the peak that accounts for
the linkage signal. The next step is typically genetic asso-
ciation analysis, ie, evaluation of a set of markers that
map under the linkage peak for association with the
trait. Genetic association provides another degree of sta-
tistical evidence, but eventually, proof of a disease-gene
relationship must rely on demonstration of a functional
effect of a variant or variants at the risk locus. ND is the
furthest of all drug-dependence (DD) traits along this
pathway, with numerous loci supported on the basis of
statistical genetic association evidence, and some of
these loci have received the higher level of support of
functional data.
Association studies
Strategy for single-nucleotide polymorphism (SNP)
selection plays a key role in association study outcome.
In general, variants predicted to have functional conse-
quences, eg, because they alter predicted amino acid
sequence, have been favored for study; alternatively,
researchers often try to capture most of the genetic vari-
ation at a locus via selection of haplotype tagging SNPs
followed by haplotype reconstruction. It is important to
recognize some of the limitations of these strategies at
the outset. Although most common putatively functional
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SNPs are known, rarer SNPs may have large phenotypic
effects, and there are many such variants yet to be dis-
covered. Not all functional SNPs are easily recognized
as such. SNPs vary by population, and populations dif-
fer in the extent to which common genetic variation has
been identified. The same population variation is
reflected in differences in haplotype structure. Finally,
haplotype reconstruction is almost always accomplished
via computer algorithms, and the results are estimated.
With these limitations in mind, we discuss several exam-
ples of genetic associations with DD phenotypes, focus-
ing on interesting physiological candidates and on repli-
cated findings. 
Association of variants that map at or near the D2
dopamine receptor (DRD2 locus) with drug or alcohol
dependence was proposed many years ago and has been
widely debated. We identified a “suggestive” linkage peak
for ND at the region of chromosome 11 that includes the
NCAM1-TTC12-ANKK1-DRD2 gene cluster.23 The
inconsistent results with DRD2 may be attributable to an
indirect effect—observed association could actually be
mediated through variation at a nearby locus in linkage
disequilibrium with DRD2. To test this hypothesis, we
genotyped 43 SNP markers in a region including DRD2
and the three adjacent genes, in an SD linkage sample of
>1600 subjects. We found very strong evidence of associ-
ation of multiple SNPs at TTC12 and ANKK1 in two dif-
ferent populations, EAs and AAs (minimal P=0.0007 in
AAs and minimal P=0.00009 in EAs), and highly signif-
icant association of a single haplotype (set of markers)
spanning TTC12 and ANKK1 to ND in the pooled sam-
ple (P=0.0000001). Thus, a risk locus for ND maps to a
region that spans TTC12 and ANKK1. The exact local-
ization of the risk haplotype depends on the disease def-
inition, and whether and which co-occurring diagnoses
are present in the study sample.24
These results support the hypothesis that the DRD2
findings could be attributable to variants in nearby loci.
Such variants could reflect either functional variation
that affect those loci (and not DRD2), or relatively dis-
tant regulatory regions important for DRD2 function.
The ANKK1 finding in ND has been replicated.25
Another set of risk loci that are of interest in relation to
the risk of drug dependence are those encoding proteins
that regulate or mediate opioidergic function. All of the
opioid receptor genes have been reported to be associ-
ated with substance dependence liability. A functional
polymorphism in OPRM1 (Asn40Asp), which encodes
the mu-opioid receptor, has been the most extensively
studied in this regard, though the association is contro-
versial. Although multiple studies have shown a signifi-
cant allelic association with DD, they are nearly evenly
divided between those showing a significant excess of
the Asp40 allele among cases26,27 and those showing a sig-
nificant excess of the Asp40 allele among controls.28-30
Consequently, meta-analyses of that literature failed to
show a reliable association of the SNP with either OD31
or any SD disorder.32 However, Zhang et al33 examined
13 SNPs spanning the coding region of OPRM1 in a
sample of EAs with AD and/or DD and 338 EA healthy
controls. The SNPs formed two haplotype blocks. There
were significant differences between cases and controls
in allele and/or genotype frequencies for SNPs in Block
I and in Block II, after correction for multiple testing.
Haplotypes constructed from five tag SNPs differed sig-
nificantly in frequency between both AD and DD sub-
jects and controls. Logistic regression analyses in which
the sex and age of subjects and alleles, genotypes, hap-
lotypes, or diplotypes of the five tag SNPs were consid-
ered confirmed the association between OPRM1 vari-
ants and SD. 
Zhang et al34 also examined the genes encoding the
other two opioidergic receptors: OPRD1 (which encodes
the delta receptor) and OPRK1 (which encodes the
kappa receptor). Eleven SNPs spanning OPRD1 were
examined in EAs with AD, CD, and/or OD, and control
subjects. Although nominally significant associations
were observed for five SNPs with SD, only the associa-
tion of the nonsynonymous variant G80T with OD
remained significant after correction for multiple test-
ing. Haplotype analyses with six tag SNPs indicated that
a specific haplotype was significantly associated with AD
and OD (P<0.001). In logistic regression analyses, con-
trolling for sex and age, this haplotype had a risk effect
on AD and, to a much greater extent, on OD. In addi-
tion, seven SNPs covering OPRK1 were examined in the
majority of subjects and although there were no signif-
icant differences in allele, genotype, or haplotype fre-
quency distributions between cases and controls, a spe-
cific OPRK1 haplotype was significantly associated with
AD, but not DD. In summary, these findings demon-
strated a robust positive association between OPRD1
variants and SD, particularly OD. 
Finally, Zhang et al35 studied POMC, the gene that
encodes pro-opioimelanocortin, from which functionally
different peptides are derived via tissue-specific post-
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translational processing; of particular relevance here are
two principal elements of the hypothalamic-pituitary-
adrenal axis: adrenocorticotropin (ACTH) and β-endor-
phin. Five SNPs spanning POMC were examined in
independent family and case-control samples of EAs
and AAs. The families were ascertained based on a pair
of siblings affected with cocaine and/or opioid depen-
dence. Case-control studies included cases affected with
AD, CD and/or OD and controls. Family-based analyses
revealed an association of one SNP (rs6719226) with
OD in AA families, and a different SNP (rs6713532)
with CD in EA families. Case-control analyses demon-
strated an association of rs6713532 with AD or CD.
Moreover, the minor allele of a third SNP was a risk fac-
tor for CD or OD in AAs, and for AD, CD, or OD in
EAs. Logistic regression analyses in which sex and age
were considered and population stratification analyses
confirmed these findings. Additionally, specific haplo-
types increased risk for CD in AAs and OD in EAs. 
In summary, as might be expected given that the brain’s
opioidergic system plays a central role in reinforcement,
which has important implications for addiction,36 varia-
tion in a number of functional candidate genes encoding
opioidergic proteins have been implicated in depen-
dence on alcohol, cocaine, and opioids. Assuming inde-
pendent replication of these findings, a key question to
be addressed is the nature of gene-gene and gene by
environment interactions to which risk of SD is attrib-
utable.
Other studies have demonstrated associations with the
cannabinoid receptor gene (CNR1),37-39 neurexin 1
(NRXN1),40 and a set of alcohol-metabolizing
enzymes.41 A clear pattern emerges from the examina-
tion of this sampling of candidate gene associations with
SD: insofar as genes with known function are con-
cerned, there are no big surprises with respect to phys-
iology. (This can not be said about genes without clearly
delineated functional roles, such as ANKK1, which was
identified, not incidentally, based on its position, rather
than its function.) This highlights the limitations of the
candidate gene approach, which is often inherently
biased by prior knowledge about physiology. Unbiased
studies have greater potential to reveal new mecha-
nisms of addiction, and that is a key attraction of the
genome-wide association study (GWAS) methodology
discussed below.
GWASs are an alternative to linkage for locating genes
anywhere in the genome without prior hypotheses.
GWAS designs are of interest due to their potential to
identify risk loci of relatively small effect, much smaller
than through linkage strategies. (In fact, one controversy
engendered by the widespread adoption of GWAS
designs is that often risk alleles are identified that have
such a small effect—typically with odds ratios less than
1.2—that it is hard to know what to do with them once
they have been identified.) A second advantage of
GWASs is that they may be based on case-control sam-
ples, which are easier to recruit than family sampling
schemes, which must be deployed to prepare for linkage.
Family samples are more difficult to recruit (markedly
so for many kinds of SD because of the tendency of
these disorders to fragment families) and can introduce
certain kinds of bias. The first GWAS for a specific SD
trait, excluding studies that used a pooling methodology
exclusively (see ref 42), examined ND.43 This study
employed a two-stage design; first pooled DNA was
used to screen 2.4 million SNPs; second, >30 000 SNPs
selected from the first stage were screened individually
in ~1000 each cases and controls. Numerous genes were
identified as possibly associated to ND, including both
novel genes and genes that were previously considered
candidates based on known physiology (eg, cholinergic
receptor, nicotinic, beta 3, CHRNB3). The latter finding
has been confirmed in larger studies: subsequent
GWASs have demonstrated highly significant associa-
tions between variation in the nicotinic receptor gene
cluster CHRNA5-CHRNA3-CHRNB4 and ND and
related traits44,45 and with lung cancer.46,47
In a hypothesis-generating study, we studied a set of
5633 SNP markers in 1699 subjects from 339 AA fami-
lies and 334 EA families ascertained through a sib pair
meeting DSM-IV criteria for either CD or OD. This is
considered a sparse marker set for the purposes of
GWAS. It is expected to interrogate <10% of the
genome, thus, cannot be considered to be a study of truly
genome-wide depth. Associations between these mark-
ers and five substance dependence traits (CD, OD, AD,
ND, and cocaine-induced paranoia) were assessed by
family-based association tests (FBAT). The top-ranked
result was an association of a specific SNP in the
MANEA gene with cocaine-induced paranoia. This
study provided an initial SD trait-specific blueprint of
associated regions for future candidate gene studies.
There are, at the time of this writing, no published
GWAS studies for several of these traits. The MANEA
finding was replicated and extended in a larger sample.48
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Discussion
We identify two main ways to account for the relatively
consistent results seen in this field. First, diagnosis can
be made with high reliability. Second, the phenotypes are
relatively straightforward because they are, in their
essence, pharmacogenetic. That is, SD phenotypes reflect
genetic moderation of the subjective response to drugs
of abuse.
While results in this research field have been relatively
consistent, most of the genetic risk for DD has yet to be
attributed to specific alleles. Initially, it was thought that
the GWAS was the answer to the problem. But applica-
tion in other complex traits (eg, schizophrenia, bipolar
affective disorder, autism) has revealed a more complex
picture, such that even clinical samples that should have
been adequately powered have fallen short of providing
definitive and significant results. The explanation for this
situation may reside in the fundamental genetic archi-
tecture of some complex traits. GWAS is based on a
common-disease-influenced-by-common-allele model.
However, we are now learning that many phenotypes
are influenced instead by sets of variants, in sets of loci,
each of which is rare on a population level. Such variants
are likely to be uncovered only by extensive sequencing
of affected and unaffected individuals. Copy number
variation (CNV) is another mechanism that is proving
to be important in modulating disease risk. Such varia-
tion is important for at least some behavioral traits; for
example, Sebat et al49 have reported on the relationship
of CNV to autism, and several groups have reported
association of rare structural variants with schizophre-
nia.50-53
We have seen several successful examples of genetic
association identified following a linkage finding, a
sequence that demonstrates the main utility of genetic
linkage. But there have also been surprisingly many
instances when strong genetic association has not been
identified readily. There are many ways to account for
such a circumstance—genetic heterogeneity, random
variation, and population variation, to name a few.
Another intriguing possibility has become more promi-
nent of late. The linkage-to-association-to-gene model is
premised basically on the common disease-common
variant model discussed above. This model may not be
as applicable as was thought; there is increasing evidence
that heritability may be accounted for by many rare vari-
ants in either a single locus, or a set of related loci. Since
linkage depends on the identification of coinheritance
of trait and marker within families, it stands to reason
that a set of different rare variants could be detected by
linkage (even if the responsible variants differed greatly
between families in the discovery set). Such variants
would be very resistant to discovery by ordinary tagging
haplotype association strategies. Similarly, such variants
would be expected to be refractory to discovery by
GWAS methodology. Deep sequencing studies have suc-
cessfully accounted for the “missing” genetic variance in
some cases. For example Nejentsev et al54 found a set of
individually rare variants at the IFIH1 locus that affect
risk for type 1 diabetes, following up on a GWAS study.
Ji et al55 started with a set of genes known to have large
effects on blood pressure in a small number of severely
affected families, and sequenced them in a large number
of unrelated individuals. Rare variants with smaller
effects on blood pressure were identified. These findings
are likely to be relevant for SD genetics research as well,
inasmuch as deep sequencing of candidate loci in many
unrelated individuals may be necessary to account for a
greater proportion of the genetic risk than is presently
known.
Whole-genome sequencing is becoming progressively
less expensive, and will surely ultimately be feasible for
locating genetic variants that increase risk for complex
genetic traits, albeit at the risk of daunting statistical
problems. Sequencing of expressed sequences only
(‘whole exome”) may be a valuable interim step. Ng et
al56 have demonstrated the feasibility of this approach.
In summary, new developments in a variety of genetic
methods and in the accumulating molecular evidence of
the genetic risk for SD promise to yield greater insights
into the etiology of these disorders, bringing into relief
the environmental contributions and creating opportu-
nities for prevention and new therapeutic options.
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Genética de la dependencia de drogas
Los trastornos de dependencia de drogas (aquí se
revisa cocaína, opioides y nicotina) tienen una
influencia genética. Primariamente la localización
de los genes de riesgo se ha basado en estudios de
ligamiento y la identificación en estudios de aso-
ciación genética. En este artículo se revisan resulta-
dos destacados sobre metodologías de estudio de
ligamiento, asociación y asociación del genoma
completo y se discuten las posibilidades futuras
para la identificación del riesgo de alelos en base a
estas y otras metodologías más recientes. Aunque
se ha realizado un progreso considerable, es pro-
bable que la aplicación de secuenciaciones más
amplias que las que se han practicado previamente
serán requeridas para identificar un mayor rango
de variantes de riesgo. 
Génétique de la toxicomanie
Il existe une prédisposition génétique à la toxico-
manie (dans cet article, nous nous intéresserons à
la dépendance à la cocaïne, aux opioïdes et à la
nicotine). Des gènes de ce risque ont été localisés
initialement  à partir d’études de liaisons géné-
tiques et identifiés à partir d’études d’association
génétique. Nous présentons dans cet article les prin-
cipaux résultats issus d'études d’association sur le
génome entier, de liaisons et d’associations ainsi
que les perspectives d’identification d’un allèle du
risque fondées sur ces méthodologies et de  plus
récentes. Malgré des progrès considérables, un
séquençage plus étendu que celui effectué aupara-
vant sera probablement nécessaire pour identifier
une gamme plus complète de variants du risque.
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chizophrenia and bipolar affective disorder
(bipolar disorder, manic depression) are major psychi-
atric disorders. They profoundly affect thought, percep-
tion, emotion, and behavior, and their symptoms cause
significant social and/or occupational dysfunction. The
World Health Organization ranks both disorders among
the top 10 leading causes of the global burden of disease
for the 15-to-44 age group.
Schizophrenia and bipolar disorder are illnesses with a
largely unknown pathophysiology and etiology. However,
genetic epidemiology has demonstrated that modern psy-
chiatric diagnostic criteria define disorders that are highly
heritable. Estimates of heritability range between 70%
and 90% for schizophrenia1 and 60% and 80% for bipo-
lar disorder.2 It is generally accepted that the inheritance
of psychiatric disorders is complex. Multiple genetic and
environmental factors contribute to the development of
a disorder3-9 and it is possible that gene-gene interactions
also occur.10,11
Extensive efforts have been made over the past 20 years
to identify the susceptibility genes for psychiatric disor-
ders on a molecular genetic level, although this has
proven to be a far more difficult undertaking than was
first anticipated. Until recently, the linkage approach and
microscopic cytogenetic studies were the only available
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Schizophrenia and bipolar disorder have a largely
unknown pathophysiology and etiology, but they are
highly heritable. Although linkage and association stud-
ies have identified a series of chromosomal regions likely
to contain susceptibility genes, progress in identifying
causative genes has been largely disappointing. However,
rapid technological advances are beginning to lead to
new insights. Systematic genome-wide association and fol-
low-up studies have reported genome-wide significant
association findings of common variants for schizophre-
nia and bipolar disorder. The risk conferred by individual
variants is small, and some variants confer a risk for both
disorders. In addition, recent studies have identified rare,
large structural variants (copy number variants) that con-
fer a greater risk for schizophrenia. This review summa-
rizes recent developments in genetic research into schiz-
ophrenia and bipolar disorder, and discusses possible
future directions in this field.   
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methods of systematically searching the genome. A dis-
advantage of these two methods is their low level of res-
olution. Linkage studies have identified a series of chro-
mosomal regions that are likely to contain susceptibility
genes, and highly promising association findings have
been obtained for several genes in these regions (eg,
neuregulin 1 [NRG1], G72/G30 locus, dystrobrevin-bind-
ing protein 1 [DTNBP1]).12-14 However, it has not yet
been possible to identify any genetic variant that confers
a direct functional effect and which is consistently asso-
ciated with disease across populations. Cytogenetic stud-
ies have also generated some highly promising candidate
genes such as the disrupted-in-schizophrenia-1 gene
(DISC1).15 Subsequent studies have reported highly
interesting findings regarding the function of these genes
and their associated pathways.16
Recently, however, important advances have been made
as a result of rapid developments in technologies that
are able to decipher the variability of the human
genome at high resolution, and which allow systematic
investigation of the impact of such variability in large
samples. This article summarizes these developments in
genetic research into schizophrenia and bipolar disorder,
and discusses possible future directions in this field.
Genome-wide association studies
The introduction of the genome-wide association study
(GWAS) is the result of enormous technological
advances. GWASs involve the use of arrays that simul-
taneously genotype several hundred thousand single
nucleotide polymorphisms (SNPs) per individual. This
enables a hypothesis–free search of every gene and most
intergenic regions of the genome in samples of unrelated
patients and controls. In this respect GWASs resemble
genome-wide linkage studies (genome scans), but they
have several major advantages: (i) they are not depen-
dent on the recruitment of families; (ii) they have better
resolution since (in contrast to linkage) they detect link-
age disequilibrium with susceptibility variants, which
usually extends over smaller genomic regions (in the
range of a few ten thousand base pairs); and (iii) they
have greater power to detect small genetic effects. In
contrast to linkage studies, however, they are restricted
to the investigation of common variants, since SNPs with
low minor allele frequencies are poorly represented on
currently available arrays. A serious difficulty in evalu-
ating the results of GWASs is the issue of multiple test-
ing. A large number of SNPs may be tested within the
same study for their association with a disease, and this
generates many nominally significant findings that are
actually false positives. It is therefore necessary to cor-
rect for multiple testing to achieve the level of genome-
wide significance. This level is dependent upon the num-
ber of SNPs analyzed, and the threshold for currently
available GWA chips is approximately 5 x 10-8 (660 000
to 1 000 000 SNPs).17-19 This correction method is very
conservative since the association findings of each SNP
are considered to be independent, and the haplotype
structure of the genome is not taken into account.
Conservative correction for multiple testing reduces the
risk of false-positive findings, but hampers the detection
of true association signals that represent small effects on
disease risk.
Following the publication of the first GWAS in age-
related macular degeneration,20 successful GWASs have
been conducted for a variety of common, complex dis-
eases including type 2 diabetes, myocardial infarction,
breast cancer, and Crohn’s disease (for details of all pub-
lished studies see http://www.genome.gov/gwastudies/).
Schizophrenia
The first GWASs for schizophrenia have recently been
published.21-30 Three of these studies used pooled DNA
samples.21,26,27 The best supported variants in these three
studies failed to achieve genome-wide significance 21,26,27
(Table I). This is a cost-effective method of performing
GWASs and has proved to be effective in identifying dis-
ease genes (eg, refs 31,32). However, due to errors in
DNA quantification, this method is less sensitive than
individual genotyping and has less power. Furthermore,
the evaluation of data is limited to the study of (esti-
mated) allele frequencies at the level of individual SNPs.
This method does not detect the effect of haplotypes,
interactions between SNPs, or the effects of genotypes
that do not show differences in allele frequencies. The
first individual-genotyping-based GWAS of schizophre-
nia involved a very small sample of 178 cases and 144
controls.29 The best hit was for a variant near the colony-
stimulating factor-2 receptor alpha (CSF2RA) gene, but
this did not achieve genome-wide significance.29 The sec-
ond GWAS of this type included 738 patients and 733
controls. Although a few signals coincided with genomic
regions that had been implicated in previous linkage
studies of schizophrenia, this study found no genome-
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Study N° SNPs Supported Supported Genomic P value N° samples P value N° samples, 
analyzed gene variant region discovery discovery combined replication/ 
meta-analysis
Mah et al ~ 25 000 plexin A2 (PLXNA2) rs752016 1q32.2 0.006 320 cases 0.035 200 cases (EA)
(2006) 325 controls 230 controls (EA)
Lencz et al ~ 500 000 colony stimulating rs4129148 Xp22.33 3.7 x 10-7 178 cases ND ND
(2007) factor receptor 2 Yp22.32 144 controls
alpha (CSF2RA)
Sullivan et al ~ 500 000 nearest gene: rs4846033 1p36.22 4.4 x 10-6 738 cases ND ND
(2008) angiotensin II receptor- 733 controls
associated protein
(AGTRAP)
O´Donovan et al ~ 500 000 zinc finger protein rs1344706 2q32.1 1.8 x 10-6 479 cases 1.6 x 10-7 7308 cases
(2008) 804A (ZNF804A) 2937 controls 12834 controls
Shifman et al ~ 500 000 reelin (RELN) rs7341475 7q22.1 2.9 x 10-5 745 cases 8.8 x 10-7 2274 cases
(2008) (in females) 2644 controls (in females) 4401 controls
Kirov et al ~ 550 000 coiled coiled domain rs11064768 12q24.23 1.2 x 10-6 574 trios ND ND
(2009) containing 60 (CCDC60)
Need et al ~ 550 000 ADAMTS like 3 rs2135551 15q25.2 1.3 x 10-6 871 cases NR 1460 cases
(2009) (ADAMTSL3) 863 controls 12995 controls
Shi et al (2009) ~ 600 000 ArfGAP with GTPase rs13025591 2q37.2 4.6 x 10-7 2681 cases ND
domain, ankyrin repeat (in EA) 2653 controls
and PH domain 1 (EA)
(AGAP1)
v-erb-a erythroblastic rs1851196 2q34 2.1 x 10-6 1286 cases ND
leukemia viral oncogene (in AA) 973 controls
homolog 4 (avian) (AA)
(ERBB4)
major histocompatibility rs9272219 6p21.32 ND 6.9 x 10-8 8008 cases (EA)
complex (MHC) rs9272535 6p21.32 ND 8.9 x 10-8 19077 controls (EA)
cluster of histone rs13194053 6p22.1 1.4 x 10-2 9.5 x 10-9
protein genes (in EA)
The ~ 1 000 000 myosin XVIIIB rs5761163 22q12.1 3.4 x 10-7 3322 cases ND 8008 cases
International (MYO18B) 3587 controls 9.5 x 10-9 19077 controls
Schizophrenia major histocompatibility rs13194053 6p22.1 ND
Consortium (2009) complex (MHC)
Stefansson et al ~ 300 000 major histocompatibility 5 variants 6p21.3 – 0.0027- 2663 cases 1.1 x 10-9- 12945 cases
(2009) complex (MHC) 6p22.1 0.00023 13498 controls 1.4x 10-12 34591 controls
neurogranin (NRGN) rs12807809 11q24.2 0.00045 2.4 x 10-9
transcription factor 4 rs9960767 18q21.1 0.0011 4.1 x 10-9
(TCF4)
Table I. Published genome-wide association studies (GWASs) for schizophrenia.21-30,32 The number of variants investigated, the best associated sin-
gle-nucleotide polymorphism(s)–SNP(s)—found and the gene(s) containing the SNP(s), the corresponding P value(s), and the number of cases
and controls in the discovery and the replication/meta-analysis sample are all given. Genome-wide significant findings are highlighted in bold.
EA, European Ancestry Individuals; AA, African-American Individuals; ND, no data available; NR, no replication
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wide significant association.30 O’Donovan et al initially
performed a GWAS using a moderately sized patient
sample (n=479). They then performed a follow-up study
of 12 markers with a P value ≤10-5 in a much larger sam-
ple to enhance the statistical power.25 Strong evidence
for replication was obtained for 3 of these 12 markers (P
≤5 x 10-4), although the best supported variant still failed
to achieve genome-wide significance (Table I). The high-
est-ranking SNP identified in this study is located in an
intron of the zinc finger protein 804A gene (ZNF804A),
a putative transcription factor which had never been
implicated previously in the risk for schizophrenia. The
case sample was then extended to include bipolar
patients. The P value for the total sample surpassed the
level of genome-wide significance (P=9 x 10-9). The asso-
ciation between ZNF804A and schizophrenia has
recently been replicated by the International
Schizophrenia Consortium,24 and ZNF804A is therefore
a promising susceptibility gene for schizophrenia. A
recent imaging genetics study of ZNF804A risk geno-
types has provided evidence in support of these genetic
findings. This study demonstrated that healthy carriers
of ZNF804A risk genotypes display pronounced gene-
dosage-dependent alterations in functional coupling
between the hippocampus and the dorsolateral pre-
frontal cortex (DLPFC) across the two hemispheres,
which mirrors findings in patients.33
Three recent multicenter studies have provided impor-
tant insights. The initial findings of these three studies
failed to surpass the level of genome-wide significance.
However, a meta-analysis was then performed using the
best hits from the European data of these studies and
data from a replication study by Stefansson et al.22 This
revealed a cluster of genome-wide significant SNPs in
the major histocompatibility (MHC) region of chromo-
some 6p22.1 that were in substantial linkage disequilib-
rium.22-24 These results provide evidence that the
immunological system may play a role in the pathogen-
esis of schizophrenia. Furthermore, a variant upstream
of neurogranin (NRGN; P=2.4 x 10-9) and a SNP in tran-
scription factor 4 (TCF4; P= 4.1 x 10-9) achieved genome-
wide significance in Stefansson et al's study.22 These stud-
ies demonstrate that GWASs of large samples can
overcome limitations in power and detect common risk
variants for complex psychiatric disorders.
In the study by the International Schizophrenia
Consortium, it was demonstrated that possible risk vari-
ants may have been among the nominally significant
SNPs that failed to reach genome-wide significance.
Nominally significant SNPs were grouped into a “set of
score alleles” and analyzed in an independent case-con-
trol sample, and it was shown that they distinguished
cases from controls.24 This study also demonstrated that
this set of genes distinguished bipolar cases from con-
trols, thus providing further evidence for a genetic over-
lap between schizophrenia and bipolar disorder.
Although these SNPs explained only approximately 3%
of the variance in schizophrenia risk, this may be
regarded as a step towards molecular genetic evidence
for the polygenic inheritance of schizophrenia.
Bipolar disorder
Six GWASs have been published to date for bipolar dis-
order34-39 (Table II) including the landmark study by the
Wellcome Trust Case Control Consortium (WTCCC)
which investigated seven common disorders.36 These
studies were all based upon individual genotyping, with
the exception of the study by Baum et al39 which
involved DNA pooling. Although there has been some
inconsistency across studies in terms of their most asso-
ciated genomic regions,35-39 meta-analyses of some of
these studies have revealed common association signals.
A meta-analysis of the Baum et al39 and the WTCCC36
datasets found a consistent association between bipolar
disorder and variants in the genes junction adhesion mol-
ecule 3 (JAM3) (rs10791345, P=1 x 10-6), and solute car-
rier family 39 (zinc transporter), member 3 (SLC39A3)
(rs4806874, P=5 x 10-6).40 A combined analysis of the
Sklar et al35 and WTCCC36 studies, which included a total
of 4387 patients and 6209 controls, identified the first
genome-wide significant association signal for bipolar
disorder for ankyrin 3, node of Ranvier (ANK3)
(rs10994336, P=9.1 x 10-9).34 The second most strongly
associated region was marked rs1006737 in calcium
channel, voltage-dependent, L type, alpha 1C subunit
CACNA1C (P=7 x 10-8). Further independent support
for ANK3 rs10994336 has recently been obtained by
Schulze et al41 in samples from Germany and the United
States (US); this study also found evidence for allelic
heterogeneity at the ANK3 locus.
Although GWASs of bipolar disorder have identified a
number of potentially relevant genetic variants, the
widely acknowledged formal threshold for genome-wide
significance of P=5 x 10-8 has only been surpassed so far
for variation in ANK3.
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Future studies involving larger samples, the pooling of
datasets, and higher statistical power are expected to
identify additional specific risk factors for bipolar disor-
der and schizophrenia. 
Copy number variations
Small chromosomal aberrations (microdeletions and
microduplications, collectively known as copy number
variations, CNV) may confer a risk for schizophrenia, as
illustrated by the 22q11.2 deletion syndrome (22q11.2DS).
This is a common microdeletion syndrome with congeni-
tal and late-onset features. Patients have a high risk for
neuropsychiatric diseases including psychotic disorders
and major depression.42-44 It has not been possible to cor-
relate the extent of the deletion with the occurrence of
schizophrenia in these patients, and there is experimental
evidence that increased susceptibility may require the
altered expression of several genes within the 22q11.2
region.45,46 This may explain why no replicable results have
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Study N° SNPs Supported Supported Genomic P value N° samples, P value N° samples, 
analyzed gene variant region discovery discovery combined replication/ 
meta-analysis
Baum et al ~ 550 000 diacylglycerol kinase rs1012053 13q14.11 0.0002 461 cases 1.5 x 10-8 772 cases
(2007) eta (DGKH) 563 controls 876 controls
Welcome Trust ~ 500 000 partner and localizer rs42059 7q21.3 6.3 x 10-8 1868 cases ND ND
Case Control of BRCA2 (PALB2) 2938 controls
Consortium 
(WTCCC; 2007)
Sklar et al ~ 400 000 tetraspanin-8 (TSPAN8) rs1705236 12q21.1 6.1x 10-7 1461 cases NR
(2008) myosin5B (MYO5B) rs4939921 18q21.1 1.7 x 10-7 2008 controls NR
voltage-dependent 3329 cases
calcium channel, L-type, rs1006737 12p13.33 8.8 x 10-4 3.1 x 10-6 4946 controls
alpha 1C subunit
(CACNA1C)
Ferreira et al ~ 1 800 000 ankyrin G (ANK3) rs10994336 10q21.2 0.0002 1098 cases 9.1 x 10-9 4387 cases
(2008) (imputed) rs1938526 10q21.2 0.0002 1267 controls 1.3 x 10-8 6209 controls
~ 300 000 voltage-dependent rs1006737 7.0 x 10-8
(genotyped) calcium channel, L-type, 12p13.33 0.0108
alpha 1C subunit
(CACNA1C)
Scott et al ~ 550 000 inter-alpha (globulin) rs1042779 3p21.1 2076 cases 1.8 x 10-7 3683 cases
(2009) inhibitor H1 (ITIH1) 1676 controls 14507 controls
multiple C2 domains, rs17418283 5q15 ND
transmembrane 1 1.3 x 10-7
(MCTP1)
nuclear factor 1 A-type rs472913 1p32.1 2.0 x 10-7
(NF1A)
Smith et al ~ 700 000 nck-associated protein 5 rs10193871 2q21.2 9.8 x 10-6 1001 cases ND ND
(2009) (NAP5) 1033 controls
(EA)
dpy-19-like 3 (DPY19L3) rs2111504 19q13.11 1.5 x 10-6 345 cases
670 controls
(AA)
Table II. Published genome-wide association studies (GWASs) for bipolar disorder.34-39 The number of variants investigated, the best associated single-
nucleotide polymorphism(s)–SNP(s)—found and the gene(s) containing that SNP(s), the corresponding P value(s), and the number of cases
and controls in the discovery and the replication/meta-analysis sample are all given. Genome-wide significant findings are highlighted in bold.
EA, European Ancestry Individuals; AA, African-American Individuals; ND, no data available; NR, no replication
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been obtained from attempts to implicate individual
genes within the deletion region as susceptibility genes for
schizophrenia.47
Schizophrenia
The application of new technologies such as compara-
tive genomic hybridization (CGH) and SNP arrays in
GWASs has enabled the identification of small chromo-
somal aberrations on a genome-wide scale. Initial stud-
ies reported an increased rate of aberrations in schizo-
phrenia48,49 and subsequent studies have implicated
specific chromosomal regions.28,50-54 Implicated aberra-
tions include microdeletions in chromosomal regions
1q21.1, 2p16.3, 15q11.2, and 15q13.3, as well as microdu-
plications in chromosomal regions 15q13.1 and 16p11.2.
Although all of these variants are observed more fre-
quently in patients than in controls (with odds ratios of
>10 for some variants), the frequency of each individual
variant in schizophrenia patients is low (<1%). Further
studies are required to determine the penetrance and
mutation rate of these aberrations, as well as their phe-
notypic spectrum. Research has shown that some vari-
ants also occur more frequently in patients with other
central nervous system phenotypes such as autism, men-
tal disability, and epilepsy.55-58 The mechanisms that
underlie the phenotypic outcome however, remain
unknown. The fact that de novo mutations are found in
a proportion of patients with CNVs supports the hypoth-
esis that the negative effect on reproductive fitness
observed in schizophrenia patients may be at least partly
offset by the occurrence of new mutations.
Bipolar disorder
There have been few CNV studies of bipolar disorder.59-61
Lachman et al investigated a mixed cohort of Caucasian
patients (n=227) and controls (n=276) from the Czech
Republic and the United States, and found that CNVs
involving the gene glycogen synthase kinase 3 beta
(GSK3beta) were significantly increased in patients com-
pared with controls.59 Using a European American sample
of 1001 BD patients and 1034 controls, Zhang et al inves-
tigated singleton microdeletions (ie, those occurring only
once in the total dataset of patients and controls) of more
than 100 kb and found that they were overrepresented in
patients.60 The effect was strongest in a subgroup of
patients with an early onset of mania (<18 years of age). A
recent study of a three-generation Older Amish pedigree
with segregating affective disorder61 identified a set of 4
CNVs on chromosomes 6q27, 9q21, 12p13, and 15q11 that
were enriched in affected family members and which
altered the expression of neuronal genes.
No CNV with a genetic effect comparable to those iden-
tified for neuropsychiatric disorders such as schizophre-
nia or autism has yet been identified for bipolar disor-
der. In view of the limited number of studies performed,
it is not possible to evaluate the influence of CNVs on
disease development. 
Outlook
The first GWASs of schizophrenia and bipolar disorder
have recently been published, and many more are in
progress. Large international collaborations have been
initiated to combine GWAS data sets in order to increase
statistical power, the largest being the Psychiatric GWAS
Consortium, which is expected to publish its first results
in 2010 (The Psychiatric GWAS Consortium Steering
Committee 2009). Currently available research findings
suggest that the variants identified through GWASs con-
fer only small individual risks. The major limitation of
GWASs is that they are only able to investigate common
variants. If a large fraction of the genetic contribution is
conferred by rare variants, other approaches will be nec-
essary to identify them. A successful first step in this
direction has been the identification of associations
between rare CNVs and psychiatric diseases, in particu-
lar schizophrenia. However, due to methodological con-
straints, this approach remains restricted to the investi-
gation of aberrations of at least several thousand base
pairs. Continuing technological developments will pro-
vide future studies with increasing resolution, and the
availability of low-cost whole genome sequencing tech-
nology will ultimately make it possible to obtain the com-
plete genomic sequences of large patient samples for
comparison with controls. In principle, this will allow the
systematic identification of rare variants that are associ-
ated with disease risk, although the existence of a myriad
of rare variants in the human genome will render this a
complex task. It is hoped that some rare variants confer
a larger disease risk, as this will facilitate the detection of
association in large case-control samples. Rare variants
with small disease risk may be extremely difficult to
detect, since prohibitively large sample sizes may be
required to demonstrate any significant association. 
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It is likely, however, that even after the identification of
all common and rare risk variants a substantial fraction
of the familial clustering will remain unexplained. This
“missing heritability” in complex diseases is the subject
of intense debate and several potential explanations
have been proposed, including epistasis and epigenetic
mechanisms.62-64 It will be necessary to apply specific
research strategies to further investigate this issue,
although these may require prohibitively large sample
sizes or tissue samples that are difficult to access in
human subjects.
It is not yet clear whether any of the association findings
identified by GWASs represent causal variants.
Systematic resequencing of the associated genomic
regions will provide a comprehensive overview of such
variants. In cases where association findings are due to
linkage disequilibrium, it is possible that the causal vari-
ants have a stronger genetic effect than has been previ-
ously suspected. It is also theoretically possible that a
given association finding is not attributable to a common
causal variant. A simulation study has shown that the
“synthetic” effect of multiple rare variants may be
responsible for signals detected for common variants. It
has also been shown that the location of these variants
may be relatively far (up to 2 megabases) from the site
identified in GWASs.65 If this were the case for an asso-
ciated locus, resequencing over large genomic distances
in large samples would be required to identify the true
causative variants. Ultimately, it is necessary to identify
a direct functional effect for each potential causal vari-
ant, such as an effect on the function or expression of a
gene.
GWASs performed to date have indicated that certain
genes contribute to a susceptibility to both schizophre-
nia and bipolar disorder. It is clear that some of these
genes convey a rather nonspecific susceptibility that
overlaps diagnostic boundaries, and it is highly probable
that this also overlaps with other psychiatric disorders.
Other genes, however, convey specific effects. Future
studies of the phenotypic dimensions that are most
strongly associated with a specific gene will include
analysis of clinical symptoms and endophenotypes. The
latter may be particularly suited to guiding researchers
in the selection of the most promising phenotypes for
animal studies.66
The identification of disease-associated genes is likely to
increase our knowledge of the underlying pathophysiol-
ogy of psychiatric disorders in an as-yet unforeseen man-
ner. The identification of biological pathways has the
potential to revolutionize diagnostics and treatment.  ❏
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Nuevos hallazgos en la genética de las 
principales psicosis
La esquizofrenia y el trastorno bipolar tienen una
etiología y una fisiopatología en gran medida
desconocidas, pero son altamente heredables.
Aunque los estudios de ligamiento y de asociación
han identificado una serie de regiones cromosó-
micas que contienen probablemente genes sus-
ceptibles, el progreso en la identificación de
genes causales ha sido muy decepcionante. Sin
embargo, los rápidos avances tecnológicos están
dando origen a nuevos conocimientos. Los estu-
dios sistemáticos de asociación del genoma com-
pleto y de seguimiento han informado acerca de
hallazgos de asociación significativa del genoma
completo y variantes comunes para la esquizo-
frenia y el trastorno bipolar. El riesgo que deter-
minan las variantes individuales es pequeño y
algunas de ellas confieren un riesgo para ambos
trastornos. Además, estudios recientes han iden-
tificado variantes estructurales largas y raras
(variantes de número de copias) que otorgan un
mayor riego para la esquizofrenia. Esta revisión
resume los desarrollos recientes en la investiga-
ción genética de la esquizofrenia y del trastorno
bipolar y discute las posibles direcciones futuras
en este campo. 
Nouvelles découvertes en génétique des
principales psychoses
La physiopathologie et l’étiologie de la schizo-
phrénie et des troubles bipolaires restent large-
ment méconnues mais fortement héréditaires.
Des études de liaison et d’association ont identi-
fié des séries de régions chromosomiques conte-
nant probablement des gènes de susceptibilité,
mais l’identification des gènes de causalité est
extrêmement décevante. Des avancées technolo-
giques rapides commencent cependant à voir le
jour. Des études systématiques d’association sur le
génome entier et de suivi ont découvert une asso-
ciation significative au niveau du génome entier
de variants communs pour la schizophrénie et les
troubles bipolaires. Le risque inhérent aux
variants individuels est faible, et certains variants
comportent un risque pour les deux pathologies.
De plus, des études récentes ont identifié des
variants structurels importants et rares (CNV =
copy number variants, variants du nombre de
copies) liés à un risque plus élevé de schizophré-
nie. Cet article résume les avancées récentes de la
recherche génétique concernant la schizophrénie
et les troubles bipolaires et analyse les perspec-
tives possibles dans ce domaine.
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or more than 10 years, genome research has
focused on finding genetic risk factors for common dis-
orders, based on the “common disease—common vari-
ant (CDCV)” hypothesis—the intuitive but unproven
assumption that for most of the common disorders like
dementia, diabetes, coronary heart disease, autism, and
hypertension, there are common genetic risk factors.
Since 2007, after many years of growing frustration with
the disappointing results of genome-wide association
studies (GWAS), associated markers were identified for
a wide variety of complex disorders; this was hailed as a
decisive breakthrough in this field. However, these asso-
ciations were only found after massively increasing
cohort sizes and marker densities, meaning that the vast
majority of the associated risk factors have small effects
and that they are of no diagnostic and prognostic rele-
vance. Moreover, many markers were found to be
located in noncoding sequences, and thus, very few pro-
C l i n i c a l  r e s e a r c h
F
Single gene disorders come into focus—again
Hans-Hilger Ropers, MD, PhD   
Keywords: single gene disorder; genome research; mental retardation; next-
generation sequencing; health care
Author affiliations: Max Planck Institute for Molecular Genetics, Berlin, Germany  
Address for correspondence: Max Planck Institute for Molecular Genetics,
Ihnestrasse 73, D-14195 Berlin, Germany 
(e-mail: ropers@molgen.mpg.de)
In the early 1990s, when the second 5-year plan for the Human Genome Project—which requested more money than
any previous research project in biology—was written, common disorders were presented as the future target of
genome research. This was a clever move to ensure continued public support for this endeavor, which had been justi-
fied previously by the prospect that it would lead to the diagnosis, prevention, and therapy of severe, but mostly rare,
Mendelian disorders. Today, more than 15 years later, after billions of dollars have been spent on genome-wide asso-
ciation studies (GWAS), very few major genetic risk factors for common diseases have been identified, and the enthu-
siasm for large GWAS is dwindling. At the same time, there is renewed interest for studying single gene disorders,
which are now considered by some as a better clue to the understanding of common diseases. While this is probably
true, Mendelian disorders are also important in their own right, since they must be far more common than gener-
ally thought. As discussed here, various efficient strategies exist for the elucidation of single gene defects, and their
systematic application in combination with novel genome partitioning and massive parallel sequencing techniques,
will have far-reaching implications for health care.
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vided novel insights into the underlying pathogenetic
mechanisms. Ironically, therefore, very shortly after this
“breakthrough,” there is growing support for the notion
that for most common disorders, the CDCV hypothesis
must be wrong.1,2
This is certainly true for mental retardation (MR)—the
biggest unsolved problem of clinical genetics and the
largest socioeconomic burden of health care—where
most severe forms are due to defined chromosomal
abnormalities or single gene defects, instead of resulting
from multifactorial inheritance, ie, the interaction of
many different gene variants and environmental factors.
However, there is increasing evidence that single gene
defects also play a significant, previously underesti-
mated, role in other complex disorders. This has led to
growing uneasiness about the validity of the idea that
GWAS is the preferred approach for identifying
sequence variants in the human genome that predispose
to, or cause, disease. Moreover, it has raised serious
doubts about the strategy, first proposed in the early
1990s and uncritically adopted by leading genome cen-
ters worldwide, to focus exclusively on complex disor-
ders. 
After the introduction of massive parallel next-genera-
tion sequencing techniques, there are now indications for
a paradigm shift in this field, with a renewed focus on
single gene disorders. At a recent meeting,3 two groups
reported on their efforts to unravel the molecular basis
of Mendelian disorders by sequencing all exons in the
genomes of patients and their unaffected parents.
Moreover, leading genome researchers expressed their
belief that instead of GWAS, whole genome sequencing-
based, large-scale elucidation of single gene disorders
will be the strategy of choice for shedding more light on
the molecular architecture of common disorders. 
In the late 1980s, before common disorders were pro-
claimed as the central target of genome research, along
with overly optimistic assumptions about the medical
implications of this research, the revolutionary and
costly project to elucidate the structure of the human
genome had been justified by the prospect that it
would lead to unambiguous diagnosis, prevention, and,
eventually, therapies for severe Mendelian disorders.
Now, almost 20 years after the official commencement
of the Human Genome Project, and 6 years after its
completion, it appears that genome research is coming
around full circle by once again focusing on single gene
defects.
Single gene defects are important 
for health care
Single gene defects have significance in their own right.
In contrast to many complex disorders such as type 2
diabetes and obesity, which are lifestyle-related, become
manifest only later in life, or are relatively mild, single
gene disorders are mostly severe, early-onset conditions,
necessitating lifelong care and support. Moreover, single
gene disorders are far more numerous than generally
assumed, and as a group, they are certainly not rare. 
According to OMIM, the comprehensive catalogue of
human traits that are inherited in a Mendelian fashion
(http://www.ncbi.nlm.nih.gov/sites/entrez?db=omim),
only slightly more than 2500 human genes have been
linked to disease, and there are approximately 3500
Mendelian diseases for which the molecular cause is not
yet known. It is likely, however, that this is a wide under-
estimate, and that the number of genes which are indis-
pensable for normal embryonic and postnatal develop-
ment, homeostasis, and aging is much higher. 
In mice with induced defects of single genes (ie,
“knockout mice”), conspicuous (disease) phenotypes
or embryonic lethality are the rule rather than the
exception, as discussed elsewhere.2 In humans, the pro-
portion of gene defects that are associated with recog-
nizable disorders must be even higher, because rela-
tively subtle (eg, behavioral) abnormalities are readily
detectable in man, even without specific clinical exam-
ination. Milder mutations in the same genes known to
cause embryonic lethality when affected by loss-of-
function mutations may be compatible with life but
also cause disease.
Functional considerations and empirical data from
model organisms suggest that most disease-associated
gene defects are inherited as recessive traits. At least in
Western societies, this means that most patients will be
isolated cases, due to small family sizes and the fact that
in these populations, parental consanguinity is rare. In
sporadic cases without specific, previously described
combinations of clinical symptoms, single gene defects
are unlikely to be considered as the underlying cause. In
particular, this holds for patients with complex disorders
and presumed multifactorial inheritance. Thus, as dis-
cussed for MR, it is likely that many Mendelian disor-
ders have not been identified yet because in the well-
studied Western populations, they do not segregate in
families. Irrespective of family sizes and parental con-
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sanguinity, this also holds for all severe autosomal dom-
inant disorders conferring a significant reproductive dis-
advantage (eg, severe mental handicaps). Most of these
patients will carry new mutations and therefore will be
isolated cases as well.
For most common diseases, the possibility that there is a
sizable “contamination” by monogenic forms has not
been excluded, and the proportion of cases that are due
to single gene defects is hitherto unknown. As indicated
above, this does not hold for MR, however. Prompted by
the early observation that males are more often affected
than females,4 and by the description of several large
families where MR segregated in an X-linked fashion
(see ref 5, for example), the hypothesis that single gene
defects on the X chromosome play a major role in MR
was put forward in the early 1970s.6,7
Since the 1990s, genetic research into the molecular
causes of MR has focused on X-chromosomal genes,8
and at the time of writing (September 2009), mutations
in 90 X-chromosomal genes have been implicated in
Mendelian forms of MR, demonstrating that this condi-
tion is extremely heterogeneous. Surprisingly, screening
of several hundred families with X-linked MR (XLMR)
has revealed that these 90 genes account for at most
50% of all mutations9; see also ref 10. This means that
there must be many more genes on the X chromosome
which are indispensable for the normal function of the
human brain. The X chromosome carries about 4% of
all human genes, and even though there is evidence sug-
gesting that on the X, the density of MR genes is higher
than on autosomes,11 extrapolation of these data suggests
that defects in several thousand human genes may give
rise to cognitive dysfunction. However, the systematic
search for these autosomal MR genes has only just
begun, as discussed below. 
There is increasing evidence that single gene defects also
have important roles in the etiology of other complex
disorders. For example, several homozygous deletions
were recently described in autistic offspring of healthy
consanguineous parents,12 strongly suggesting that auto-
somal recessive gene defects are important causes of
autism, too. In view of the growing molecular evidence
that MR, autism, and schizophrenia are etiologically
related,2,13 it is likely that many cases of schizophrenia
are also due to a variety of single gene defects. There is
reason to believe that the same holds true for many
other complex diseases that are generally considered
multifactorial.14
Systematic elucidation of 
single gene disorders
There are various efficient strategies for elucidating the
molecular defects underlying Mendelian disorders, as
discussed in detail elsewhere.2 Most of them consist of
two steps, the chromosomal and regional mapping of the
relevant defect and the search for mutations in posi-
tional and functional candidate genes. 
Disease-associated balanced chromosome 
rearrangements 
Systematic breakpoint mapping and cloning in patients
with disease-associated balanced chromosome rearrange-
ments (DBCRs) has been employed by several groups to
identify genes that are truncated or inactivated by the
rearrangement (Figure 1a). Most de novo balanced chro-
mosome rearrangements can be identified by conven-
tional karyotyping, and, with an incidence of 1 in 2000,
they are not rare. About 6% of these are associated with
MR or other clinical abnormalities, which means that in
the European Union, with its 495 million inhabitants,
there must be almost 15 000 patients with de novo
DBCRs, and even more familial cases. So far, only a small
percentage of these patients have been identified, which
argues for systematic karyotyping in all patients where a
genetic cause of the disorder cannot be ruled out.
Unfortunately, however, the ongoing substitution of con-
ventional karyotype analyses with array CGH techniques
(see below) means that balanced chromosome rearrange-
ments will no longer be detected upon routine cytoge-
netic examination.
Mapping of chromosomal breakpoints has been facili-
tated by the availability of an ordered set of large over-
lapping genomic clones that serve as probes for fluo-
rescent in situ hybridization (FISH). Still, determining
the precise sequence of the breakpoint region
remained quite time-consuming. Recently, Chen et al15
have overcome this problem by preparative sorting of
derivative chromosomes followed by next-generation
sequencing in three mentally retarded patients with
DBCRs, which enabled the identification of three novel
candidate genes for MR. In follow-up studies, they
showed that it is even possible (by paired-end sequenc-
ing) to identify breakpoint-spanning DNA fragments
in total genomic DNA, ie, without prior sorting of chro-
mosomes.16
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Screening for microdeletions and duplications 
Small deletions, barely detectable by high-resolution
karyotyping, illuminated the way to pinpointing the
Duchenne muscular dystrophy gene17; later on,
microdeletions were instrumental in the identification of
many other disease genes. Through the recent introduc-
tion of array-based comparative genomic hybridization
(array CGH), screening of the entire human genome for
submicroscopic copy number variants (CNVs) has
become possible, thereby providing a very powerful new
strategy for finding the molecular defects underlying
Mendelian disorders (Figure 1b). Employing tiling path
BAC arrays or, more recently, high-density oligonu-
cleotide arrays, apparently causative de novo microdele-
tions or duplications can be found in more than 10% of
mentally retarded patients,18 which means that these
small variations are about as common as chromosome
rearrangements that can be seen under the microscope.
Recurrent CNVs that are flanked by low-copy repeats
account for about half of the cases (B. de Vries,
Nijmegen, personal communication, 2009), and for many
of these new “genomic disorders,” 19 both deletions and
duplications have been observed. 
Apart from CNVs causing disease, eg, by disturbing the
stoichiometry of protein complexes or by unmasking
recessive gene defects,20 the vast majority of CNVs occur
in healthy individuals, and most of them are functionally
neutral polymorphisms. Using tiling oligonucleotide
microarrays to detect CNVs greater than 450 basepairs,
Conrad et al21 have identified, on average, more than
1000 validated CNVs when comparing genomes of two
unrelated individuals. 
However, not all CNVs can be assigned unambiguously
to one of these two groups. There is a third category of
CNVs which are neither functionally neutral nor strictly
pathogenic; they are significantly more common in
patients with specific disorders than in healthy individ-
uals. One of the first CNVs of this kind observed, a
recurrent, sometimes familial 1 to 2 Mb deletion/dupli-
cation on chromosome 16p13, was detected in a cohort
of 300 patients with autism spectrum disorder and/or
MR.22 Follow-up studies23 have shown that this CNV, and
another on chromosome 15q11.2, are among the most
common and important risk factors for MR and autism
known to date, both raising the risk for these diseases
about 5-fold. Moreover, according to a recent report, the
dup16p13.1 is also a significant risk factor for schizo-
phrenia.13 This CNV encompasses the NDE1 gene, which
interacts with DISC1, a known schizophrenia suscepti-
bility gene, and has also been implicated in Asperger
syndrome, as discussed elsewhere.2 Thus, there is no
sharp demarcation line separating functionally neutral
polymorphisms and clinically relevant CNVs, and dis-
tinguishing them is not a trivial task (see below). 
Linkage mapping 
X-linked disorders are easily recognizable because of
their characteristic pattern of inheritance. This is why
they are over-represented in OMIM, and why the under-
lying molecular defect has been elucidated in many
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Figure 1. Strategies for the elucidation of monogenic disorders. CGH, comparative genome hybridization; SNP, single-nucleotide polymorphism
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instances, as already discussed for X-linked MR.
Autosomal dominant disorders also run in families, if
they are not lethal in early life, or are so severe that
affected individuals do not reproduce. For this reason,
they are also easily identifiable, which explains why so
many of them are known. In contrast, autosomal reces-
sive disorders are likely to be under-represented,
because in Western populations, most patients are iso-
lated cases; the monogenic nature of these disorders is
thus not recognized, as discussed above. 
Homozygosity mapping in large, consanguineous fami-
lies is the strategy of choice for mapping recessive dis-
orders (Figure 1c). Such families are common in pre-
dominantly Islamic countries of the “consanguinity
belt”24 that extends from Morocco into India.
Significantly elevated miscarriage rates and a two-to-
threefold higher prevalence of MR and congenital mal-
formations in these countries are generally ascribed to
malnutrition and poor standards of hygiene. However,
there is evidence that these disorders are also more com-
mon in Muslim families living abroad, such as Turkish
families in Germany and families from Pakistan in the
UK, which suggests that recessive gene defects are
another important cause.
Specific forms of autosomal recessive MR (ARMR)
that are due to primary microcephaly have been inves-
tigated by homozygosity mapping in consanguineous
families from Pakistan and India, which led to the iden-
tification of 7 loci and 5 microcephaly genes.25-27
Similarly, large-scale homozygosity mapping in consan-
guineous Iranian families has revealed numerous novel
loci and several new genes for nonsyndromic ARMR,
which is thought to be more common than syndromic
forms.28-31 These studies showed that nonsyndromic
ARMR is extremely heterogeneous, thereby refuting
earlier speculations that, analogous to the fragile X syn-
drome in X-linked MR and to connexin 26 mutations in
nonsyndromic deafness (eg, see ref 32), there might be
frequent forms of this disorder. There is recent evidence,
however, that ARMR is not quite as heterogeneous as
previously suggested. Systematic homozygosity map-
ping and mutation screening in 250 Iranian families has
identified numerous new loci for ARMR and several
allelic mutations in the relevant genes (Kuss, Kahrizi,
Tzschach, Najmabadi, Ropers et al, unpublished).
Analogous studies have also greatly expanded our
knowledge of recessive defects in other diseases such as
deafness, and there is now evidence that recessive forms
also exist in autism and other frequent disorders that
are considered to be multifactorial.
Identification of functional candidate genes 
Many of the clinically relevant deletions detected by
array CGH are larger than 1 to 2 Mb, and most linkage
intervals are even larger, often comprising several hun-
dred genes. This renders mutation screening of all genes
in these intervals very time-consuming and costly.
Numerous software packages have been developed,
including PosMed, Endeavour, and Polyphen (see ref 2)
that can be employed to identify and prioritize func-
tional candidate genes corresponding to the relevant dis-
ease phenotype. The utility of these programs depends
on the specificity of the phenotype; not unexpectedly,
their performance is still relatively poor for nonsyn-
dromic MR, but much better for easily recognizable syn-
dromes. Undoubtedly, it will improve once more is
known about regulatory pathways and the interaction
partners of genes and proteins. 
As mutation detection techniques are rapidly evolving,
sometimes either functional or positional information
may suffice for finding specific gene defects. For exam-
ple, fine-tuning of synaptic transmission is essential for
proper brain function, and there are about 1200 proteins
that are expressed predominantly in the synapse. Even
with conventional Sanger sequencing techniques, screen-
ing of all synapse proteins to isolate gene defects respon-
sible for brain dysfunction is no longer an impossible
task,33 and novel technologies are around the corner,
which will further facilitate large-scale mutation screen-
ing (see below). 
Why not search for the mutation directly? 
In a recent attempt to identify nearly all genes involved
in X-linked MR in one sweep, an international consor-
tium has employed Sanger sequencing to screen 208
families with X-linked MR for mutations in more than
700 fully annotated X-chromosomal genes.10 This heroic
effort has revealed recurrent truncating mutations in 9
novel XLMR genes, and, notably, also almost 1000 mis-
sense changes. Some of these are allelic and probably
functionally relevant, eg, there are several such muta-
tions in the IQSEC2 gene, which codes for a guanine
nucleotide exchange factor.34 Recent follow-up studies
revealed apparently pathogenic CNVs in >10% of the
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families,35 but for more than half of the families studied,
the causative molecular defect is still unknown. 
This pioneering study has highlighted the possibilities,
but also some of the problems, that researchers will face
when trying to identify a single pathogenic mutation in
an entire genome full of mostly neutral sequence vari-
ants. As shown by two independent studies,36,37 the cod-
ing portion of individual genomes contains approxi-
mately 10 000 nonsynonymous nucleotide changes, even
after excluding those that are known as single-nucleotide
polymorphisms (SNPs). These figures should dampen
the enthusiasm of those proposing to elucidate unknown
monogenic disorders by whole-genome sequencing of
single patients and their healthy parents, using exon
enrichment and next-generation sequencing techniques
(Figure 1d),3 even though, admittedly, some of the under-
lying defects may be detectable in this way, depending
on the nature of the relevant mutation.
There are now various efficient methods for the enrich-
ment of exons or defined genomic intervals, including
custom-made oligonucleotide arrays, commercial enrich-
ment kits based on hybridization in solution, or
advanced PCR-based techniques (for details, see the
recent review by Tucker et al38). Preparative chromo-
some sorting and next-generation sequencing39 is
another attractive alternative for facilitating mutation
detection when the chromosomal location of the defect
is known. An advantage of this approach is that it will
allow us to detect mutations everywhere on the relevant
chromosome, including introns and intergenic sequences.
Moreover, sequencing of sorted chromosomes yields a
more even coverage than other enrichment strategies
that involve PCR amplification (Chen, Wrogemann, Hu,
Haas, Ropers et al, unpublished).
Each of these methods has its limitations, however, and
the same holds for next-generation sequencing techniques
with their usually small read length, which is a problem
for (re)sequencing of repeat-rich genome segments. Still,
in combination, genome partitioning methods and next-
generation sequencing techniques are a great asset for the
detection of mutations in defined genomic intervals, which
has been one of the stumbling blocks for the large-scale
elucidation of single gene disorders.
Conclusions and outlook
With the implementation of these novel methods, the
stage is set for the systematic identification of single
gene defects, which is overdue and will have far-reach-
ing implications for health care. Recessive disorders
likely represent the bulk of the disorders that are hith-
erto unknown, but they are easily overlooked in indus-
trialized countries because most of the patients will be
isolated cases, particularly those without clearly distin-
guishable phenotypes. Their identification and recruit-
ment is much easier in countries where large families
and parental consanguinity are common, but due to
more urgent problems, like the scarcity of clean drink-
ing water, malnutrition, or high perinatal and infant mor-
tality, the diagnosis, prevention, and therapy of single
gene defects is not high on their agenda, even though
these disorders are even more common in these coun-
tries than they are in outbred Western populations. This
argues for collaborations between emerging and indus-
trialized countries, as exemplified by the long-standing
collaboration between our group and an effective
Iranian partner, which was instrumental in the elucidat-
ing the gene defects responsible for several recessive
forms of MR, thereby paving the way for the diagnosis,
prevention and—eventually—therapy of these disorders. 
So far, recessive disorders are considered too rare to jus-
tify carrier screening, but this is likely to change as soon
as there is a reliable and inexpensive test for all reces-
sive disorders. According to leading manufacturers,
“third-generation” sequencing technologies that enable
sequencing of the entire human genome for less than
$5000 US will be on the market by the end of 2010 or
early in 2011, which indicates that carrier tests for all
known recessive disorders will be available sooner
rather than later. Indeed, the (US) National Center for
Genome Resources has recently teamed up with the
Beyond Batten Disease Foundation to develop such a
test for approximately 448 single gene defects using
available next-generation sequencing technology. With
such a carrier test at hand, premarital screening can be
offered to rule out the possibility that both spouses are
heterozygous for defects in the same gene, and preven-
tion programs can be set up, similar to the successful pre-
vention of Tay-Sachs disease in Ashkenazim, which was
initiated in the 1970s.40
Whole genome sequencing (WGS) is not only the
method of choice for the large-scale elucidation of
Mendelian disorders, but it is also a superior alternative
for risk factor screening in complex diseases, because it
is not fraught with the inherent limitations of GWAS.2,41
There is no doubt that there exist genetic factors which
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predispose individuals to disease without sufficing for
disease manifestation, as discussed for CNVs that are
risk factors for MR, autism, and schizophrenia. Another
telling example is a deletion on chromosome 1q that
seems to be a necessary but not sufficient prerequisite
for thrombocytopenia/absent radius syndrome.42 CNVs
predisposing for disease can only be identified efficiently
by large case-control studies; attempts to find them by
investigating the normal variation, ie, by excluding all
CNVs present in healthy individuals, are bound to fail
because risk factors for common disorders will be found
in the healthy controls, too. From the health care point
of view it is unfortunate, therefore, that large sums were
invested to generate inventories of normal CNVs,
instead of focusing on disease-relevant CNVs right from
the start—and the same criticism applies to the even
more costly “1000 genome project,” which uses GWS to
study the normal genome variation in 1000 healthy indi-
viduals.
It is a commonly held view that mild forms of MR are
multifactorial, while severe forms are largely due to cat-
astrophic genetic defects, including chromosomal aber-
rations and mutations of single genes. Lehrke6,7 assumed
that MR genes and genes determining the IQ were iden-
tical, and others speculated that risk factors for mild MR
might be allelic variants of these genes,43,44 exerting a
moderate effect on the IQ. As the number of MR genes
is increasing, and in view of the novel methods for high-
throughput mutation detection, everything seems to be
in place for putting these ideas to the test.  ❏
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Los trastornos por un gen único vuelven a
estar en el foco de la investigación
A comienzos de los años 1990, cuando se escribió la
segunda fase de cinco años del Proyecto del Genoma
Humano –el cual ha requerido más dinero que cual-
quier otro proyecto de investigación en biología-  los
trastornos comunes fueron presentados como los
blancos futuros de la investigación del genoma. Esta
fue una medida ingeniosa para asegurar un finan-
ciamiento público continuo para este esfuerzo, el
cual se había justificado previamente por las pers-
pectivas que conducirían al diagnóstico, la preven-
ción y el tratamiento de los trastornos Mendelianos,
que si bien son graves ocurren con escasa frecuencia.
Hoy día, después de más de quince años y luego de
haber gastado billones de dólares en los estudios de
asociación del genoma completo (EAGC), se han
identificado muy pocos factores de riesgo genético
importantes para las enfermedades comunes, y el
entusiasmo por grandes EAGC está disminuyendo. Al
mismo tiempo, hay un renovado interés en el estu-
dio de trastornos por un gen único, los cuales son
considerados ahora por algunos investigadores como
una mejor pista para la comprensión de las enfer-
medades comunes. Aunque esto es probablemente
cierto, los trastornos Mendelianos también son
importantes por derecho propio, ya que ellos deben
ser mucho más comunes de lo que generalmente se
piensa. Como se discute aquí, existen varias estrate-
gias eficientes para aclarar los defectos de un gen
único y su aplicación sistemática en combinación con
nuevas técnicas de división del genoma y de secuen-
ciación paralela masiva, tendrán efectos de gran
alcance para los cuidados en salud.  
Les maladies monogéniques attirent à 
nouveau  l’attention
Au début des années 90, lorsque le second plan
quinquennal du projet du génome humain (Human
Genome Project) (plus dispendieux que tout autre
projet de recherche précédent en biologie) a été
écrit, les maladies courantes furent présentées
comme la future cible de la recherche sur le
génome. C’était une manœuvre intelligente desti-
née à s’assurer d’un soutien publique prolongé
pour cette tentative, préalablement justifié par la
perspective du diagnostic, de la prévention et du
traitement des maladies mendéliennes sévères mais
rares pour la plupart. Aujourd’hui, après plus de 15
ans et des milliards de dollars dépensés pour des
études d’association sur le génome entier (GWAS
pour Genome-Wide Association Studies), très peu
de facteurs majeurs de risque génétique pour les
maladies courantes ont été identifiés et l’enthou-
siasme pour les grandes études d’association faiblit.
Au même moment, il existe un regain d’intérêt
pour  l’étude des maladies monogéniques, consi-
dérées maintenant par certains comme une
meilleure piste pour la compréhension des maladies
courantes. C’est probablement le cas, d’autant que
les maladies mendéliennes sont elles-mêmes impor-
tantes puisque beaucoup plus fréquentes qu’on ne
le pense généralement. Dans cet article, nous exa-
minons les différentes stratégies efficaces pour
comprendre les anomalies monogéniques et leur
application systématique en association aux nou-
velles techniques de partition du génome et de
séquençage parallèle massif. Ces stratégies auront
des implications considérables pour la Santé.
DCNS_44_5.qxd:DCNS#44  10/03/10  1:44  Page 102
he introduction of personality disorders (PDs)
as diagnostic categories on a separate axis (Axis II) in
the third edition of the Diagnostic and Statistical Manual
of Mental Disorders (DSM-III) in 19801 had a dramatic
effect on the level of interest in these disorders among
researchers, and the number of published articles
increased substantially. However, the number of genetic
epidemiologic studies of the DSM PDs has remained
limited compared with studies on both clinical disorders
like schizophrenia, depression, and anxiety disorders
(which are classified on Axis I in DSM), and on normal
personality traits.2-4
The understanding of the role of genetic factors in the
etiology of disorders and traits is inseparably linked to
classification, since a precise definition of the phenotype
is a prerequisite for all successful genetic studies. In this
review we will focus on PDs as they are classified in the
DSM; a system that serves many purposes, and is not
specifically designed for genetic studies. This is a prob-
lem not only for the genetics of PDs, and the search for
better phenotypes for genetic studies of mental disorders
is especially well illustrated in the literature on schizo-
phrenia (eg, refs 5, 6). 
The goal of psychiatric genetic epidemiology is to under-
stand the role of genetic and environmental factors in
the etiology of mental disorders.7 In this paper we will
focus mainly on the genetic factors. After a brief outline
of the current DSM axis II PD classification, we will
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Genetic epidemiologic studies indicate that all ten per-
sonality disorders (PDs) classified on the DSM-IV axis II
are modestly to moderately heritable. Shared environ-
mental and nonadditive genetic factors are of minor or
no importance. No sex differences have been identified.
Multivariate studies suggest that the extensive comor-
bidity between the PDs can be explained by three com-
mon genetic and environmental risk factors. The genetic
factors do not reflect the DSM-IV cluster structure, but
rather: i) broad vulnerability to PD pathology or nega-
tive emotionality; ii) high impulsivity/low agreeableness;
and iii) introversion. Common genetic and environmen-
tal liability factors contribute to comorbidity between
pairs or clusters of axis I and axis II disorders. Molecular
genetic studies of PDs, mostly candidate gene association
studies, indicate that genes linked to neurotransmitter
pathways, especially in the serotonergic and dopamin-
ergic systems, are involved. Future studies, using newer
methods like genome-wide association, might take
advantage of the use of endophenotypes.  
© 2010, LLS SAS Dialogues Clin Neurosci. 2010;12:103-114.
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evaluate the evidence for genetic influences on PDs and
examine quantitative genetic studies that explore the
specificity of the genetic effects, ie, to what extent genetic
risk factors are shared between PDs, or between PDs
and axis I disorders. Molecular genetic studies that aim
to identify gene variants associated with PDs will then
be reviewed. It is likely that PDs, like most other psy-
chiatric disorders, are etiologically complex, ie, that they
are influenced by a number of genetic and environmen-
tal risk factors. Studies examining the interplay between
genes and the environment will be addressed both in
relation to quantitative and molecular methods. Finally,
future directions will be discussed.
The classification of personality disorders
A PD is defined by DSM-IV as an enduring pattern of
inner experience and behavior that deviates markedly
from the expectations of the individual's culture, is per-
vasive and inflexible, has an onset in adolescence or
early adulthood, is stable over time, and leads to distress
or impairment.8 The DSM-IV classification includes 10
categorical PD diagnoses grouped into three clusters: A
or the “odd-eccentric,” B or the “dramatic-emotional,”
and C or the “anxious-fearful.”8 Cluster A includes para-
noid, schizoid, and schizotypal PD, and Cluster B anti-
social, borderline, histrionic, and narcissistic PD, while
cluster C includes avoidant, dependent, and obsessive-
compulsive PD. Appendix B includes two additional dis-
orders: depressive and passive-aggressive PDs.
Although the classification of PDs in DSM-IV is more
empirically based than in former versions, there are sev-
eral controversial issues that are unresolved. Substantial
co-occurrence between the DSM PDs has consistently
been found in both clinical9 and community samples.10,11
The majority of individuals with a PD receive more than
one PD diagnosis, and this high degree of overlap seri-
ously challenges the descriptive validity of the PD clas-
sification. Comorbidity with Axis I disorders is also
extensive, and results from both clinical and population-
based studies indicate that the key features in the DSM-
IV definition (stability over time and early age of onset)
do not distinguish PDs from axis I disorders.12 The
underlying validity of the DSM axis I - axis II division
has therefore been questioned (eg, refs 12-14). The
higher order clustering system has serious limitations,
and has not been consistently validated,8 and factor ana-
lytic studies often do not find support for this three-fac-
tor structure.15 One of the most controversial and long-
standing issues in the field of PD classification is, how-
ever, whether PDs should be conceptualized dimen-
sionally or as discrete categories. There seems to be a
general agreement that PDs are best classified dimen-
sionally,16-18 and several alternative systems are discussed
for DSM-V (see ref 19). 
Basic quantitative studies
In quantitative genetics, which include family, twin, and
adoption studies, the degree to which individual liability
to a disorder results from familial effects (in family stud-
ies) or genetic and environmental factors (in twin and
adoption studies) is estimated. Twin studies have been
most commonly used to examine the effects of genetic
risk factors on mental disorders, including PDs, and
sophisticated analytical models and statistical tools have
been developed.20,21 The proportion of phenotypic dif-
ferences between individuals (or proportion of variance)
in a particular population that can be attributed to
genetic differences is called heritability. In the classical
twin model the total variance in a phenotype is parti-
tioned into three variance components, each accounted
for by three latent variables: additive genetic, shared
environment, and individual-specific environment. This
implies that the genetic and environmental effects are
not directly measured, ie, we do not know which specific
genes or environmental factors influencing the pheno-
type. Genetic effects are usually additive, meaning that
the independent effects of different alleles or loci act in
an additive way to increase risk for the disorder or trait,
but they can also be nonadditive, which means that dif-
ferent alleles or loci interact with other alleles or loci
(epistasis) or different alleles in the same locus (domi-
nance). Shared environment includes all environmental
exposures that contribute to making twins similar, and
individual-specific or unique environment includes all
environmental exposures that make them different, plus
measurement error. 
Modern twin studies are based on the liability-threshold
model,22 which assumes that a large number of genetic
and environmental risk factors with small individual
effects are involved, resulting in a distribution of liabil-
ity or risk in the population that approximates normal-
ity. A dichotomous disorder will appear when a certain
threshold is exceeded. Twin studies can be used regard-
less of whether PDs are defined categorically or dimen-
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sionally, but the statistical power is higher if the pheno-
type is ordinal or continuous.23
Normal and abnormal personality traits
Normal personality traits have repeatedly been shown to
be influenced by genetic factors with heritability estimates
ranging from approximately 30% to 60%.24,25 The genetic
effects are mainly additive, but nonadditive contributions
of a smaller magnitude have been identified in studies
with sufficient statistical power.24 Shared environmental
factors are usually found to be of minor on no impor-
tance.24 Similar heritability estimates have been found for
a dimensional classification of personality disorders based
on self-report.26 Numerous studies have shown relatively
high correlations between DSM PDs and normal person-
ality traits of the five-factor model,  which includes five
broad bipolar domains of extraversion (vs introversion),
agreeableness  (vs antagonism) conscientiousness (vs
impulsivity), neuroticism (vs emotional stability), and
openness (vs closedness to experience),27 but the extent to
which this is due to genetic factors is not known. 
DSM personality disorders
Cluster A 
Prior studies have suggested that familial/genetic factors
contribute to the etiology of the three PDs making up the
DSM Cluster A.28 A series of twin studies that examine
various measures of schizoid, schizotypal, and paranoid-
like traits using self-report questionnaires have nearly uni-
formly found significant heritability for these traits and
failed to find shared environmental effects (eg, refs 29-33).
Heritabilities are typically in the range of 35% to 60%. In
a twin study using structured interview data, but based on
a clinical sample, Torgersen et al34 found lower heritabil-
ity estimates for paranoid PD (28%) and schizoid PD
(29%), but much higher heritability for schizotypal PD
(61%). The method of ascertainment and the relatively
low number of participants make the estimates from this
study uncertain. In a more recent population-based study
of dimensional representations of the DSM-IV cluster A
PDs based on structured interviews, Kendler et al35 esti-
mated heritability to be 21% for paranoid, 28% for
schizotypal, and 26% for schizoid PD. No shared envi-
ronmental effects or sex differences were found. 
In twin studies unreliability of measurement will decrease
the heritability estimates. Although the inter-rater relia-
bility in Kendler et al’s abovementioned study was excel-
lent, the test-retest reliability or stability of measurement
for PDs has been shown to be imperfect.36 It is also likely
that genetic and environmental risk factors assessed by
self-report questionnaires vs interviews are different. A
second study from the same sample was therefore under-
taken.37 Data from a previous self-report questionnaire
study were used in addition to the abovementioned inter-
view data to account for unreliability of measurement by
using two measures differing in both time and mode of
assessment. The estimated heritabilities were substantially
higher than in the first study: 66% for paranoid, 55% to
59% for schizoid, and 72% for schizotypal PD.
Cluster B 
Antisocial PD-like measures have been extensively stud-
ied using genetic epidemiological methods. In a meta-
analysis of 51 twin and adoption studies on antisocial
behavior based largely on records, self-report, and fam-
ily report, Rhee & Waldman38 found that the variance
could most parsimoniously be explained by additive
genetic factors (32%), nonadditive genetic factors (9%),
shared environmental factors (16%) and individual-spe-
cific environmental factors (43%). There were no sig-
nificant differences in the magnitude of genetic and envi-
ronmental influences for males and females. 
In a review of family studies on borderline PD, White et
al39 found the disorder to aggregate in families. However,
significant methodological problems made the results
uncertain. Distel et al estimated that additive genetic fac-
tors explained 42% of the variance in borderline PD fea-
tures assessed by self-report questionnaire, using data from
three countries.40 Non-shared environment accounted for
the rest. In a subsequent extended twin-family study by the
same group the heritability of borderline PD features was
found to be 45%, but the genetic effects were both addi-
tive (21%) and dominant (24%).41 Nonadditive effects are
difficult to detect using the classical twin model due to lack
of statistical power.23 However, such effects have been
found for normal personality traits in twin-sibling studies
with large samples.42
Results from a twin study based on structured interviews
in a clinical sample suggest that heritability estimates for
borderline, histrionic, and narcissistic PD were high, 69%,
63%, and 77% respectively.34 More recently, however,
Torgersen et al43 conducted a population-based twin study
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of dimensional representations of the DSM-IV cluster B
PDs. Heritability was estimated to be 38% for antisocial
PD, 31% for histrionic PD, 24% for narcissistic PD and
35% for borderline PD. No shared environmental influ-
ences or sex or effects were found. 
Cluster C 
A family study of the anxious-fearful cluster indicated sig-
nificant familiality for DSM-III avoidant and dependent
PD,44 and in a clinically based twin study, heritability esti-
mates for avoidant, dependent, and obsessive-compulsive
PD were found to be 28%, 57%, and 77%, respectively.34
Results from a population-based study of dimensional
representations of DSM-IV Cluster C PDs,45 however,
indicated that heritability estimates were similar for
avoidant PD (35%), but lower for dependent (31%) and
for obsessive-compulsive PD (27%), again illustrating the
importance of method of ascertainment. This discrepancy
is probably in part due to difference in methods of ascer-
tainment.  No shared environmental effects or sex differ-
ences have been found for cluster C PDs.  
Disorders in Appendix B
In a population-based twin study of depressive PD,
Ørstavik et al46 found that liability could best be
explained by additive genetic and unique environmen-
tal factors alone, with heritability estimates of 49% in
females and 25% in males. Unlike the results for the
other DSM-IV PDs, both quantitative and qualitative
sex-differences were found corresponding to findings
from studies on major depression.47 Significant familial
aggregation has also been found for DSM-IV passive
aggressive PD.48
Multivariate studies
If heritability has been established, several more com-
plex models can be employed to explore the nature and
mode of action of the genetic risk factors.7 Multivariate
analyses, which comprise models where several pheno-
types are included and different structures of the latent
factors can be specified,20 can be used to estimate to
what extent genetic and environmental risk factors are
Figure 1. Genetic parameter estimates from best fitting model for ten DSM-IV personality disorders. Path estimates are standardized regression coef-
ficients, so they must be squared to equal the proportion of variance accounted for in the dependent variable. A stands for additive genetic
effects.  The subscripts C and S stand, respectively, for common factor and disorder-specific effects. The first, second and third genetic com-
mon factors are indicated by the subscripts C1, C2 and C3. Paths with values ≥ +0.28 (which account for ≥ 8% of phenotypic variance) are col-
ored with the first, second, and third common factor indicated by, respectively, red, green, and blue and the disorder-specific factors by magenta.
Paths not exceeding the + 0.28 cutoff are depicted in gray.
From ref 52: Kendler KS, Aggen SH, Czajkowski N, et al. The structure of genetic and environmental risk factors for DSM-IV personality disorders a multivariate
twin study. Arch Gen Psychiatry. 2008;65:1438-1446. Copyright © American Medical Association 2008
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specific to a given PD or shared in common with other
PDs or axis I disorders, and thus to investigate sources
of comorbididity.49,50 By including measures of the same
phenotypes on different points in time, they can also be
used to determine if genetic effects differ over time in
a developmental perspective.
DSM-IV personality disorders 
Cluster A PDs have been found to aggregate in families
of probands with schizophrenia (see below). Familial
coaggregation has also been found for borderline PD and
antisocial PD39 and for borderline PD and all the other
cluster B PDs,51 as well as for the DSM-III cluster C
PDs.44 A population-based twin study including all PDs
within cluster B indicated that borderline PD and anti-
social PD appeared to share genetic risk factors above
and beyond those shared in common with the other clus-
ter B disorders,43 and a twin study of cluster C PDs sug-
gested that genetic factors influencing obsessive-com-
pulsive PD appeared to be relative specific to this
disorder.45 Kendler et al, in the only population-based
multivariate twin study including all 10 DSM-IV PDs
that has been published,52 found that the best-fitting
model included three genetic and three environmental
factors in addition to disorder-specific factors. The struc-
ture of the genetic factors is shown in Figure 1. The first
genetic factor (AC1) had high loadings on PDs from all 3
clusters including paranoid, histrionic, borderline, narcis-
sistic, dependent, and obsessive-compulsive PD. This fac-
tor probably reflects a broad vulnerability to PD pathol-
ogy and/or negative emotionality, and is related to
genetic liability to the normal personality trait neuroti-
cism. The second genetic factor (AC2)was quite specific
with substantial loadings only on borderline and antiso-
cial PD. This is consistent with the results from the above-
mentioned family studies,39 and suggests genetic liability
to a broad phenotype for impulsive/aggressive behavior.
The third factor identified (AC3)had high loadings only
on schizoid and avoidant PD. This can be interpreted in
several ways. It might in part reflect genetic risk for schiz-
ophrenia spectrum pathology (see below). From the per-
spective of the five-factor model of normal personality it
reflects genetic liability for introversion.53 Finally, it is
noteworthy that obsessive-compulsive PD had the high-
est disorder-specific genetic loading, which parallels prior
findings that this PD shares little genetic and environ-
mental liability with the other cluster C PDs. 
The results are also to a large extent consistent with a
prior multivariate twin study of the dimensional classi-
fication system of personality disorder trait mentioned
above26 in which Livesley et al identified four genetic
factors loading on four phenotypic dimensions called
“emotional dysregulation,” “dissocial behavior,” “inhi-
bition,” and “compulsivity.”
Taken together these results indicate that genetic risk
factors for DSM-IV PDs do not reflect the cluster A, B,
and C typology. However, this is well reflected in the
structure of the environmental risk factors, suggesting
that the comorbidity of PDs within clusters is due to
environmental experiences.
Personality disorders and Axis I disorders
Several lines of evidence indicate specific axis I/axis II
relationships,54,55 suggesting that common genetic or envi-
ronmental liability factors might predispose to several
disorders within clusters that transcend the axis I/axis II
division.13,49,56
Schizophrenia
A number of family and adoption studies have exam-
ined the risk for paranoid, schizoid, and schizotypal PDs
in relatives of schizophrenic and control probands. While
a few studies can be found where all three cluster A PDs
are at increased risk in relatives of schizophrenic
probands,57,58 more common are studies that find that
only schizotypal PD59-63 or schizotypal PD and paranoid
PD64 have a significant familial relationship with schizo-
phrenia. Taken together, these results suggest that
schizotypal PD has the closest familial relationship to
schizophrenia, followed by paranoid and schizoid PD,
and are consistent with the hypothesis that a common
genetic risk factor for cluster A PDs reflects—in the gen-
eral population—the liability to schizophrenia.35 The
extended phenotype believed to reflect this genetic lia-
bility to schizophrenia is often described by the term
schizophrenia spectrum. Schizotypal PD has been sug-
gested to be the prototypical disorder in this spectrum.65
In a recent family study, Fogelson et al66 showed that
avoidant PD, currently classified in DSM cluster C, also
occurred more frequently in relatives of probands with
schizophrenia even after controlling for schizotypal and
paranoid PD. This replicates findings from earlier stud-
ies,58,67 and suggest that avoidant PD should also be
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included in this spectrum. It is also in part in accordance
with the results from the multivariate study by Kendler
et al described above,52 where avoidant and schizoid PD
share genetic liability.
Internalizing disorders 
Mood and anxiety disorders (often called internalizing
disorders) share genetic and environmental liability fac-
tors with each other,68 and with the normal personality
trait neuroticism,69 which correlates strongly with several
PDs, especially in cluster B and C.53
Family studies indicate that borderline PD and major
depression share familial risk factors.51,70 In a population-
based multivariate twin study of major depression and
DSM-IV PDs, Reichborn-Kjennerud et al71 found that
dimensional representations of borderline PD from clus-
ter B, avoidant PD from cluster C, and paranoid PD from
cluster A were all independently and significantly associ-
ated with increased risk for major depression. Multivariate
twin modeling indicated that one latent factor accounted
for the genetic covariance between major depression and
the three PDs. The genetic correlations between major
depression and borderline, avoidant, and paranoid PD
were respectively +0.56, +0.22, and +0.40. No sex differ-
ences or shared environmental effects were found. These
results indicate that vulnerability to general PD pathology
and major depression are closely related. In a bivariate
twin study, Ørstavik et al72 found that a substantial part of
the covariation between major depressive disorder and
depressive PD was accounted for by genetic factors with
a genetic correlation of 0.56. Results from another popu-
lation-based twin study, investigating the sources of co-
occurrence between social phobia and of avoidant PD in
females, indicated that social phobia and avoidant PD
were influenced by identical genetic factors, whereas the
environmental factors influencing the two disorders were
uncorrelated.73 This suggests that an individual with high
genetic liability will develop avoidant PD versus social
phobia entirely as a result of environmental risk factors
unique to each disorder, which is in accordance with the
hypothesis of underlying psychobiological dimensions cut-
ting across the axis I/ axis II classification system. 
Substance-use disorders
Numerous family, adoption and twin studies have
demonstrated that antisocial PD, conduct disorder, and
substance-use disorders (often called externalizing dis-
orders) share a common genetic liability (eg, refs 68,74).
In a family-twin study, Hicks et al75 found that a highly
heritable (80%) general vulnerability to all the exter-
nalizing disorders accounted for most of the familial
resemblance. Disorder-specific vulnerabilities were
detected for conduct disorder, alcohol dependence, and
drug dependence, but not for antisocial PD. The same
group also reported an association between externaliz-
ing disorders and reduced amplitude of the P3 compo-
nent of the brain event-related potential, suggesting that
this could be a common biological marker for the bio-
logical vulnerability to these disorders.76
Longitudinal studies
Most of the genetic studies that have investigated
changes in genetic influences on PDs over time have
used measures related to antisocial PD. The following
examples illustrate the potential of longitudinal quan-
titative genetic methods. In a twin study, Lyons et al77
demonstrated that the genetic influence on symptoms of
DSM-III-R antisocial PD was much more prominent in
adulthood than in adolescence. Silberg et al78 studying
twins between 10 and 17 years of age found a single
genetic factor that influenced antisocial behavior begin-
ning at age 10 through young adulthood, a shared envi-
ronmental effect beginning in adolescence, a transient
genetic effect at puberty and genetic influences specific
to adult antisocial behavior. In another recent twin study
of externalizing disorders, biometric analyses revealed
increasing genetic variation and heritability for men but
a trend toward decreasing genetic variation and increas-
ing environmental effects for women.79
Gene-environment interplay
In the traditional models of disease etiology in psychiatric
epidemiology the causal pathway is conceptualized as
moving from the environment to the organism. However,
since genes influence behavior, genetic factors can indi-
rectly influence or control exposure to the environment,20
called gene-environment correlation.20,80,81 Genetic factors
can also control an individual’s sensitivity to the environ-
ment, ie, genetic factors influence or alter an organism’s
response to environmental stressors.20,80,81 This is usually
called gene-environment interaction. In quantitative stud-
ies of gene-environment interplay, genetic factors are
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either inferred (eg, disorder in biological parent in adop-
tion studies) or modeled as a latent variable.80,82
Twin and adoption studies have provided much of the
evidence for gene-environment correlations by demon-
strating genetic influences for a number of measures of
the environment.80 Overall, the evidence from twin and
adoption studies suggests that gene-environment corre-
lations are mediated by heritable personality traits and
possibly PDs.81,83,84
The initial indications that gene-environment interac-
tion was likely to be operating came from adoption and
twin studies.85 Gene-environment interaction was
demonstrated in an adoption study as early as in 1974,
when Crowe86 found that early institutional care was a
risk factor for later antisocial behavior only when a
genetic risk factor was present. In another adoption
study, Cadoret et al87 found significant gene-environ-
ment interaction by showing that there was a negligible
risk for antisocial behavior from a genetic risk alone
(antisocial behavior in the biological parent), no effect
of an adverse adoptive family environment alone, but a
substantial effect when both were present. The finding
was replicated in a later study with a larger number of
adoptees,88 Jaffe et al,89 using a twin design, found sig-
nificant gene-environment interaction with respect to
childhood maltreatment and the development of anti-
social behavior, and in a twin study Tuvblad et al90
demonstrated a significant gene-environment interac-
tion by showing that the heritability for adolescent anti-
social behavior is higher in socioeconomic advantaged
environments. Using an advanced family design,
Feinberg et al91 recently found an interaction of geno-
type and both parental negativity and low warmth pre-
dicting antisocial behavior. Significant gene-environ-
ment interaction has also been demonstrated in
schizophrenia spectrum disorders. In an adoption study
Tienari et al92 showed that there was a significant asso-
ciation between disordered rearing and the diagnosis of
schizophrenia spectrum disorder in the offspring of
mothers with but not in offspring of mothers without
the diagnoses. In a community based twin study, Hicks
et al demonstrated a significant gene-environment
interaction with a number of environmental risk factors
showing that greater environmental adversity was asso-
ciated with increased genetic risk for antisocial PD and
substance use disorders.93 Significant gene-environment
interaction has also been demonstrated in quantitative
studies of anxiety and mood disorders.81
Molecular genetic studies
Traditionally, linkage and association studies have been
most commonly used for mapping disease loci.94 Most of
the molecular genetic studies of PDs has been done
using hypothesis-driven candidate gene association stud-
ies95 focusing on particular genes related to the neuro-
transmitter pathways, especially in the serotonergic and
dopaminergic systems. Although the number of genetic
association studies are increasing exponentially, only a
very small fraction of positive results are replicated.96,97
Until further replications are published the results
reviewed below must therefore be considered tentative. 
Cluster A
Consistent with the hypothesis that schizophrenia and
related PDs are linked to dopaminergic dysfunction,
Rosmond et al98 found that Cluster A PDs were associ-
ated with a polymorphism in the gene coding for the
dopamine 2 receptor (DRD2). Building on results from
quantitative genetic studies indicating that common
genetic risk factors exist for schizotypal PD and schizo-
phrenia, Stefanis et al99 examined the potential impact
of SNPs within the four most prominent candidate genes
for schizophrenia. Dysbindin (DTNBP1) and D-amino-
acid oxidase (DAAO) both showed associations with
symptoms of schizotypy. Similarly, Fanous et al100 using a
linkage approach, found that a subset of schizophrenia
susceptibility genes also affect schizotypy in nonpsy-
chotic relatives. Significant associations with schizotypal
personality traits have also been found in several stud-
ies with polymorphisms in the gene coding for catechol-
O-methyltransferase (COMT)100,102,103 an enzyme involved
in the degradation of catecholamines, and linked to the
etiology of schizophrenia.104
Cluster B
Multiple lines of evidence suggest that dysfunction in the
serotonin (5-HT) system is associated with impulsivity,
aggression, affective lability, and suicide. Genes linked
to the function of this neurotransmitter can therefore be
considered possible candidate genes for borderline and
antisocial PD. Kennedy and coworkers found that bor-
derline PD was associated with polymorphisms in the
serotonin transporter gene (5-HTTLPR),105 and poly-
morphisms in the gene coding for the catabolic enzyme
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monoamine oxidase A (MAOA), involved in the regu-
lation of biogenic amines like serotonin, norepinephrine,
and dopamine,106 but not polymorphisms in the gene
coding for the serotonin 5-HT2A receptor.107 Recently
the group has conducted a gene-gene interaction study
with a number of polymorphisms in seven serotonin
genes (including the three mentioned above), conclud-
ing that “serotonin genes and their interaction may play
a role in the susceptibility to borderline PD.”108 Other
groups have reported similar findings. A main effect of
the 5-HTTLPR polymorphism on borderline PD has
been found in bulimic women,109 and Lyons-Ruth et al
found a significant relationship between the short
5HTTLPR allele and both borderline and antisocial
PD,110 but other studies have failed to find an association
between this polymorphism and cluster B PDs.111
Polymorphisms in the MAOA gene have been found to
be associated with cluster B PDs,112 and antisocial
traits.113 Tryptophan hydroxylase is the rate-limiting
enzyme in the serotonin metabolic pathway. Two genes
related to this enzyme, the tryptophan hydroxylase 1 and
2 genes (TPH1and TPH2), have been associated with
borderline PD114 and personality traits related to emo-
tional instability, as well as to cluster B and cluster C
PDs.115 Taken together, these findings suggest that bor-
derline and antisocial PD and possibly also the other
cluster B PDs, are influenced by genes regulating the
serotonergic system. They are also consistent with the
finding of shared genetic influence on borderline PD
and antisocial PD, and on borderline PD and the other
cluster B PDs found in multivariate twin studies.43,52
Cluster C
It has previously been suggested that the 5-HTTLPR
polymorphism was associated with anxiety-related
traits,116 but later studies have yielded conflicting results
(see ref 117). Patients diagnosed with cluster C PDs,
have not been found to be significantly higher in the fre-
quency of the short form allele of the 5-
HTTLPR.111Recent results, on the other hand, indicate
that variations in the COMT gene contribute to genetic
risk shared across a range of anxiety-related pheno-
types.118,119 Joyce120 found an association between avoidant
and obsessive-compulsive PD symptoms and the
dopamine D3 receptor (DRD3) polymorphism. In a
later study and a meta-analysis, the finding for obsessive-
compulsive symptoms were replicated, leading the
authors to conclude that DRD3 may contribute to the
development of obsessive-compulsive PD.121
Gene-environment interplay
Few studies of gene-environment correlation using mea-
sured genes and measured environments have been pub-
lished. Dick et al121 found that individuals who had a poly-
morphism in a gene (GABRA2) associated with alcohol
dependence were less likely to be married, in part because
they were at higher risk for antisocial PD and were less
likely to be motivated by a desire to please others. Other
results confirm the existence of gene-environment corre-
lation with measured genes in both the dopaminergic and
serotonergic system, and provide preliminary support for
the finding that correlations are mediated by behavioral
and personality characteristics.84
Gene-environment interaction studies using identified
susceptibility genes rather than unmeasured latent
genetic factors can provide more secure estimates.84
Based on results from quantitative genetic studies show-
ing gene-environment interaction for antisocial behav-
ior, Caspi et al123 studied the association between child-
hood maltreatment, and a functional polymorphism in
the promoter region of the MAOA gene on antisocial
behavior assessed through a range of categorical and
dimensional measures using questionnaire and interview
data plus official records. The results showed no main
effect of the gene, a main effect for maltreatment and a
substantial and significant interaction between the gene
and adversity. The maltreated children whose genotype
conferred low levels of MAOA expression more often
developed conduct disorder and antisocial personality
than children with a high activity MAOA genotype.
Foley et al124 replicated this finding and extended the ini-
tial analysis by showing that the gene-environment inter-
action could not be accounted for by gene-environment
correlation. Other studies have failed to replicate the
gene-environment interaction effect (eg, ref 125). In a
recent meta-analysis, however, the original finding was
replicated. In addition the findings was extended to
include childhood (closer in time to the maltreatment),
and the possibility of a spurious finding was ruled out by
accounting for gene-environment correlation.126 The
interaction between MAOA and childhood maltreat-
ment in the etiology of antisocial PD appear to be one
of the few replicated findings in the molecular genetics
of PDs.
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Future directions
Information from genetic epidemiologic studies can con-
tribute to improvement in the validity of diagnoses of men-
tal disorders, and thereby a more empirically based classifi-
cation system.49,56,127 Several lines of evidence, including
multivariate twin studies, have shown that common axis I
disorders can be divided into two main groups (internalizing
and externalizing) based on shared etiological factors.49,68
Currently an alternative classification system are being con-
sidered for DSM-V based on the hypothesis that, in addition
to phenotypic similarity, spectra or clusters of disorder can
be identified based on shared liability or risk factors.56 Such
clusters transcend the axis I-axis II division. Multivariate twin
studies, including a comprehensive number of axis I and axis
II disorders, could provide new important insights relevant
to this proposal and further clarify the etiology of mental dis-
orders by identifying genetic and environmental risk factors
shared in common between groups of disorders.
Methods like genome-wide association studies,128
analyses of copy-number variation,129 studies of rare
genetic variants,130 epigenetic methods,131 and deep
sequencing of genomic regions132 have not yet been
applied to PDs, and will hopefully contribute to our
understanding of the genetic etiology of these disor-
ders in the future. One problem is, however, that the
current phenotypes might be inadequate.128 It is highly
unlikely that the new DSM-V classification of PDs will
provide a solution. A strategy that has been proposed
to increase the rate of success for molecular genetics
in psychiatry is the use of endophenotypes, defined as
a heritable characteristic that is along the pathway
between a disorder and genotype.5 Although the strat-
egy has not yet proven to be successful,133 it has been
suggested that this approach should be applied to the
study of PDs by using clinical dimensions like for
example affective instability, impulsivity, and aggres-
sion instead of diagnoses.134
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A glossary of relevant genetic terms
Deborah J. Morris-Rosendahl, PhD
Allele
One of two or more alternate forms of a gene or marker
at a particular locus on a chromosome.
Anticipation (genetic)
Apparent earlier age of onset and increased severity of a
disease in successive generations, eg, Huntington’s disease.
cDNA 
Single-stranded complementary DNA, ie, a DNA mole-
cule synthesized from a RNA template by reverse tran-
scription of RNA.
Common disorder common variant (CDCV) 
hypothesis
A theory that many common diseases are caused by
common alleles that individually have little effect, but in
concert confer a high risk.
Complex disease
A disorder in which the cause is considered to be a com-
bination of genetic effects and environmental influences.
Comparative genome hybridization (CGH)
CGH is a molecular-cytogenetic method for the analy-
sis of copy number changes (gains or losses) in the DNA
content of a given individual’s DNA.
Compound heterozygosity
Heterozygosity for two different mutant alleles of a
gene, often the case for autosomal recessive disorders.
Copy number variation (CNV)
A segment of DNA in which copy number differences
have been found by comparison of two or more
genomes. The segment may range from one kilobase to
several megabases in size. The variation is usually due to
deletion or duplication.
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Deep resequencing
A technique for sequencing a gene in several thousand
subjects, typically using one of the new high-throughput
sequencing technologies.
Epigenetics
Heritable changes to DNA structure that do not alter
the underlying DNA sequence, eg, DNA methylation.
Epigenomics
The application of epigenetics to the whole genome.
Exome
The approximately 1% of the human genome that com-
prises all exons and therefore the entire protein-coding
region of the genome.
Genetic association
The nonrandom occurrence of a genetic marker (usu-
ally a particular allele of a polymorphism) with a trait,
which suggests an association between the genetic
marker (or marker close to it) and disease pathogene-
sis.
Genome
In eukaryotes, the basic (monoploid) chromosome set,
consisting of a species-specific number of linkage groups
and the genes contained therein. For example, in
humans, the genome consists of the 24 different chro-
mosomes (22 autosomes, X and Y chromosomes). The
mitochondrial DNA is usually considered to be a sepa-
rate “mitochondrial” genome. 
Genome-wide association study 
(GWAS)
A test for the association between genetic polymor-
phisms spread evenly over the entire genome, and a dis-
ease. Usually at least 300 000 markers are required to
adequately cover the genome. 
Genotype
The genetic constitution with respect to the alleles at
one or more pairs of genetic loci under observation.
The genotype of an individual is the sum total of the
genetic information contained on the chromosomes, as
distinguished from the individual’s phenotype (idio-
type).
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Haploid
A single genome or set of chromosomes (eg, in human
gametes, n=23), compared to the normal diploid (dou-
ble) set of chromosomes (n=46).
Haplotype
A combination of alleles at closely linked gene loci that
are inherited together.
Hemizygous
When one or more genes is present in only one, instead
of two copies, eg, men are hemizygous for most genes on
the X and Y chromosomes.
Heterozygous
Having different alleles for one or more genes in homol-
ogous chromosome segments, as opposed to being
homozygous with identical alleles at these loci.
Linkage
Genetic linkage refers to the observation that two or
more genes located on the same chromosome are inher-
ited together. The ratio of being transmitted together
versus being separated allows an estimate of their dis-
tance from each other (recombination fraction). 
Linkage disequilibrium (LD)
Alleles at different loci that are inherited together more
frequently or less frequently than expected by their indi-
vidual frequencies are said to show linkage disequilibrium.
Methylation (of DNA)
The attachment of a methyl group to DNA. In verte-
brates, this typically occurs at CpG sites (cytosine-phos-
phate-guanine sites) in the DNA sequence, resulting in
the conversion of cytosine to 5-methylcytosine.
Monogenic disorder
Disorder caused by one or more mutations in a single
gene, eg, cystic fibrosis (mutations in the CFTR gene).
Such disorders are also sometimes referred to
Mendelian diseases.
Penetrance
The frequency (in percent) with which a dominant or
homozygous recessive gene or gene combination mani-
fests itself in the phenotype of the carriers.
Pharmacogenetics
A branch of genetics which deals with the genetic vari-
ability in individual responses to drugs and drug metab-
olism.
Phenocopy
A nonhereditary, phenotypic modification (caused by
special environmental conditions) that mimics a similar
phenotype caused by a gene mutation.
Phenotype
The observable properties (structural and functional) of
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organism’s genotype and the environment in which it
finds itself.
Pleiotropy
Genes or mutations that result in the production of mul-
tiple, apparently unrelated, effects at the phenotypic
level. For example, patients with phenylketonuria,
caused by mutations in the PAH (phenylalanine hydrox-
ylase) gene, have reduced hair and skin pigmentation in
addition to mental retardation, resulting from toxic lev-
els of phenylalanine.
Polymorphism (genetic)
A chromosome or DNA variant that is observed in nat-
ural populations. A gene locus is defined as polymorphic
if a rare allele has a frequency of 0.01 (1%) or more.
Positional cloning
Finding disease genes based on knowledge of their
chromosomal location (usually found via linkage analy-
sis in families with the disease) as opposed to knowl-
edge of the function of the gene or protein encoded by
the gene.
Second- or next-generation sequencing (also referred
to as high-throughput sequencing)
New techniques that have increased the speed and
decreased the cost of DNA sequencing by two orders of
magnitude, enabling the sequencing of the entire
genomes of many individuals.
Single nucleotide polymorphism (SNP)
Heritable polymorphism resulting from a single base
pair change. SNPs generally have only two alleles.
Structural variant
Structural genomic variation includes any genetic vari-
ant that alters chromosomal structure, including inver-
sions, translocations, duplications and deletions.
Duplications and deletions, collectively known as CNVs
(see copy number variation) are the most common form
of structural variation in the human genome.
Synonymous nucleotide change/non-synonymous
nucleotide change
A change in the DNA sequence which does not result in
the change in the amino acid sequence, eg, GTT>GTC
both code for Valine (Val or V). A nonsynonymous
change results in the coding of a different amino acid
(eg, GTT>GAT results in Val>Asp). 
Trinucleotide repeat expansion
An increased number of contiguous trinucleotide
repeats (eg, CAG, CGG) in the DNA sequence from
one generation to the next. When the expansion extends
into the pathological range, this type of mutation causes
diseases such as Huntington’s disease, fragile X syn-
drome, myotonic dystrophy, and many forms of spin-
ocerebellar ataxia. 
X-inactivation
The random, early embryological, inactivation of one of
the X chromosomes in females, so that the expression of
X-chromosomal genes is the same as that in males.
Useful genetic databases
National Center for Biotechnology information
(NCBI)
http://www.ncbi.nlm.nih.gov/
Provides links to many other databases, including many
of the databases below.
Online Mendelian Inheritance in Man (OMIM)
http://www.ncbi.nlm.nih.gov/sites/entrez?db=omim
A comprehensive, authoritative, and timely compendium
of human genes and genetic phenotypes.
Genome Database (GDB)
http://gdbwww.gdb.org/
Gene and protein sequence database.
UCSC Genome Browser/Bioinformatics site
http://genome.ucsc.edu/index.html
Provides the reference sequence and working draft
assemblies for a large number of genomes. The browser
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has many useful tools, eg, for searching for sequences




A genome database for vertebrates and other species,
providing gene sequence data as well as chromosomal




Database for single nucleotide polymorphisms and other
classes of minor genetic variation.
The SNP Consortium Ltd. (TSC)
http://snp.cshl.org/
A non-profit foundation organized to develop up to 
300 000 single nucleotide polymorphisms (SNPs) dis-
tributed evenly throughout the human genome and to
make the information related to these SNPs available to
the public without intellectual property restrictions.
European Bioinformatics Institute (EBI)
http://www2.ebi.ac.uk/
A  centre for research and services in bioinformatics, which




Summarizes most available information on a particular




A partnership of scientists and funding agencies from
Canada, China, Japan, Nigeria, the United Kingdom, and
the USA to develop a public resource that will help
researchers find genes associated with human disease
and response to pharmaceuticals.
The Human Genome Variation Database
http://hgvbase.cgb.ki.se/
A reference for the nomenclature of genetic variation;
also provides links to various mutation databases
The Human Gene Mutation Database
http://archive.uwcm.ac.uk/uwcm/mg/hgmd0.html
Database of published mutations for different disease
genes.
The Pharmacogenomics and Pharmacogenetics
Knowledgebase
http://pharmgkb.org/do/serve?id=home.welcome
The Human Variome Project
http://www.humanvariomeproject.org/
Web site of the global initiative to collect and curate all
human genetic variation affecting human health.
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